*January 19, 2022*

**CURRICULUM VITAE**

**NAME:** Douglas Grant McFadden

**PRESENT POSITION:** Professor, School of Life Sciences (SOLS) at Arizona State University

Director, Biodesign Center for Immunotherapy, Vaccines and Virotherapy (B-CIVV)

Biodesign Institute

727 E Tyler Street, Rm A330E

Tempe, Arizona 85287-7501

Tel: (480) 727-3388

Cell: (352) 672-2263

Fax: (480) 965-1844

Email: grantmcf@asu.edu

Website: <https://biodesign.asu.edu/grant-mcfadden>

ORCID: https://orcid.org/0000-0002-2556-3526

**DATE AND PLACE** December 2, 1949

**OF BIRTH:** St. Thomas, Ontario, Canada

**NATIONALITY:** Canada, United States (Dual citizen)

**MARITAL STATUS:** Married, three children

**DEGREES:** B.Sc. (Honors Biochemistry) McGill University 1970

Ph.D. (Biochemistry) McGill University 1975

**PROFESSIONAL EXPERIENCE:**

# Summer Research, Pathology Dept, Royal Victoria Hospital, Montreal, Quebec 1969

# Doctoral Research, Biochemistry Department,

# McGill University, Montreal, Quebec (Supervisor: Dr. D.T. Denhardt) 1970-1975

# Postdoctoral Research, Dept. of Microbiology and Immunology,

# University of Western Ontario, London, Ontario (Supervisor: Dr. S. Dales) 1976-1980

# Assistant Professor, Biochemistry Department, University of Alberta 1981-1984

Associate Professor, Biochemistry Department, University of Alberta 1984-1988

# Tenure awarded (University of Alberta) 1986

Sabbatical Research, Dept. of Microbiology and Molecular Biology,

# Harvard University (Host: Dr. M. Greenberg) 1987-1988

Professor, Biochemistry Department, University of Alberta 1989-1996

Director, Group on the Molecular Mechanisms of Growth Control, U Alberta 1991-1996

Professor, Dept. of Microbiology and Immunology, U Western Ontario, London, ON 1997-2006

Co-director, Biotherapeutics Group, Robarts Research Institute, London, Ontario 2001-2006

Member, UF Shands Cancer Center, Gainesville, Florida 2006-2016

Collaborative Member, Chem. Biol. & Mol. Med., Moffit Cancer Center, Tampa 2009-2016

Professor, Dept. of Molecular Genetics and Microbiology, College of Medicine,

University of Florida, Gainesville, Florida 2006-2016

Professor (Courtesy), Dept. Molecular Genetics & Microbiology, U Florida 2016-2018

Professor, School of Life Sciences, Arizona State University (ASU), Tempe, Arizona 2016-present

Affiliate member, University of Arizona Cancer Biology Program, Phoenix, AZ 2018-present

Director, ASU Biodesign Center for Immunotherapy, Vaccines & Virotherapy (B-CIVV) 2016-present

**SCHOLARSHIPS AND AWARDS:**

T.W. Smith Award for Outstanding Graduating Student 1965

Dow Chemical Academic Scholarship 1965-1970

Dean's Honor List 1975

MRC Scholarship (Declined) 1980

AHFMR Scholarship (Accepted) 1980-1985

AHFMR Scholarship renewed (5 year award) 1986-1991

Canadian Microbiology Society Travelling Lectureship 1986

NCI Terry Fox Team Development Award (Group Coordinator) 1989-1996

Alberta Science and Technology Award Finalist for Outstanding Leadership 1994

AHFMR Medical Scientist 1991-1996

Associate Scientist of the Australian Cooperative Research Centre for the Biological Control

of Vertebrate Pests, Canberra 1993-2004

MRC Senior Scientist award 1996-2001

American Society for Virology Bill Joklik Lectureship 1998

Marcel-Piché Lectureship, Montreal 2000

# Von Royen Lectureship, Dalhousie 2001

Canada Research Chair (Tier I), U.W.O. 2001-2006

Ontario Innovation Trust, Ontario Distinguished Researcher Award 2001

The Hellmuth Prize for Research Excellence 2002

Dean’s Award of Excellence, U.W.O. 2002

2004 Allan Granoff Lecturer Award, St. Jude’s Hospital 2004

2004 ASM Division E. Lecture Award, New Orleans 2004

Royal Society of Canada, Fellow 2004-present

Canadian Academy of Health Sciences, Fellow 2005-present

Howard Hughes Medical Institute International Scholarship 2005-2008

Prix Galien Award (to VIRON, co-founded by G. McFadden & A. Lucas) 2005

American Academy of Microbiology, Fellow 2007-present

Beijerinck Award Lecturer, Amsterdam, the Netherlands 2009

Sidney E. Grossberg Lecturer, Medical College of Wisconsin, WI 2009

Remi Amelunxen Symposium Lecturer, U Kansas, Kansas City (Keynote) 2011

U Florida Research Foundation (UFRF) Professorship award 2012-14

U Florida College of Medicine Basic Science Research Award 2013

Danny Thomas 2014 Lecturer, St Jude Children’s Research Hospital, Memphis 2014

Elected President, American Society of Virology 2015-16

Keynote Speaker, International Union of Microbial Sciences (IUMS 2017), Singapore 2017

PharmaVOICE Top 100 Honoree 2021

**PROFESSIONAL SOCIETIES**:

# American Society for Virology, Member 1982-present

American Society for Microbiology, Member 1982-present

American Society for Leukocyte Biology 1995-2016

American Association for the Advancement of Science, Member 1989-2016

# Who's Who in Science and Engineering, Inductee 1995-2016

International Cytokine Society, Member 1997-2016

Faculty of 1000, Member 2001-2017

American Society of Gene and Cell Therapy, Member 2011-present

AAAS, Member 2021-present

**EXTERNAL GRANTS REVIEWER:**

CIHR, NCI, NSERC, BCHCFMR, AHFMR (Canada) 1984-2006

NIH, NSF (USA) 1984-2006

NIH (Site Review team - Molecular Virology), USA 1986

Invited *ad hoc* reviewer for USDA/CSRS/CGO Panel, USA 1991-2000

Wellcome Trust and MRC, U.K. 1993-2006

Saskatchewan Cancer Foundation 1994-2000

# Academica Sinica, Taipei, Taiwan (External Reviewer) 1999

Australian Research Council 2000-2010

Institute of Medicine, External Reviewer (smallpox report) 2009

Australia National University, Canberra (external assessor) 2009-2010

Academia Sinica, Taipei, Taiwan (External Reviewer) 2012

CIHR, Canada (External Reviewer) 2016

Canada Research Excellence Chair (CERC): External reviewer 2017

Academia Sinica, Taipei, Taiwan (External Reviewer) 2018

Wellcome Trust, U.K. 2019

Academia Sinica, Taipei, Taiwan (External Reviewer) 2020

**GRANTS PANEL MEMBER**:

AHFMR (Studentship/Fellowship) 1983-1985

Alberta Cancer Board - panel 1984-1985

National Cancer Institute of Canada (NCI) Panel F (Molecular Biology) 1984-1991

Chairperson, NCI, Panel F 1989-1991

Chairperson, NIH Special Study Section, USA 1988

AHFMR (Equipment) 1988-1991

Chairperson, NCI site review team 1991 and 1994

Fellowship Panel, NCI 1993-1995

Chairperson, NCI programme project review panel 1993

NCI Restructuring Workshop (Grantee representative) 1994

MRC Biochemistry/Molecular Biology B Panel 1994-1997

FDA/CBER site review team, Bethesda, MD 1997

MRC Microbiology/Infectious Disease Panel 1998

NCI Molecular Biology Panel 1998-1999

Panel Member, National Academy of Science Review Team on Variola Virus 1998-1999

# MRC Panel for Michael Smith Award for Excellence Panel 1998-2000

MRC Site Review Team (Chair) 1999

NCI Site Review Team (Chair) 1999

# MRC Panel, Virology and Viral Pathogenesis 1999-2000

Ontario Challenge Fund Genomics Committee 1999-2002

Chair, MRC Panel (Virology and Viral Pathogenesis) 2000

NIH Genomics/Bioinformatics Panel 2000

CIHR Panel, Virology and Viral Pathogenesis (Chair) 2000-2003

NIH Bioterrorism Grants Panel 2002-2003

NCI Personal Awards Panel 2002-2004

NCI Panel F (Member) 2003-2006

NCI Panel F (Chair) 2005-2006

CIHR team Grants, Panel B 2006

UF Research Opportunity, Incentive Seed Fund Competition 2007

NIAID Biodefense Grant Panel, U.S. 2007  
NIAID Special Emphasis Grant Panel (U19) 2008  
Canada Foundation for Innovation Infectious Disease Expert Panel (Member) 2009

NIH RC1 Challenge Grant Reviewer 2009

NIH Virology B Study Section (ad hoc member) 2010

US Army Medical Research and Material Command (USAMRMC) (grant reviewer) 2010

NIH RC4 Grant Reviewer 2010

Australian National University, J. Curtin Medical School (External Reviewer) 2010

NIH Virology B Study Section (standing member) 2010-2014

NIH Intramural Review, Bethesda, Md (Ad Hoc Reviewer) 2012

NIH Virology B Study Section (Chair) 2012-2014

BioCanRx Oncolytic Virotherapy grant panel (member) 2015-2020

Prostate Cancer Oncolytic Vaccine consortium (advisor) 2015-2018

NIH Special Emphasis Panels (4): Topics in Virology, Microbiology, & ID (Chair) 2016-17

NIAID Board of Scientific Counselors (BSC) Review, Bethesda, MD (ad hoc) 2017

NIAID Special Emphasis Panel on Infectious Disease (Chair) 2018

NIAID Special Emphasis Panel on Virology (Chair) 2018

NIAID Special Emphasis Panel on Virology (Chair) 2019

NIH Antiviral Drug Discovery (AViDD) Panel U19 Grant Review Committee (Chair) 2022

**COMMITTEES:**

**Until 1996 (in Alberta):**

# Department Chairman Review Committee 1984

Medical Sciences Ph.D. Candidacy Committee 1984

AFHMR Heritage Days Program Committee 1984

International Committee of the Taxonomy of Viruses (Member: Poxvirus Subcommittee) 1985-1996

Central Research Fund Grants Committee 1986-1988

Search and Selection Committee (Cross Cancer Institute) 1988-1992

NCI Group Search and Selection Committee, Dept Med Micro & ID (Chairman) 1989-1994

Committee on Course Restructuring (Department of Biochemistry) 1990-1993

Departmental Space Allocation Committee (Biochemistry) 1991-1995

Search and Selection Committee: Chair, Biochemistry 1993

Recruiting Committee, Department of Biochemistry 1995-1996

**Committees, 1996-2006 (in London, Ontario):**

Graduate Studies Committee, Dept. of Microbiology/Immunology, UWO 1997-2004

# Faculty of Medicine Promotion and Tenure, UWO 1997-1998

# Institute of Medicine (IoM) Committee for Assessment of Live Variola Virus, Washington, DC 1999

# Search and Selection Committee, Director, Micro. Bureau, Health Canada 1999-2000

Gairdner Foundation, Award sub-committee in Virology (Chair) 1999-2005

# Faculty of Medicine Opportunities Committee (UWO) 1999-2000

CIHR Advisory Group 2000

Ontario Genomics Institute Steering Committee 2000-2001

CIHR Program and Peer Review Committee 2000-2002

WHO Variola Advisory Committee 2000-2002

Chair, Graduate Program, Dept. of Microbiology/Immunology, UWO 2000-2004

Scientific Advisory Board of CRC/BCPA (Australia) 2000-2004

Immunology Search Committee, Robarts Research Institute 2000-2004

Credentials Committee, Robarts Research Institute 2000-2006

Search & Selection Committee, Chair, Microbiology & Immunology, UWO 2001-2003

Member: Review Panel, Hamilton Regional Cancer Center 2001-2002

NIH Blue Ribbon Panel on Bioterrorism 2001-2002

Reviewing Board, Human Frontier Science Program 2001-2003

Reviewer, CRC Site Review Team, Canberra, Australia 2002

National Advisory Committee on Chemical, Biological, Radionuclear

Safety, Security and Research (Canadian Ministry of Health) 2002-2004

Proteomics Selection Committee, UWO 2002-2005

Advisory Board, Pacific Rim Biodefence Centre, Oregon 2002-2004

Scientific Advisor, Smallpox Grid Project, United Devices, Texas 2002-2004

Hellmuth Prize Selection Committee, UWO 2003-2005

Institute of Medicine Committee on Variola Drugs, Washington, DC 2003

Promotion and Tenure Committee, Microbiology & Immunology, UWO 2003-2005

Scientific Advisory Committee Canadian SARS Research Consortium 2003

Member, American Academy Micro Genome and Pathogenesis Colloquim 2003

External Reviewer, Dept. Microbiology, Dalhousie University 2004

Gates Foundation Global Challenge Fund (U.S.A.) Reviewing Board Member 2004

DARPA (USA) Committee on Recombinant Viruses, member 2004

Functional Genomics Nominating Committee (UWO) member 2004

Scientist Promotion Committee, Dept. Microbiology & Immunology, UWO 2004-2006

Clinical Appointments and Promotion Committee, Dept Micro & Immunology, UWO 2004-2006

Scientific Advisory Committee member, MRCE, Washington University, St Louis, MO 2004-2006

Taylor Awards Committee, Robarts Research Institute 2000, 2004, 2005

Infection & Immunity Institute Committee on ISTC (Chair) 2005

MRI (9.4T) Operating Committee, Robarts Research Institute 2005-2006

External reviewer, Dept. Biology, University of Western Michigan 2005

**Committees, 2006-2016 (in Florida):**

Virology Image Library, board member 2006-2013

Emerging Pathogens Architect/Engineer Selection Committee 2006

Emerging Pathogens Construction Manager Selection Committee 2006

Emerging Pathogens Building Selection Committee 2006-2007

National Biodefense Analysis & Countermeasures Center “Expert Team on  
 the Development of Animal Models for Human Orthopoxvirus Infections” 2007

Scientific Advisory Board, Int. Consortium of Anti-Virals 2005-2006

Int. Com. Taxonomy of Viruses (ICTV), committee member (poxviruses) 1996-2019

WHO Advisory Committee on Variola Virus Research 2007-2019

Search Committee member, UF Dept of Microbiology & Cell Science 2008

External Advisory Board member, Midwest Regional Center of Excellence 2008-2014

Scientific Advisory Board, Oregon National Primate Research Center 2008-2014

Search Committee member, UF Dept of Molecular Genetics & Microbiology 2008-2011

Scientific Advisory Board, M.G. DeGroote Institute for Infectious Disease

Research, McMaster University 2008-2017

External Advisory Board member, Pacific NW Regional Center of Excellence 2008-2011

Structural Genomics Center for Infectious Diseases (SSGCID) Board Member

(Seattle, Washington) 2009-2012

ASV Travel Award Committee for ICV, Member 2009-2012

Search Committee Member, UF Dept. of Inf. Disease & Pathology, College Vet Medicine 2009-2012

Search Committee Member, UF College of Dentistry 2009-2011

UF CPET Reviewer/Judge, Jan 24-26, 2010 2010

Search Committee Member (Virology), UF Dept. Molec. Genetics & Microbio. 2010-2011

External Review, Academia Sinica, Taipei, Taiwan 2011-2012

T32 Training grant mentor (Basic Micro. and Infectious Diseases, U Florida) 2008-2016

T32 Training grant mentor (Autoimmunity, U Florida) 2010-2015

T32 Training grant mentor (Cancer Biology, U Florida) 2011-2016

PLoS Dual Use Committee (Chair) 2012-2019

ASGCT Abstract Review Chair for Cancer-Oncolytic Viruses 2012-13

Target Selection Board member for the Seattle Structural Genomics Center for

Infectious Diseases (SSGCID) and the Center for Structural Genomics of

Infectious Diseases (CSGID) 2012-2017

IDP Medical Guild Competition, U Florida College of Medicine, Chair 2014

WHO Working Group on Synthetic Biology and Variola Virus 2015

BioCanRx Oncolytic Virotherapy Consotium (SAB member) 2015-2020

Prostate Cancer Canada OV Project (SAB member) 2015-2018

PLoS EIC Advisory Committee (member) 2016-2019

**Committees, 2016-present (in Arizona):**

Faculty Virology Search and Selection Committee: SOLS/B-CIVV (Chair) 2016-2017

VIMID Leader, Arizona Well-Being Commons: ASU, Tempe 2017-2020

External Scientific Reviewer, Institute of Molecular Biology, Taipei, Taiwan 2018

ASU Biotechnology Advisory Board (member) 2018-present

Faculty Immunology Search and Selection Committee: SOLS/B-CIVV (Co-Chair) 2018-2020

Scientific Advisory Board, OncoMyx Therapeutics (member) 2019-present

COVID-19 Research Response Team (Biodesign, ASU) (member) 2020

Communications Committee of American Society for Virology, ASV (member) 2020-23

**ORGANIZER/CHAIRMANSHIPS FOR SCIENTIFIC MEETINGS:**

American Society for Virology meeting (Poxvirus Session) Madison, WI 1984

Canadian Federation of Biological Scientists meeting (Virology Section) Toronto, ON 1985

6th Poxvirus/Iridovirus Workshop (DNA repair/replication session) Cold Spring Harbor, NY 1986

7th Int. Congress of Virology (Poxvirus/Iridovirus Symposium), Edmonton, AB 1987

7th Poxvirus/Iridovirus Workshop (DNA replication session) Heidelberg, West Germany 1988

8th Poxvirus/Iridovirus International Meeting (DNA replication session) Wintergreen, VA 1990

Co-organizer of AHFMR Workshop on "Cancer Genes", Edmonton, Alberta 1990

9th Poxvirus/Iridovirus Workshop (Viral DNA Session), Les Diablerets, Switzerland 1992

Co-organizer of 2nd Int Meeting on Signal Transduction in Normal and Cancer Cells, Banff, ALB 1993

9th Int. Congress of Virology (Co-Chairman, Poxvirus Workshop), Glasgow, Scotland 1993

Elected co-organizer of 10th Poxvirus/Iridovirus International Meeting, Banff, AB 1994

Co-organizer of AACR Meeting on Signal Transduction in Normal and Cancer Cells, Banff ALB 1995

American Society for Virology Meeting, Austin, TX (Chair, poxvirus session) 1995

Co-organizer of 11th Poxvirus/Iridovirus International Meeting, Madrid, Spain 1996

Co-chair, NIH Congress on Cytokines/Chemokines, Bethesda, MD 1999

Organizer, Symposium of Viral Evasion of the Immune System, 1999

# Canadian Society of Immunology Meeting, Lake Louise, AB 1999

Organizer and Co-Chair, Symposium on Viruses and the Immune System, 1999

UWO Department of Microbiology and Immunology, 60th Anniversary Meeting 2000

# Chair, Poxvirus Workshop, American Society for Virology Meeting, Ft Collins, CO 2000

# Chair, ICS/ISICR Congress, Amsterdam 2001

Chair, Chemokine Symposium, International Congress of Immunology, Stockholm 2001

Organizer, CIHR International Conference on Biological Terrorism, Toronto 2002

Chair, Host-Pathogen Interaction Workshop, Cancer Society of Immunology, Collingwood, ON 2002

Chair, Chemokine Session, Juan Marche Symposium, Madrid 2002

Co-organizer, Poxvirus Symposium, Lake Placid, New York 2002

Chair, Host/virus Session, Poxvirus Symposium, Lake Placid New York 2002

Co-chair, Virus-Host Interaction Symposium, ICI/FOCIS, Montreal 2004

Chair, Viral Ecology Symposium, ASV meeting, Montreal 2004

Convener, Educational Workshop, ASV, Montreal 2004

Co-chair, ASM Symposium on Viruses and Immune Evasion, New Orleans 2004

ASV Educational Workshop, Montreal (Panel participant) 2004

Co-chair, Gordon Conference, Il Ciocco, Italy 2005

Co-organizer, ASM workshop on Viral Evasion, Acapulco, Mexico 2005

Co-chair, Poxvirus Workshop, Int. Cong. Virology, San Francisco 2005

Co-chair, Emerging Pathogens Workshop, NIH, Bethesda 2005

Co-moderator, 5th ASM Biodefense Meeting, Washington, D.C. 2007

Co-chair, 107th ASM Meeting, Toronto, Canada 2007  
Co-organizer, 5th Int’l Meeting on Replicating Oncolytic Virus Therapies, Banff, Alberta, Canada 2009

Co-chair, ASV Meeting, Poxvirus Workshop, Vancouver, B.C. 2009

Co-organizer, Pathogen-derived Therapeutics Keystone Meeting, Snowbird, Utah 2009-2011

Co-organizer, 6th Int’l Meeting on Oncolytic Viruses, Scottsdale, Arizona 2009-2011

Co-organizer, 7th Int’l Meeting of Oncolytic Viruses, Quebec City, Canada 2011-2013

Chair, Virus-Host Interaction session, Poxvirus Conference, Salamanca, Spain 2012

Co-Chair, Mechanisms of Viral Replication, 7th Int. Oncolytic Virus Meeting, Quebec 2013

Chair, Abstract Selection Committee, Am Society of Gene & Cell Therapy meeting 2013

Co-Chair, Mini-Symposium 4, ICIS Annual Meeting, San Francisco 2013

Advisory Committee member, Int. Congress of Virology, Montreal, Canada 2014

Chair, Therapeutics Session, International Poxvirus meeting, Victoria, BC 2014

Organizing Committee, 9th Int Conference on Oncolytic Virus Therapeutics, Boston 2015

Chair, Oncolytic Viruses and Gene Therapy Session, ASV meeting, London, Ontario 2015

Co-Chair, Engineering 2 Session, Int. Conference on Oncolytic Virus Therapeutics, Boston 2015

Discussion Leader, Anti-virals and Vaccines, Gordon Research Conference, Girona, Spain 2015

Keynote & Symposia speaker invitations, ASV meeting, Virginia Tech, VA 2016

Organizing Committee, 10th Int Conf on Oncolytic Virus Therapeutics, Vancouver, BC 2016

Advisor, ASM Colloquim on Zika virus, Washington, DC 2016

NCI SBIR Development Meeting, Washington, DC (Chair) 2017

Organizing Committee, 11th Int Conf on Oncolytic Virus Therapeutics, Oxford, UK 2017-18

Leader, Theme meeting for Viruses, Immunity, Microbiomes and Infectious Diseases

(VIMID) of the Arizona WellBeing Commons 2017

Co-organizer, Arizona-wide Virology Symposium, at ASU Biodesign Institute 2017

Organizer, Arizona WellBeing Commons VIMID meeting, Biodesign Institute 2017

Co-organizer, Arizona WellBeing Commons VIMID/Cancer meeting, ASU 2018

Organizing Committee, 12th Int Conf on Oncolytic Virus Therapeutics, Mayo Clinic, Rochester 2018-19

Co-organizer, Arizona-wide Virology Symposium, at U Arizona BIO5 Institute, Tucson, AZ 2019

Co-organizer, Arizona WellBeing Commons VIMID meeting, U Arizona, Phoenix 2019

Co-organizer, Arizona WellBeing Commons VIMID/Cancer meeting, U Arizona, Phoenix 2019

Organizing Committee, 13th Int Conf on Oncolytic Virus Therapeutics, Sedona, AZ 2021

Organizing Committee, 14th Int Conf on Oncolytic Virus Therapeutics, Tokyo, Japan 2022

**EDITORIAL BOARDS:**

Editor for "Viroceptors, Virokines, and Related Mechanisms of Immune

Modulation by DNA viruses" (Molecular Biology Intelligence Unit

Publication series, R.G. Landes Co.) 1993-1994

Associate Editor for *Virology* 1988-2010

*Viral Immunology* (Editorial Board) 1999-2006

*Current Drug Targets* (Editorial Board) 2000-2006

*J. Virology* (Member, Editorial Board) 2003-2007

*PLoS Pathogens* (Associate Editor) 2004-2006

*PLoS Pathogens* (Section Editor for Viral Pathogenesis) 2006-2007

*PLoS Pathogens* (Deputy Editor-in-Chief) 2007-2013

*Future Microbiology* (Special Edition Co-Editor) 2009-2010

*Current Opinion in Virology* (Special Edition Co-Editor) 2011

*Recent Patents on Anti-Infective Drug Discovery* (Editorial Board) 2005-2013

*The Open Immunology Journal* (Editorial Board) 2007-2010

*Journal of Infection in Developing Countries* (Editorial Board) 2007-2016

*Oncolytic Virotherapy* (Member, Editorial Board) 2012-2018

*Journal of Innate Immunity* (Editorial Board) 2008-2016

*J. Virology* (Senior Editor) 2007-2017

*PLoS Pathogens* (Co-Editor-in-Chief) 2013-2019

*Current Opinion in Virology* (Special Edition on Oncolytic Viruses, Co-Editor) 2014-2015

*Molecular Therapy-Oncolytics* (Editorial Board member) 2014-2017

*Molecular Therapy-Oncolytics* (Deputy Editor) 2017-present

*Journal for the ImmunoTherapy of* *Cancer* (Co-Editor for Special Issue) 2017-18

*Journal for the ImmunoTherapy of Cancer* (White Paper Co-lead author) 2017-18

**GRADUATE STUDENT SUPERVISORY OR EXAMINING COMMITTEES:**

**University of Alberta (until 1996)**

D. Rafter (Biochemistry) 1983

J. Ng (Biochemistry) 1983-1984

K. Meerovitch (Biochemistry) 1984-1986

B. Pasloske (Biochemistry) 1984-1989

M. Lewis (Medicine) 1982-1985

J. Zwaagstra (Medicine) 1984

A. Chen (Genetics) 1984-1986

F. Diaz-Mitoma (Medicine) 1986-1990

G. Lee (Genetics) 1986-1991

C. Fregeau (Biochemistry) 1987-1991

P. Barker (Anatomy) 1988-1991

A. Viera (Biochemistry) 1990-1994

C. Helgason (Biochemistry) 1990-1993

D. Senger (Anatomy) 1992-1996

W. Eamon (Biochemistry) 1992-1996

O. Jakiwczyk (Pharmacology) 1993-1994

A. Howe (Medical Microbiology & Infectious Diseases) 1990-1995

L. Shen (Immunology) 1995-1996

## At RRI/UWO (1997-2006)

H. Tung (Microbiology and Immunology) Sup. Committee 1997-1999

# B. Matheson (Microbiology and Immunology) MSc Thesis 1997

D. Naigamwalla (Biochemistry) MSc Thesis 1997

D. Whang (Medicine) Sup. Committee 1999-2000

M. Rosu-Myles (Microbiology and Immunology) Sup. Committee 1999-2003

P. Shenoy (Microbiology and Immunology) MSc Thesis 1999

M. Elgady (McMaster, Biology) PhD Thesis 1999-2000

# A. Peters (Microbiology and Immunology) MSc Thesis 2000

C. McCormick (UBC, Microbiology and Immunology) PhD Thesis 2000

C. Michalski (Microbiology and Immunology) Sup. Committee 2000-2006

N. Avvakumov (Microbiology and Immunology) Sup. Committee 2001-2005

K. Holmes (Microbiology and Immunology) PhD Candidacy 2001

C. O’Neill (Microbiology and Immunology) Committee 2001-2005

Y. Tourand (Microbiology and Immunology) Sup. Committee 2001-2005

H. Sadlish (Microbiology and Immunology) PhD Thesis 2002

G. N. Kim (Microbiology and Immunology) PhD Thesis 2002

F. McArthur (Microbiology and Immunology) PhD Candidacy 2002

J. Diao (U of Toronto) PhD Thesis, external examiner 2002

E. Lister (Microbiology and Immunology) Sup. Committee 2002-2005

M. Saraiva (Cambridge) PhD Thesis, external examiner 2002

J. Trowbridge (Microbiology and Immunology) PhD Candidacy 2004

M. Holowaty (Dept. Medical Genetics & Micro, U of Toronto) PhD, ext. examiner 2004

V. Panchanathan (ANU, Canberra) PhD, external examiner 2004

C. Meagher (Micro & Imm, UWO) PhD, examiner 2004

J. Herbert (Micro & Imm, UWO) Sup. Committee 2004-2006

W. Teff (Micro & Imm, UWO) PhD, Candidacy Exam 2005

M. Adams (Aust. Nat. University) PhD external examiner 2005

K. Adeyanju (Micro & Imm, UWO) Sup. Committee 2005-2006

J. Ablack (Micro & Imm, UWO) MSc examiner 2005

I. Mendez (Micro & Inf. Dis., U Calgary) PhD examiner 2005

D. Canton (Biochem. Dept., UWO) PhD examiner 2005

## At University of Florida (2006-2016)

K. Dunston (U New South Wales, Australia) PhD examiner 2007

I. Sakala (Australian National University, Canberra) PhD examiner 2008

S. Sonnberg (U of Otago, New Zealand), PhD examiner 2008

Z. “Levi” Watson (Molec Gen & Microbio., Univ. of Florida), Sup. Committee 2008-2013

S. “Tina” Halder (Biochem & Molec Bio., Univ. of Florida), Sup. Committee 2008-2012

D. Fitzpatrick (Entomology & Nematology Dept., U Florida), Sup. Committee 2009

N. Johns (Mol. Gen. & Microbio., Univ. Florida), Sup. Committee 2009-2015

Y.S. Tseng (Biochem & Mol. Bio, U Florida), Sup. Committee 2010-2014

J. Smith/Lyles (Mol. Gen. & Microbiology, Univ. Florida), Sup. Committee 2010-2014

S. Appelberg (Path. Immun. and Lab Medicine, U Florida), Sup. Committee 2010-2014

I. Velsko (Peridontology and Oral Biology, U Florida), Sup Committee 2011-2014

Ma. Junaliah Tauzon (ANU, Canberra, Australia) External PhD Examiner 2013

D. Pritesh (U Florida) PhD Supervisory Committee 2014-2017

N. Aytes (U Florida) PhD Supervisory Committee 2014-2016

D. Phelan (U Florida) PhD Candidacy Examiner 2014

J. van Vloten (U Guelph) PhD Candidate Supervisory Committee member 2015-2016

C. Kober (U Wurtzburg) PhD External thesis examiner 2015

H. Chen (U Florida) PhD, Supervisory Committee member 2015-2016

## At Arizona State University (2016-present)

J. van Vloten (U Guelph) PhD Candidate Supervisory Committee member 2016-2020

J. Christie (ASU) PhD, Mentor 2016-present

L. Wang (ASU) PhD, Supervisory Committee member 2017-present

R. Nitiyanandan (ASU), PhD Supervisory Committee (member) 2018-present

K. Pfeffer (ASU), PhD Supervisory Committee member, and Chair 2019-present

M. Di Palma (ASU) PhD Supervisory Committee member 2021-present

Joey Mamola (ASU) MSc Thesis mentor (3+1) 2018-2020

Karthika Krishna (ASU) MSc Thesis co-mentor (4+1) 2021-present

**PERSONNEL SUPERVISED:**

**At University of Alberta (1980-1996)**

A.M. Delange Postdoctoral Fellow 1981-1985

C. Upton Postdoctoral Fellow/P.A./FSO 1982-86/86-89/89-1993

W. Block Postdoctoral Fellow 1982-1985

C. Macaulay Graduate Student (PhD) 1983-1989

A. Opgenorth Graduate Student (PhD) 1985-1992

C. Gregson Medical Student (research rotation) 1983

F. Bugeja Medical student (summer) 1985

W. Patton Medical Student (summer) 1985

M. Reddy Visiting Graduate Student (summer) 1985

D. Stuart Graduate Student (PhD) 1986-1991

# J. Macen Undergraduate Summer/Graduate Student (PhD) 1985-1995

K. Graham Postdoctoral Fellow/research associate 1989-1996

M. Schreiber Graduate Student (PhD) 1989-1995

J. Liu Summer student 1990

T. Witbeck Medical Student (summer) 1990

J. Pimm Summer Student 1991

K. Ellison Postdoctoral Fellow/research associate 1991-1996

T. Dowdeswell Summer Student 1992/1993

D. Boot Summer Student 1992

K. Mossman Graduate Student (PhD) 1992-1995

A. Ahmed Summer Student 1993

W.D. Yang Rotating Graduate Student 1993

M. Barry Postdoctoral Fellow 1993-1997

P. Kerr Visiting Scientist (CSIRO) 1994

# J. Finnegan Visiting scientist (CSIRO) 1994

J. Lisztman Summer Student 1994/1995

M. Cabrita Summer Student (co-supervisor with K. Kane) 1994

L. Sedger Postdoctoral Fellow 1995-1997

W. Peng Summer Student 1995/1996

K. Jahns Summer Student 1996

A. Scott Summer Student 1996

C. Hodgkinson Summer Student 1996

## At RRI/UWO (1997-2006)

A. Lalani Graduate Student (University of Alberta) (PhD) 1993-1999

P. Nash Graduate Student (University of Alberta) (PhD) 1994-1999

H. Everett Graduate Student (University of Alberta) (PhD) 1994-2002

# X. Xu Graduate Student (Univ. of Alberta/UWO) (MSc) 1996-1999

J. Robichaud Graduate Student (UWO) (MSc) 1996-1999

C. Cameron Graduate Student (UWO) (PhD) 1997-2005

S. Hnatiuk Graduate Student (UWO) (MSc) 1996-1999

B. Seet Graduate Student (UWO) (PhD) 1997-2002

C. Hodgkinson Summer Student (RRI) 1997/98

J. Masters Summer Student (RRI) 1997/98

J. Heger Summer Student (RRI) 1997/98

C. Macaulay Research Associate 1997-1998

S. Hota-Mitchell Postdoctoral Fellow 1998-2000

# J. Cao Research Associate 1998-2000

R. Singh Research Associate 1998-2006

J. Barrett Research Associate 1998-2006

S. Hota Summer Student 1998

S. Weppler Summer Student 1998

K. Summerhurst Summer Student 1998

P. Belda Summer Student 1998

M. Curtis Summer Student 1999

# C. Chang Postdoctoral Fellow 1999-2002

# T. Baumgartner Summer Student 2000

J. Sypula Summer Student 2000-2001

F. Wang Research Associate 2000-2006

C. Brunetti Research Associate 2000-2003

G. Wang Postdoctoral Fellow/Research Associate 2000-2005

Ashley Ten Haaf High School Student Rotation 2001

J. Johnston Postdoctoral Fellow 2001-2004

J. Sypula Graduate Student (UWO) (PhD) 2001-2004

S. Nazarian Graduate Student (UWO) (PhD) 2001-2007

Y. Sun Research Associate 2001-2005

Dan Ricciuto Summer Student 2002

Nicole Davis-Faroque Summer Student 2002

Emma Burke Summer Student 2002

Jennifer Forde Summer Student 2002

Jing Qin Summer Student 2002 & 2003

Judith Kivinen Undergraduate Research Rotation 2002-2003

# Christina (Hoiki) Chan Summer Student, Rotating Undergraduate 2003-2004

Karim Essani Visiting Sabbatical Professor 2003

Megan Goodwin Rotating Undergraduate 2003

Tammy Lewis Lab Assistant 2003-2005

Zhuhong (Shirley) Shao Lab Assistant 2004-2005

Michael Saltes High School Student Rotation 2004

Christina Wong Summer Student 2004

Tara Belisto Summer Student 2004

Kristen Ban Summer Student 2004

Marianne Stanford Postdoctoral Fellow 2004-2006

Jin Su Postdoctoral Fellow 2004-2006

Masmudur Rahman Postdoctoral Fellow 2004-2006

Mae Shaban Graduate Student (UWO) (MSc) 2004-2006

Samara Krause Undergraduate Lab Volunteer 2004-2005

Steven Werden Summer Student/Rotating Undergraduate 2004-2005

Erin Falconer Summer Student 2005

Chalice Valeriano Summer Student/Rotating Undergraduate 2005-2006

Catherine Barrett Summer Student/Rotating Undergraduate 2005-2006

Andrew Wheeler Summer Student 2005

Steven Werden Graduate Student 2005-2006

Songpeng Zhang Graduate Student (co-sup. with L. Hertel) 2005-2006

Alexandra Lacko Rotating Undergraduate 2005

Josh Sookman Rotating Undergraduate 2005

Aarica Arora Co-op Student (A.B. Lucas High School) 2005

Rishi Patpatia Co-Op Student (A.B. Lucas High School) 2005

Danielle Villeneuve Co-op Student (Catholic Central High School) 2005

Joe Bondy-Denomy Undergraduate (co-op student) 2005-2006

Philippe-Alexandre Gilbert Postdoctoral Fellow/Research Associate 2005-2006

Johanne Lacasse Research Associate 2006

Gavin Shokar Undergraduate (lab assistant) 2006

Lindsey Alston Summer Student 2006

Suzana Buac Summer Student 2006

Jodi Idema Summer Student 2006

Jeffery Werden Summer Student 2006

Christy Willert Summer Student 2006

**At University of Florida (2006-2016)**

Philippe-Alexandre Gilbert Senior Biological Scientist 2006

Johanne Lacasse Bioscientist 2006-2007

Edra Ijames Administrative Assistant 2006-2008

Sherin Smallwood Senior Biological Scientist 2006-2014

Dorothy Smith Senior Lab Technician 2006-2014

Masmudur Rahman Postdoctoral Fellow/Research Assistant Professor 2006-2016

Steven Werden Graduate Student (PhD) 2006-2010

Suzana Buac Summer Student 2006

Jodi Idema Summer Student/Lab Technician 2006

Chalice Valeriano Summer Student 2005-2006

Jeffery Werden Summer Student 2006

Maria Rojas Lab Technician 2006-2008

Jia Liu Postdoctoral Fellow/Assistant Scientist 2007-2013

Sonia Wennier Postdoctoral Fellow 2007-2010

Kim Van Vliet Postdoctoral Fellow 2007-2009

Manbok Kim Postdoctoral Fellow 2007-2009

Mohamed Mohamed Postdoctoral Fellow 2007-2009

Nancy Villa Postdoctoral Fellow 2007-2010

Eric Bartee Postdoctoral Fellow 2007-2012

Leiliang Zhang Postdoctoral Fellow 2007-2009

Zachary “Levi” Watson Rotating Graduate Student 2007

Robby Newman Rotating Graduate Student 2007

Cameron Lilly Rotating Graduate Student 2008

Stephen Mayper Undergraduate Student Research Volunteer 2008-2011

Hoang Duc Huynh Undergraduate Student Research Volunteer 2008

Mahmoud Mona Undergraduate Student Research Volunteer 2008-2011

Jessica Essex Grants Assistant 2009-2011

Edith Gerlach Undergraduate Student Research Volunteer (from Germany) 2009

Anupam Saha Undergraduate Student Research Volunteer 2009-2010

Nick Figura Undergraduate Student Research Volunteer 2009-2011

Florine Scholte Undergrad Student Res Volunteer (from Netherlands) 2009-2010

Sofia Appelberg Rotating IDP Graduate Student 2009

Stephanie Lamb IDP Graduate Student 2010-2014

Shoudong Li Assistant Scientist 2010-2012

Winnie Chan Postdoctoral Fellow 2011-2014

Nikea Aytes MSc Biotechnology Graduate Student 2011-2013

Angelika Linowski Volunteer (visiting Moffit-based researcher) 2011-2012

Deniz Ucar Volunteer (animal model technician) 2011-2012

Sarah Aiyar Volunteer 2011-2012

Cody Jackson Volunteer (UF undergraduate)/MSc Student 2011-2015

Akila Raja Volunteer (UF undergraduate) 2011-2014

Meghan Penrith Volunteer (UF undergraduate) 2012-2013

Ana Lemos de Matos Visiting Graduate Student (Porto, Portugal) 2012

Matthew Apicella Volunteer (UF undergraduate) 2012-2014

Jonas Albarnaz Visiting Graduate Student (Sao Paulo, Brazil) 2012-13

Brian Clancy Volunteer (UF undergraduate) 2013-2014

Nakul Bhatt Volunteer (UF undergraduate) 2012-2013

Eugenie Bagdassarian Visiting Graduate Student (U Claude Bernard, Lyon, Fr) 2013

Tom Hofland Visiting Graduate Student (U Utecht, Netherlands) 2013-14

Mohamed Ahmed Ali Visiting Professor (U Cairo, Egypt) 2013-2014

Jessica Essex Lab Assistant 2014

Nancy Villa Research Assistant Prof. (Co-mentor, with C. Cogle) 2013-2016

Cameron Lilly Postdoctoral fellow 2014-2016

Ana Lemos de Matos Postdoctoral fellow 2014-2016

Jieun Lee Volunteer (UF Undergraduate) 2014-2016

Haidar Ali Volunteer (UF Undergraduate) 2014-2016

Bradley Maller Volunteer (UF Undergraduate) 2014-2016

Jess Dhillon (JD) OPS Lab Technician 2014-2015

Jacqueline Bornstein Volunteer (UF Undergraduate) 2014-2016

Farheed Chowdhury Volunteer (UF undergraduate) 2014-2015

Harald Messer Postdoctoral fellow 2015-2016

Kyle Varkoly OPS Lab Technician 2015

Kate McManus Rotating IDP graduate student 2015

Nissin Moussatche Research Associate Professor 2015-2016

Rekha Garg Volunteer scientist 2015

Jay-Shing Wang Volunteer (UF undergraduate) 2015-2016

Rekha Garg OPS postdoctoral researcher 2016

Jeb Wild Volunteer (UF undergraduate) 2016

Jieun Lee MSc graduate student (UF) 2016

**At Arizona State University (2016-present)**

Jieun Lee MSc graduate student (UF) 2016-2018

Masmudur Rahman Research Associate Professor 2016-present

Nancy Villa Research Assistant Professor 2016-2020

John Christie PhD graduate student (ASU) 2016-2021

Ana Lemos de Matos Postdoctoral Fellow/Research Scientist 2016-present

Mario Abrantes Associate Research Technologist 2016-2020

Honor Glenn Research Scientist/Director Biodesign Imaging Core 2016-2020

Hannah Canter Undergraduate student volunteer 2017-2018

Justin Blankenbaker Undergraduate student volunteer 2017

Laura Hansen Research volunteer 2017-2018

Lina Franco Postdoctoral fellow 2017-2020

Ami Gutierrez-Jensen Research Technologist 2017-present

Laura Belmont Undergraduate student volunteer 2017-2019

Julia D’Isabella Undergraduate student volunteer 2017-2019

Joanna Jazowieka Visiting scientist (from Poland) 2017

Aleksander Sochanik Visiting scientist (from Poland) 2017

Lino Torres Postdoctoral fellow 2017-2020

Jaz Michelle Undergraduate student volunteer 2017-2020

Sanna Naveed Undergraduate student volunteer 2018

Joseph Mamola Undergraduate student volunteer 2018-2019

Sarah George Undergraduate student volunteer 2018-2019

Miranda Yousif Undergraduate student volunteer 2018-2019

Tyler Robbins Undergraduate student volunteer 2018-2019

Matthew McArthur Undergraduate student volunteer 2018-2020

Sai Kottapalli Undergraduate student volunteer 2018-2019

Casandra Kein Undergraduate student volunteer 2018-2019

Zachary Tacner Undergraduate student volunteer 2018-2019

Camryn Garza Undergraduate student volunteer 2018-2019

Joseph Mamola MSc student (ASU) 2019-2020

Ana Pinto Visiting graduate student (from Portugal) 2019-2020

Felix Herbst Undergraduate student volunteer 2019

Simona Joop Kraberger Postdoctoral fellow 2019-2020

Anne Everts Visiting graduate student (from Netherlands) 2020

Rachel Dutcher Undergraduate student (ASU) 2020

Arshia Diyya Undergraduate student (ASU) 2021-present

Jamie Sprout Undergraduate student (ASU) 2019-2021

Sahar Davoudi Undergraduate student (ASU) 2019-2021

Karthika Krishna Undergraduate student (ASU) 2021-present

Hrithik Patel Undergraduate student (ASU) 2020-present

Hummad Sheikh Undergraduate student (ASU) 2020-2021

Junior Ayuk Enow Research Technologist 2021-2022

Whitney Purtha Undergraduate student (ASU) 2021-present

Steffen Fallini Undergraduate student (ASU) 2021-present

Fleur Oosterom Visiting graduate student (from Netherlands) 2022

Junior Ayuk Enow PhD graduate student (ASU) 2022-present

**TEACHING:**

**AT U of Alberta (1980-1997) Subjects Taught**

Biochemistry 301 DNA structure and replication, transcription,

translation, gene control, recombinant DNA

# Biochemistry 430 Molecular biology of nucleic acids and gene expression

Biochemistry 501 Lab techniques of recombinant DNA

Biochemistry 512 Eukaryotic gene control (promoters, enhancers,

splicing, repressors, hormonal regulation)

Biochemistry 612 Selected topics in molecular biology

Biochemistry 671 Student seminars

Biochemistry 450 Molecular virology

Oncology 500 DNA and RNA tumor viruses

# Biochemistry 623 Seminars in current aspects of nucleic acids

Microbiology and I.D. 415 Mechanisms of pathogenesis

**At U of Western Ontario (1997-2006) Subjects Taught**

Microbiology and Immunology 511a Viral Pathogenesis

Biochemistry 483/484 Student Research Projects

Microbiology and Immunology 473a Advanced Immunology

Microbiology and Immunology 461b Virology

Phase I and II Medicine Viral Pathogenesis

Business 622 Biotechnology and Academics

Microbiology & Immunology 585y Virology Journal Club (course coordinator)

Pathology 520b Biotechnology

**AT U OF FLORIDA (2006-2016) Subjects Taught**

Mini-medical school Virology 2006

JSEHS Virology 2007

UF Student Science Training Program Virus & Cancer 2007

GMS 7979 Advanced Research 2006-2016

IDH 3931 Virology 2007-2016

GMS 6121 Infectious Diseases 2007-2016

GMS 6034/6035 Virology 2007-2016

GMS 6191-HIV Journal Club Infectious Diseases 2008

BMS 6300C Virology (CTIM) 2009-2016

GMS 5095 Oncolytic Viruses 2012

Open Access Week Science Publishing 2009, 2011-2016

GMS 6252 Oncolytic Virology 2014, 2016

T32 BMID Training Grant Ethics in Publishing 2016

**Guest Course Lecturer (Virology) while at U Florida (2006-2016)**

# Univ. of British Columbia Department of Microbiology 1998

Yale University Department of Genetics 2000

Cleveland Clinic Department of Cancer Biology 2001

New York University Department of Microbiology 2002

Lady Davis Research Institute Department of Microbiology 2002

SUNY, Buffalo Department of Microbiology 2004

Rockefeller University Virology and Infectious Diseases 2003-2015

Univ. of Texas, San Antonio Health Science Center 2007

Helmholtz Centre for Infection Research, Hannover Medical Summer School, Germany 2012

FEBS Summer School, Spetses, Greece 2012

Ecole Normale Superiore, ENS Lyon, France 2013, 2016

Montana State U, Virology Course (Remote lecture: Mark Young Co-ordinator) 2013

**COMMUNITY OUTREACH (at U Florida 2006-2016)**

Center for Precollegiate Education & Training (CPET) Lecture 2007, 2009-2012, 2014

UF Student Science Training Program (UF-SSTP) Lecture 2007, 2009, 2011, 2013-16

Medical Clinic service, Fort Liberte, Haiti (Volunteer) 2012, 2014

(<http://blogs.plos.org/speakingofmedicine/2012/03/02/pathogens-and-people-reflections-from-haiti/>)

HHMI ICORE summer school lecture 2011-2012, 2014

JSEHS at U Florida (Keynote speaker) 2015

Cancer Connections at U Florida (Invited speaker) 2015

**TEACHING AT ASU (2016-present):**

**TEACHING/LECTURES (at ASU) Subjects Taught**

MCB556 (Lecturer) Oncolytic viruses 2017-present

MIC501 (Lecturer) DNA viruses/cancer 2017-present

MIC591/BIO591 (Instructor) Viroholics (Journal club) 2017-present

MIC485/598 (Lecturer) Virology (Oncolytic virotherapy) 2017-present

BIO494/591 (Lecturer) Biotechnology Viruses as Tools 2018-present

BIO494/598 (Lecturer) Cancer Immunology 2018-present

BDE598 (Lecturer) Biological design 2018

CBIO555/PHCL555 (Lecturer) Cancer Therapeutics (U Arizona) 2021

**Guest Course external Lecturer (while at ASU 2016-present)**

# Rockefeller University, NYC Virology & virotherapy 2017, 2019

University of Technology Sydney, Aust. Oncolytic virotherapy 2017, 2018

**COMMUNITY OUTREACH (at ASU 2016-present)**

ASU 1967 Graduates Lecture (at Biodesign) 2017

March for Science (Washington, DC) 2017

ASU/Biodesign VIP Presentation 2018

CEM Undergraduate students presentation 2019

ASU Podcast: <https://askabiologist.asu.edu/listen-watch/history-rabbits-and-deadly-virus> 2019

Glendale Community College, AZ, Biotechnology Course (Invited lecturer) 2019

Wise Guise II Speaker series (Scottsdale, AZ) 2020

ASV/ASM COVID-19 Vaccination Zoom-based Public Town Halls (3) 2021

TV news and podcast coverages: 2020-present

<https://www.azfamily.com/news/asu-researchers-in-tempe-use-virus-deadly-to-rabbits-to/article_df86f522-51fd-11ea-a701-3f8dc086c884.html?utm_medium=social&utm_source=email&utm_campaign=user-share>

<https://www.abc15.com/news/region-southeast-valley/tempe/asu-scientist-one-step-closer-to-finding-a-cure-to-cancer>

<https://www.youtube.com/watch?v=7PsrFlPXLRo>

<https://science.kjzz.org/content/1505716/phoenix-based-biotech-company-working-using-virus-potential-cancer-treatment>

[https://podcasts.apple.com/ca/podcast/1-grant-mcfadden-a-pox-on-your-cancer/id1512379792?i=1000473964281](https://urldefense.proofpoint.com/v2/url?u=https-3A__podcasts.apple.com_ca_podcast_1-2Dgrant-2Dmcfadden-2Da-2Dpox-2Don-2Dyour-2Dcancer_id1512379792-3Fi-3D1000473964281&d=DwMFaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ISiKcjh6QSFdElZdYG-48VJH81jkmEHjIeu2hZqNdjE&m=9NmBMYLTwsGCsmYYMNhr2wgh-ZIj43jt0nPuq7GfyhM&s=ufHKo8gltLG4YZWhRdPe4KlTG7y50wrS8vKSWrY9UFo&e=)

<https://www.12news.com/article/news/asu-using-virus-to-kill-cancer/75-e17febb7-a6c1-4306-86b3-a8a0db2b6ac9>

<https://anchor.fm/goingbeyonddailylife/episodes/Coronavirus-Interview---Part-3-er56uc>

<https://www.youtube.com/watch?v=6E4767OeNV0>

<https://www.ozy.com/around-the-world/are-bunnies-the-secret-to-curing-cancer/430913/>

[https://podcasts.apple.com/us/podcast/az-tech-podcast/id1552562587?i=1000523850290](https://urldefense.com/v3/__https:/podcasts.apple.com/us/podcast/az-tech-podcast/id1552562587?i=1000523850290__;!!IKRxdwAv5BmarQ!MEEuZ2_EF_WL4LEQ3mCuPhTSmUA3wZjsRzePAgZDp9J89eXB2cmUpatZpvk5dC8$)

[https://open.spotify.com/episode/5M5LehFWE6j6gXyHkxJtXm?si=fb6b458b73bb4a1c](https://urldefense.com/v3/__https:/open.spotify.com/episode/5M5LehFWE6j6gXyHkxJtXm?si=fb6b458b73bb4a1c__;!!IKRxdwAv5BmarQ!MEEuZ2_EF_WL4LEQ3mCuPhTSmUA3wZjsRzePAgZDp9J89eXB2cmUpatZ7GEkFpA$)

<https://www.youtube.com/watch?v=jOYnyjPsF-U>

<https://biodesign.asu.edu/news/new-review-highlights-cancer-crushing-viruses>

<https://news.asu.edu/20211201-new-review-highlights-cancer-crushing-viruses?utm_campaign=ASU_News_Insight+12-2-21_4211799&utm_medium=email&utm_source=ASU%20News_SFMCE&utm_term=ASU&utm_content=Read+more_Viruses&ecd42=518002422&ecd73=179964251&ecd37=All%20ASU%20Employees&ecd43=12/2/2021>

<https://biodesign.asu.edu/news/new-review-highlights-cancer-crushing-viruses?utm_campaign=ASU_Biodesign_Enews_newsletter_biodall-recentopensubscribers_21112_4424370&utm_medium=email&utm_source=ASU%20Biodesign%20Institute_SFMCE&utm_term=ASU&utm_content=https%3a%2f%2fbiodesign.asu.edu%2fnews%2fnew-review-highlights-cancer-crushing-viruses&ecd42=518001904&ecd73=178147012&ecd37=e-News&ecd43=1/14/2022>

**Current Biodesign Center for Immunotherapy, Vaccines and Virotherapy (B-CIVV) website:**

<https://biodesign.asu.edu/Research/Centers/immunotherapy-vaccines-and-virotherapy>

**Organizer of ongoing weekly seminar series (at ASU Biodesign Institute, 2016-present):**

**CIVV-oholics:** A weekly seminar series at 12 noon on Wednesdays for ASU/Biodesign members of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy (B-CIVV): 2017-present

**Viroholics:** A weekly seminar series at 12 noon on Fridays for members for the Arizona-wide community of Virologists (Formal ASU Course MIC 591 83131): 2017-present

Note: in early 2020, as a consequence of the COVID19 pandemic, my Viroholics co-host (Ian Hogue) and myself decided to completely revamp the Spring 2020 seminar schedule to invite some of the world’s top coronavirus experts, who agreed to present their seminars remotely via Zoom. All but one of the lectures given after March 27 were recorded and have been compiled into a single database that is available as a public record at the website of the American Society for Virology (ASV). Given the wide interest this new seminar schedule has generated, the speaker list is reproduced below:

**Viroholics 2020 Friday Seminars (COVID19-Edition)**

**12 noon – 1:00 pm Fridays (Mountain Standard Time | Pacific Daylight Time)**

**Join via Zoom from PC, Mac, Linux, iOS or Android:** <https://asu.zoom.us/j/244676617>

|  |  |  |
| --- | --- | --- |
| **March** 20 |  | **Efrem Lim PhD**, Assistant Professor, Bodesign Center for Fundamental and Applied Microbiomics;  School of Life Sciences at Arizona State University – Title: **"SARS-CoV-2 surveillance at ASU**  **and Arizona"** (not recorded) |
| 27 |  | **Brenda Hogue PhD**, Professor, Biodesign Center for Immunotherapy, Vaccines and Virotherapy;  School of Life Sciences at Arizona State University – Link to Presentation:  [“Virus-like Pa​rticles - a platform for coronavirus vaccines”](https://www.dropbox.com/s/2018lxqsjn20rp1/Brenda%20Hogue%203_27_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
|  |  |  |
| **April** 3 |  | **Alexandra Lucas MD**, Professor, Biodesign Virginia D. Piper Center for Personalized Diagnostics  at Arizona State University – Link to Presentation:  [“Fighting fire with fire: Virus-derived immune modulators for treating severe viral infections”](https://www.dropbox.com/s/25y4c1z2emymuui/Alexandra%20Lucas%204_3_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
| 10 |  | **Matthew Frieman PhD**, Associate Professor, Department of Microbiology and Immunology,  University of Maryland School of Medicine – Link to Presentation:  [“Therapeutic developments for emerging coronaviruses”](https://www.dropbox.com/s/ryjrlrs16h17voq/Matthew%20Frieman%204_10_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
| 17 |  | **Darryl Falzarano PhD**, Research Scientist II & Adjunct Professor, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac), University of Saskatchewan –  Link to Presentation: [“Animal models of SARS-CoV-2 for vaccines and therapeutics”](https://www.dropbox.com/s/i6yt1mnt9rftgzk/Darryl%20Falzarano%204_17_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
| 24 |  | **Vineet Menachery PhD**, Assistant Professor, Department of Microbiology and Immunology,  UTMB Health – Link to Presentation: [“Age-dependent coronavirus disease”](https://www.dropbox.com/s/pgsvdiom6u48ifu/Vineet%20Menachery%204_27_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
|  |  |  |
| **May** 1 |  | **Marion Koopmans DVM, PhD,** Head of the Department of Viroscience, Erasmus MC –  The Netherlands – Link to Presentation**:** [“Precision public health: assessing the role of real-time whole genome sequencing and serology for decision support in COVID-19 epidemic response in The Netherlands”](https://www.dropbox.com/s/61chr4d19t3bu0p/Marion%20Koopmans%205_1_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
| 8 |  | **Adolfo Garcia-Sastre PhD**, Professor, Department of Microbiology and Director, [Global Health and Emerging Pathogens Institute](http://icahn.mssm.edu/research/global-health) of Icahn School of Medicine at Mount Sinai, New York – Link to Presentation: [“What respiratory viral pathogen research has taught us about COVID-19”](https://www.dropbox.com/s/u5sh8ey9ss0fozv/Adolfo%20Garcia-Sastre%205_8_2020%20Viroholics_COVID19_Edition.mp4?dl=0) |
| 15 |  | **Ralph Baric MD, PhD**, William R. Kenan, Jr. Distinguished Professor, Department of Epidemiology; Professor, Department of Microbiology and Immunology, University of North Carolina, Chapel Hill –  Title: **“Epidemic and Pandemic Coronaviruses”** (not recorded) |
| 22 |  | **Stanley Perlman MD, PhD**, Professor of Microbiology and Immunology; Professor of Pediatrics, University of Iowa Health Care, Carver College of Medicine – Link to Presentation:  [“COVID-19: What do we know about the human immune response, and what do we need to know?”](https://www.dropbox.com/s/eiqv21q7hkt1nj5/Stanley%20Perlman%205_22_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
| 29 |  | **Mark Denison MD**,Director, Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center – Link to Presentation: [“Why Basic Science Matters: Developing Antivirals against COVID-19 and Future Pandemic Coronaviruses”](https://www.dropbox.com/s/4ruvuubgr4botr9/Mark%20Denison%205_22_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |

|  |  |  |
| --- | --- | --- |
| **June** 5 |  | **Kanta Subbarao MBBS, MPH**, Director of the WHO Collaborating Centre for Reference and  Research on Influenza, Doherty Institute – Link to Presentation:  [“Vaccines and Immunotherapy for COVID-19: lessons from SARS and other respiratory viruses”](https://www.dropbox.com/s/y6bxn1rkbivzia1/Kanta%20Subbarao%206_5_2020_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
| 12 |  | **Tom Gallagher PhD**, Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Loyola University Chicago – Link to Presentation:  [“Coronavirus – Cell Entry Mechanisms”](https://www.dropbox.com/s/z91riz1cdn0epkx/Thomas%20Gallagher%206_12_20_ASU_Viroholics_COVID19_Edition.mp4?dl=0) |
| 19 |  | **Arizona COVID-19 Genomics Union:** Paul Keim PhD (NAU), Brendan Larsen (UA), Hayley  Yaglom, MS, MPH (TGen), and Jason Ladner PhD (NAU) – Link to Presentation:  [“Defining the Pandemic at the State Level: Sequence-Based Epidemiology of the SARS-CoV-2 virus by the Arizona COVID-19 Genomics Union (ACGU)”](https://www.dropbox.com/s/57lq99bnpjif7ct/ACGU%206_19_20_ASU_Viroholics_COVID-19_Edition.mov?dl=0) |
| 26 |  | **Janko Nikolich-Zugich MD, PhD**, Bowman Professor and Head, Department of Immunology;  Co-Director, University of Arizona Center on Aging, University of Arizona College of Medicine,  Tucson – Link to Presentation (recording pending): “Immune response to viral infections in older  adults: a backdrop to understand (parts of) host: SARS-CoV-2 interaction outcomes” |

**INVITED SEMINARS AND SYMPOSIUM TALKS:**

DNA Replication Mini symposium, C.F.B.S., Montreal, QC 1981

5th International Congress on Virology, Strasbourg, France 1981

Department of Microbiology, University of Saskatchewan, Saskatoon, SK 1981

Cold Spring Harbor Poxvirus/Iridovirus Symposium 1982

Department of Genetics, University of Alberta, Edmonton, AB 1982

Biomedical Research Discussion Group, University of Alberta, Edmonton, AB 1984

Cross Cancer Institute, Edmonton, AB 1984

American Society for Virology: Poxvirus Symposium, WI 1984

Department of Biochemistry, University of Alberta, Edmonton, AB 1984

Department of Microbiology, University of Western Ontario, London, ON 1985

Department of Pathology, University of Texas, Houston, TX 1986

Department of Microbiology, Dalhousie University, Halifax, NS 1986

Department of Medicine, Dalhousie University, Halifax, NS 1986

Department of Biology, St. Francis Xavier University, Sackville, NB 1986

Department of Microbiology, University of Florida, Gainesville, FL 1987

Gordon Conference (Cells and Animal Viruses), Tilton, VT 1987

Mt. Sinai Research Hospital, Toronto, ON 1987

Cold Spring Harbor Symposium on Eukaryotic DNA Replication, Cold Spring Harbor, NY 1987

Children's Hospital Medical Center, Boston, MA 1987

Department of Microbiology & Molecular Genetics, Harvard Medical School, Boston, MA 1987

Applied Biotechnology, Cambridge, MA 1988

Department of Microbiology, SUNY, Buffalo, NY 1988

Department of Biochemistry, McMaster University, Hamilton, ON 1988

Dana Farber Cancer Center, Boston, MA 1988

Department of Microbiology and Immunology, SUNY-HSCAB, Brooklyn, NY 1988

Cold Spring Harbor Laboratories, NY 1988

VII International Poxvirus/Iridovirus meeting, Heidelberg, Germany 1988

Regulation of Eukaryotic DNA Replication Meeting, McGill University, Montreal, QC 1989

Department of Genetics, University of Alberta, Edmonton, AB 1989

Center for Gene Research, Oregon State University, Corvallis, CO 1990

Red Cross Transfusion Center, University of Alberta, Edmonton, AB 1990

Meeting on Signal Transduction in Normal and Cancer Cells, Banff, AB 1991

Eastern Canadian Conference on Development and Cancer, Montreal, QC 1991

Department of Plant Pathology, University of Nebraska, Lincoln, NE 1991

AHFMR Symposium on the Molecular Biology of Cancer, Calgary, AB 1991

Department of Biochemistry, UBC, Vancouver, BC 1992

Department of Immunology, University of Toronto, Toronto, ON 1992

ACB Symposium on Cancer Research, Banff, AB 1992

Department of Immunology, University of Alberta, Edmonton, AB 1993

Department of Microbiology, U. of Minnesota, Minneapolis, MN 1993

CSIRO, Canberra, Australia 1993

Australian National University, John Curtin School of Medical Research, Canberra, Australia 1993

2nd Meeting on Signal Transduction in Normal and Cancer Cells, Banff, AB 1993

Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan 1993

Fundacion Juan March Workshop, Madrid, Spain 1993

DNAX Corp., Palo Alto, CA 1993

Department Microbiology & Molecular Genetics, Harvard Medical School, Boston, MA 1994

Royal Society of Medicine, London, U.K. 1994

Zymogenetics, Inc., Seattle, WA 1994

Biogen Corp., Cambridge, MA 1994

Cytokine Research Group, University of Alberta, Edmonton, AB 1994

Department of Microbiology and Immunology, Stanford, CA 1994

Department of Anatomy and Cell Biology, University of Alberta, Edmonton, AB 1994

Department of Clinical Biochemistry, University of Toronto, Toronto, ON 1994

2nd International Cytokine Conference, Banff, AB 1994

Upjohn/University of Western Michigan, Kalamazoo, MI 1994

ACB Research Meeting, Calgary, AB 1994

Cross Cancer Institute, Edmonton, AB 1994

Department of Microbiology & Immunology, University of Western Ontario, London, ON 1994

Department of Biology & Pathology, McMaster University, Hamilton, ON 1994

AACR Meeting on Signal Transduction, Banff, AB 1995

9th International Congress of Immunology, San Francisco, CA (Symposium lecture) 1995

Australian Microbial Society Meetings, Canberra, Australia (Symposium lecture) 1995

American Society for Virology, Austin, TX (Plenary lecture) 1995

ICAAC Meeting on Infectious Diseases, San Francisco, CA (Symposium lecture) 1995

Department of Microbiology, UCLA, Los Angeles, CA 1995

John Curtin School of Medicine, Canberra, Australia 1995

Ludwig Cancer Institute, Melbourne, Australia 1995

Cybercongress on Transplantation in the Next Millennium, Washington, D.C. (Plenary Lecture) 1995

Symposium on Immunobiology of Viral Infections, Turku, Finland (Symposia lecture) 1995

Third Bristol-Myers Squibb Symposium on Infectious Diseases, New York (Symposia Lecture) 1995

The John P. Robarts Institute for Medical Research, London, ON 1995

Transplantation Division, University of Miami, Miami, FL 1996

Int Symposium on the Chemistry and Biology of Serpins, Chapel Hill, NC (Symposia lecture) 1996

Hammersmith Hospital, London, UK 1996

Department of Microbiology, Dalhousie University, Halifax, NS 1996

Scripps Research Institute, La Jolla, CA 1996

FASEB Conference on Pathogenesis, Snowmass, CO (Symposium) 1996

6th International TNF Congress, Rhodes, Hellas (Plenary) 1996

Biotechnology Laboratories, University of British Columbia, Vancouver, BC 1996

London Regional Cancer Centre, London, ON 1997

ASM Regional Meeting, Phoenix, AZ (Plenary) 1997

Department of Microbiology, University of Arizona, Tempe, AZ 1997

Department of Biochemistry, McMaster University, Hamilton, ON 1997

Gordon Conference on Viruses, Tilton, NH (Invited) 1997

MOTS Research Forum, London, ON 1997

Discovery Lecture Series, The John P. Robarts Research Institute, London, ON 1997

Department of Molecular Oncology, MD Anderson Cancer Center, Houston, TX 1997

Department of Biochemistry, SUNY Buffalo, NY 1997

Department of Biochemistry, University of Toronto, ON 1997

CAT/CTS Annual Meeting, Vancouver, BC (Invited) 1997

Banff Signal Transduction Meeting, Banff, AB (Invited) 1998

Virology Lecture Series, Harvard Medical School, Boston, MA (Invited) 1998

Second Joint International Cytokine Meeting, Jerusalem, Israel (Plenary) 1998

Cleveland Clinic Foundation, Cleveland, OH (Invited) 1998

Canadian Society of Microbiology Meeting, Guelph, ON (Symposium) 1998

Gordon Conference on Chemokines, Vermont (Symposium) 1998

American Society of Virology Meeting, Vancouver, BC (Plenary) 1998

Department of Microbiology and Immunology, McGill University, Montreal, PQ 1998

Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, ON 1998

Institute for Allergy and Immunology, La Jolla, CA 1998

AACR Meeting on Cancer and Viruses, Dana Point, CA (Symposium) 1998

American Society of Virology Meeting, Atlanta, GA (Colloquium speaker) 1998

Department of Chemistry, University of Wisconsin, Milwaukee, WI 1998

Neurovir Corporation, Vancouver, BC 1998

Department of Biochemistry, University of British Columbia, Vancouver, BC 1998

Department of Biological Regulation, Weizmann Institute, Israel 1998

Department of Microbiology, University of Wisconsin, Milwaukee, WI 1998

Institute of Medicine Public Hearings on Variola, Washington, DC 1998

Department of Biological Science, University of Guelph, Guelph, ON 1998

Dept of Pathology and Lab Medicine, Medical University of South Carolina, Charleston, SC 1999

Canadian Society of Immunology, Lake Louise, AB (Symposium) 1999

Keystone Meeting on Chemokines, Keystone, CO (Symposium) 1999

Department of Biochemistry and Microbiology, University of Ottawa, Ottawa, ON 1999

American Society of Microbiology Meeting, Chicago, IL (Symposium) 1999

Department of Molecular Microbiology & Immunology, OHSU, Portland, OR 1999

International Congress on Cytokines, Chemokines, Bethesda, MD (Symposium) 1999

Department of Biochemistry, University of Western Ontario, London, ON 1999

American Society Histo Immunogenetics, Meeting, New Orleans, LA (Plenary) 1999

Institute of Molecular Biology, Academica Sinica, Taipei, Taiwan 1999

Department of Immunology, University of Toronto, Toronto, ON 1999

Department of Microbiology, University of California, San Francisco, CA 1999

Department of Medicine, University of Pennsylvania, Philadelphia, PA 2000

Department of Genetics, Yale University, New Haven, CT 2000

Department of Biology, McMaster University, Hamilton, ON 2000

Gordon Conference on Chemokines, Kimball, NH (Invited) 2000

American Society for Microbiology, Los Angeles, CA (Symposium) 2000

Clinical Research Institute, Montreal, PQ (Marcel Piché Lecture) 2000

Department of Medical Microbiology, University of Manitoba, MB (Retreat Speaker) 2000

Institute of Molecular Virology, University of Wisconsin, Madison, WI 2000

Wadsworth Center, New York Department of Health, Albany, NY 2000

Third International ICS/ISICR Congress (Symposium), Amsterdam 2000

Department of Pathology & Medical Microbiology, Washington University, St. Louis, MO 2000

Department of Microbiology, St. Louis University, St. Louis, MO 2001

Cellular Signalling Meeting, Banff, AB (Invited Speaker) 2001

American Association of Immunologists Meeting, Orlando, FL (Symposium) 2001

Int’l Cytokine Society/Society for Leukocyte Biology Meeting, Maui, HI (Symposium) 2001

Millennium Institute, Sydney, Australia 2001

American College Veterinary Pathology annual meeting, Salt Lake City (Symposium) 2001

ISICR, Annual General Meeting, Cleveland, OH 2001

Gilead Sciences, Foster City, CA (Invited speaker) 2001

Department of Cancer Biology, Cleveland Clinic, OH 2001

Infectious Diseases Society of America Annual Meeting, San Francisco, CA (Symposium) 2001

London Regional Cancer Centre, London, ON 2001

NIH Viral Evasion Workshop, Baltimore, MD (Invited speaker) 2001

Juan Marche Symposium, Madrid, Spain (Invited Speaker) 2002

ASM Conference, Savannah, GA (Invited Speaker) 2002

Department of Molecular & Cellular Biology, Berkeley, CA 2002

European Chemokine Symposium, Madrid, Spain (Invited Speaker) 2002

Vaccine and Gene Therapy Institute, Portland, Oregon 2002

Department of Microbiology, Mt. Sinai School of Medicine, New York 2002

Department of Microbiology & Immunology, Albert Einstein College of Medicine, N.Y. 2002

Lady Davis Research Institute, Montreal, PQ 2002

Department of Medical Genetics & Microbiology, University of Toronto, ON 2002

Infection and Immunity Institute, London, ON (Invited Speaker) 2002

Brazilian Society of Virology, Bahia (Symposium) 2002

Glenmore lecture, The John P. Robarts Research Institute, London, ON 2002

Dept. Microbiology, New York University, New York, NY 2002

Ottawa Health Research Institute, Ottawa, ON 2002

New York University, Department of Microbiology, New York 2002

University of Cambridge, Department of Medicine, U.K. 2002

Gordon Conference on Cells and Viruses, Il Ciocco Italy (Invited speaker) 2003

Immunology Program, Washington University, St. Louis, MO (Invited speaker) 2003

Harvard, Department of Microbiology and Molecular Genetics, Boston, MA 2003

Oncolytic Viruses meeting, Banff, AB (Invited speaker) 2003

Rockefeller University, New York, NY (Invited speaker) 2003

American Society of Virology meeting, U. of California, Davis, CA (Symposium speaker) 2003

Vanderbilt, Dept. Microbiology & Immunology 2003

UWO Conference, Averting Disasters, London (Invited speaker) 2003

Dept. Molecular Biology and Genetics, Guelph University 2003

NIH Symposium on Cytokine Mimicry, Bethesda, MD (Plenary speaker) 2003

Aventis Biotech Challenge, London, ON (Invited speaker) 2003

NIAID, Montana (Invited speaker) 2003

Scripps, La Jolla (Invited speaker) 2004

Keystone Symposium on Pathogen-Host Standoff, Taos, NM (Symposium speaker) 2004

ASM Symposium on Host Evasion, New Orleans (Symposium speaker) 2004

NIAID Symposium on Viral Pathogenesis, Bethesda, MD (Invited speaker) 2004

New Zealand Society for Biochem and Mol. Biol. meeting, Queenstown, NZ (Plenary) 2004

ASM Biodefense Research Meeting, Baltimore, MD (Plenary speaker) 2004

Therapeutics Congress, Winnipeg, MB (Invited speaker) 2004

ICI/FOCIS Symposium on Virus-Host Interactions, Montreal (speaker) 2004

University of Delaware, Dept. Biol. Sciences (invited speaker) 2004

Genetics Institute, U of Florida, Gainesville, FL (invited speaker) 2004

Dept. Micro, U of Western Michigan, Kalamazoo (invited speaker) 2004

Dept. Biochemistry, SUNY, Buffalo (invited speaker) 2004

Robarts Research Institute, Taylor Symposium (speaker) 2004

Dept. Microbiology & Immunology, University of Otago, Dunedin, NZ (invited speaker) 2004

U of Florida, Faculty of Medicine, Gainesville, FL (invited speaker) 2005

U of Toronto, Dept. Immunology (invited speaker) 2005

International Congress of Virology, San Francisco, CA (Plenary speaker) 2005

ASM Viral Evasion meeting, Acapulco (Plenary speaker) 2005

Mass General Hospital, Boston, MA (invited speaker) 2005

MITRE Symposium on Viral Pathogens, McLean, VA (invited speaker) 2005

NIAID Poxvirus Symposium, Bethesda, MD (invited speaker) 2005

Dana Farber Institute, Harvard, Boston (invited speaker) 2005

Mayo Clinic, MN USA (invited speaker) 2005

MRCE Annual meeting, St. Louis (keynote speaker) 2005

Sloan-Kettering Cancer Institute, NYC (invited speaker) 2005

U. Calgary, Dept. Microbiology (invited speaker) 2005

International Congress of Virology, San Francisco (Plenary speaker) 2005

Myriad Corp., Salt Lake City, Utah (invited speaker) 2005

Center for Vaccines and Immunity, Ohio State U., Columbus (invited) 2005

NIAID Workshop on Emerging Viruses, Bethesda, MD (invited) 2005

ASM Biodefense Meeting, Washington, DC (invited speaker) 2006

Dept. Mol. Cell Biol and Immunology, VU University, Amsterdam (invited speaker) 2006

Dutch Society for Microbiology, Arnhem, Netherlands (plenary speaker) 2006

Dept. Microbiology, U of Colorado (invited speaker) 2006

Dept. Microbiology & Immunology, U of Arkansas, Little Rock, AK (invited speaker) 2006

Canadian Society of Microbiology Annual meeting, London (symposia speaker) 2006

FASEB Poxvirus Workshop, Indian Wells, CA (invited speaker) 2006

ImmuNet Retreat, U of Alberta, Edmonton (invited speaker) 2006

Dept. Microbiology & Immunology, U Texas Health Science Center, San Antonio (invited) 2006

Frontiers of Clinical Medicine Symposium, LaJolla, CA (invited speaker) 2006

Ernst Klenk Symposium, Cologne, Germany (invited speaker) 2006

American Academy of Microbiology Colloquium, Charleston, SC (invited speaker) 2006

HHMI Scientific meeting, Virginia (invited speaker) 2006

Science for Life Mini-Symposium on Emerging Pathogens, U of Florida (invited speaker) 2006

Frontiers of Clinical Investigation: Host Defense 2006, U California, San Diego (invited) 2006

College of Vet. Med., U of Florida (invited) 2006

BioFlorida Conference, Gainesville FL (invited) 2006

CFBS Northern Lights Meeting on Infection & Immunity, Ottawa, Canada (invited speaker) 2006

26th Annual ASV Meeting, Corvallis, Oregon (plenary speaker) 2007

5th Biodefense & Emerging Diseases Research Mtg, Washington, DC (invited speaker) 2007

Lady Davis Research Institute, Montreal (invited speaker) 2007

107th ASM Meeting, Toronto (symposia speaker) 2007

Gordon Conference on Biodefense, Ventura, CA (invited speaker) 2007

Emory Univ., Frontiers in Microbial Genetics & Pathogenesis, Atlanta GA (invited speaker) 2007

4th Oncolytic Virus Meeting, Carefree, AZ (invited speaker) 2007

University of Illinois, Urbana-Champaign, IL (invited speaker) 2007

Miami 2007 Winter Symposium, Miami, FL (invited speaker) 2007

HHMI Investigators’ Meeting, Chevy Chase, MD (invited speaker) 2007

University of British Columbia, Vancouver, BC, Canada (invited speaker) 2007

Institut de recherché cliniques de Montreal (IRCM), Montreal, Canada (invited speaker) 2007

Duke Univ. Mini-symposium on Pathogenic Human Viruses, Durha, NC(invited speaker) 2007

5th International Conference on Kinase Inhibitors, Warsaw, Poland (invited speaker) 2007

Scripps Florida, Jupiter, FL (invited speaker) 2007

University of Alabama, Dept. of Microbiology, Birmingham, AL (invited speaker) 2007

NIAID, Laboratory of Viral Diseases, Bethesda, MD (invited speaker) 2007

University of Pennsylvania, Dept. of Microbiology, Philadelphia, PA (invited speaker) 2007

NIH Biodefense Programmatic Meeting, Salt Lake City, UT (invited speaker) 2007

North Carolina State University Virology group, Durham, NC 2007

Keystone Symposium on Viral Immunity, Keystone, CO (invited speaker) 2008

New England Regional Center of Excellence for Biodefense & Emerging Infections   
Seminar, Harvard University, Boston, MA (invited speaker) 2008

German Society of Virology, Heidelberg, Germany (keynote lecturer) 2008

Emory University, Atlanta, GA (invited speaker) 2008

Society of General Microbiology Viral Group, Edinburgh, Scotland (plenary speaker) 2008

SE Regional Virology Conference, Atlanta, GA (invited speaker) 2008

Keystone Symposium, Cell Biology of Virus Entry, Replication & Pathogenesis,   
Victoria, British Columbia, Canada (invited speaker) 2008

University of TX Medical Branch, Depts of Pathology and Microbiology & Immunology   
and WHO Collaborating Center for Tropical Diseases lecture series (invited speaker) 2008

Microbiology & Cell Science Department Seminar, University of Florida (invited speaker) 2008

FOCIS Meeting, Boston, MA (symposium speaker) 2008

Poxvirus & Iridovirus Conference, Grainau, Germany (speaker) 2008

HHMI International Scholars meeting, Lisbon, Portugal (speaker) 2008

LaJolla Institute for Allergy & Immunology Seminar, LaJolla, CA (invited speaker) 2008

IAVI’s Frontiers in AIDS Vaccine Development Seminar, NY, NY (invited speaker) 2008

Inst of Medicine Workshop on Assessment of Future Needs for Live Variola Virus,   
Washingon, DC (invited speaker) 2008

Tampa Bay Research Institute Seminar, Tampa, FL (invited speaker) 2008

ICS/ISICR Cytokines 2008 Joint meeting, Montreal, Quebec, Canada (symposia speaker) 2008

Louisiana State University, New Orleans, LA (invited speaker) 2008

University of Mississippi Seminar, Jackson, MS (invited speaker) 2008

Wake Forest University School of Medicine, Winston-Salem, NC (invited speaker) 2008

UF Shands Cancer Center, University of Florida, Gainesville, FL (seminar speaker) 2008

Dutch Annual Virology Symposium, Amsterdam, the Netherlands (Symposium lecturer) 2009

5th Int’l Meeting on Replicating Oncolytic Virus Therapies, Alberta, Canada (invited speaker) 2009

Univ. of North Carolina Virology Symposium, Chapel Hill, NC (invited speaker) 2009

Univ. of Massachusetts Immunology Virology Seminar, Worcester, MA (invited speaker) 2009

Stanford, Dept. of Microbiology & Immunology, Stanford, CA. (invited speaker) 2009

MedImmune Corp., Mountainview, CA (invited speaker) 2009

McMaster University, DeGroote Institute, Hamilton, Ontario, Canada (invited speaker) 2009

Indiana University, Dept. of Biology, Bloomington, IN (invited speaker) 2009

University of Wisconsin, Dept. of Micro & Molecular Genetics, Milwaukee, WI (invited speaker) 2009

University of Connecticut, Dept. of Pathobiology & Vet. Science, Storrs, CT (invited speaker) 2009

University of Maryland, Med. School, Dept. of Microbio. & Imm., Baltimore, MD (invited speaker) 2010

University of Maryland, Dept. of Cell Biology and Mol. Gen., College Park, MD (invited speaker) 2010

University of Florida Cancer Institute, Gainesville, FL (invited speaker) 2010

ASV Medical Virology Club, Bozeman, Montana (symposium speaker) 2010

UF Dermatology Grand Rounds, Gainesville, FL (invited speaker) 2010

Terry Fox Cancer Research Labs, Vancouver, BC (invited speaker) 2010

BC Preclinical Research Symposium, Vancouver, BC (plenary speaker) 2010

Florida State U, Fowler Symposium on Host-microbe Interactions, Tallahassee, FL (Symposium) 2010

AMSMIC Meeting, St. Maartens (invited Speaker) 2011

Virology Seminar Series, Dept. Micro & Imm., U. Rochester (invited speaker) 2011

Penn State University, Dept. Microbiology, Hershey, PA (invited) 2011

Keystone Symposium, “Drugs from Bugs,” Snowbird, Utah (Symposium speaker) 2011

St. Louis University, Dept. of Mol. Micro & Immunology, St. Louis (invited speaker) 2011

University of Rochester, Dept. Micro & Immunology, Rochester (invited speaker) 2011

6th International Oncolytic Virus Meeting, Las Vegas (Symposium speaker) 2011

University of Alabama, Dept Microbiology, Birmingham, AL (Invited speaker) 2011

Am. Society of Gene & Cell Therapy Meeting, Seattle, WA (symposia speaker) 2011

University of Washington, Department of Immunology, Seattle (Invited speaker) 2011

Italian Veterinary Virology Workshop, Brescia, Italy (plenary speaker) 2011

U Kansas, Kansas City, Remi Amelunxen Symposium (Keynote speaker) 2011

Intl. Hepatitis B Meeting, Orlando, Florida (Keynote speaker) 2011

Brazilian Virology Society meeting, Sao Paulo, Brazil (Symposia speaker) 2011

Instituto de Biofisica Carlos Chagas Filho, Univ. Federal do Rio de Janeiro, Brazil (invited seminar) 2011

Cornell Program in Infection and Pathobiology, Ithica, NY (invited speaker) 2011

FSU College of Medicine, Tallahassee (Grand Rounds) 2011

Academia Sinica, Taipei, Taiwan (invited seminar) 2012

Mt Sinai School of Medicine, Dept Microbiology, NYC (invited speaker) 2012

Dutch Society of Microbiology Society, Arnhem, Netherlands (Plenary Speaker) 2012

Moffit Cancer Center, Tampa (Invited Grand Rounds speaker) 2012

Banff Conference on Infectious Diseases, Banff, Alberta (Symposium speaker) 2012

Helmholtz Centre for Infection Research, Hannover Medical School (Invited lecture) 2012

FEBS Summer School, Spetses, Greece (Invited lecture) 2012

Division of Biology, Kansas State U, Manhatten, KS (Invited speaker) 2012

Nebraska Center for Virology, Lincoln, Nebraska (Symposium Speaker) 2012

SIU School of Medicine, Dept. Microbiology, Immunology and Cell Biology (Invited Speaker) 2012

Lecturer, Viruses & Immunity, Ecole Normale Superieure, Lyon, France (Invited lecturer) 2013

Mol. Genetics & Micro Program, SUNY, Stony Brook ((Invited by Graduate Students) 2013

Gordon Conference on Cells & Viruses, Il Chioco, Italy (Invited speaker) 2013

NIH Rocky Mountain Labs, Jackson, Montana (Invited speaker) 2013

Replicating Oncolytic Virus Therapeutics 2013, Quebec City, Canada (Invited speaker) 2013

Wexner Medical Center, Ohio State University, Columbus, Ohio (Invited Speaker) 2013

NIH Workshop, Oncolytic Viruses and Stem Cells, Bethesda, Md 2013

International Cytokine Society (ICS) and International Society for Interferon and Cytokine

Research (ISICR) Annual Joint Meeting, San Francisco, CA (Invited Speaker) 2013

Dept. Microbiology & Immunology, U Illinois, Chicago, IL (Invited speaker) 2013

VTGI Florida Symposium, Port St Lucie, FL (Plenary Speaker) 2013

Fred Hutchinson Cancer Research Center, Seattle (Invited Speaker) 2013

Dept. Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN (Invited Speaker) 2014

Medical University of Vienna, 7th International Workshop, Austria (Keynote Speaker) 2014

Dept. Microbiology-Immunology, Northwestern University, Chicago (Invited Speaker) 2014

International Congress of Virology, Montreal (Oral presentation) 2014

MD Anderson Cancer Center, Houston, Texas (Invited speaker) 2014

Center for Infectious Disease Dynamics, Penn State U, University Park, PA (Invited speaker) 2014

20th International Poxvirus, Asfarvirus and Iridovirus Meeting, Victoria, BC (Oral presentation) 2014

DNAtrix Board meeting, San Francisco (invited presentation) 2015

School of Life Sciences, Arizona State University, Tempe, AR (Invited speaker) 2015

Dept. Biological Sciences, U Western Michigan, Kalamazoo, MI (Invited speaker) 2015

9th International Conference on Oncolytic Virus Therapeutics, Boston, MA (speaker) 2015

Virginia Tech University VTLSS seminar series, Blacksburg, VA (Invited Speaker) 2015

Dept Biochemistry and Molecular Biology, U Florida (Invited speaker) 2015

Cancer Research Institute, U Florida (Invited speaker) 2015

Graduate Program in Molecular Genetics, University of Toronto (Invited speaker) 2015

XXVI Brazilian Congress of Virology meeting, Florianopolis, Brazil (Symposia speaker) 2015

Dept Microbiology and Immunology, Dalhousie U, Halifax, Nova Scotia (Invited speaker) 2015

UF Hematological Malignancies and BMT Research Retreat, UF (Invited speaker) 2015

Moffit Cancer Center Oncolytic Virus Summit, Tampa (Invited speaker) 2015

Oncolytic Virotherapy Summit, San Francisco, CA (Invited speaker) 2015

UCSD seminar series, San Diego (Invited Speaker) 2015

CIRI, INSERM, Lyon, France (Invited Speaker) 2016

Dept. Molecular Genetics, University of Toronto (Invited speaker) 2016

Institute for Molecular Virology Symposium, U Minnesota, Minneapolis (Keynote speaker) 2016

Canadian Society for Virology meeting, Blacksburg, Virginia (Keynote Lecturer) 2016

Vaccine and Gene Therapy Institute, OHSU, Portland (Invited speaker) 2016

Dept. Micro. & Mol. Genetics, Medical College of Wisconsin, Milwaukee (invited speaker) 2016

2nd Int Symposium on Oncogenic Viruses & Drug Discovery, Nanjing, China (Keynote speaker) 2016

Mayo Clinic, Scottsdale, Dept Medicine (guest speaker) 2017

Barrow Neurological Institute (BNI), St Joe’s Dignity Hospital, Phoenix (invited speaker) 2017

SOLS, ASU, Tempe (noontime seminar speaker) 2017

American Society for Gene and Cell Therapy, Washington, DC (Symposia speaker) 2017

Pfizer, San Francisco (Invited Speaker) 2017

Translational Genomic Research Institute (TGen), Phoenix, AZ (Invited Speaker) 2017

IUMS/International Congress of Virology, Singapore (Keynote speaker) 2017

NCI SBIR Development Meeting, Washington, DC (Invited Speaker) 2017

University of Arizona, Dept Immunobiology, Tucson, AZ (Invited Speaker) 2017

Buller Memorial Symposium, St Louis U School of Medicine, St Louis, MO (Invited Speaker) 2017

Honor Health/TGen, Phoenix, AZ (Invited Speaker) 2017

U Arizona Cancer Symposium, U Arizona College of Medicine, Phoenix, AZ (Invited Speaker) 2017

Infectious Disease Research Day Symposium, U Kentucky, Lexington, KY (Invited Speaker) 2017

University of California Irvine, Dept Micro & Molecular Genetics, Irvine, CA (Invited Speaker) 2017

Dept Microbiology, U Texas SW, Dallas, TX (Invited speaker) 2017

Dept. Basic Mol Sciences, U Arizona, Phoenix, AZ (Invited Speaker) 2018

Dept. Micro & Immunology, Wake Forest School of Medicine, Winston-Salem, NC (Invited) 2018

International Oncolytic Virus Conference, Oxford, UK (Symposia Speeaker) 2018

Dept. Medical Microbiology and Immunology, U California, Davis (Invited Speaker) 2018

US Oncology Research Advanced Therapeutics Program Meeting, San Diego (Invited Speaker) 2018

Multiple Myeloma SPORE retreat, Mayo Clinic, Rochester, Minnesota (Invited) 2018

Dept. Biological Sciences, U Western Michigan, Kalamazoo, MI (Invited speaker) 2018

Mayo Clinic, Rochester, Minneapolis (Invited Speaker) 2018

Microbial Pathogenesis Retreat, U Utah School of Medicine, Salt Lake City, Utah (Invited speaker) 2018

Dept Microbiology & Immunol., Indiana U School of Medicine, Indianapolis, IN (Invited speaker) 2019

University of Virginia Cancer Center, U of Virginia, Charlottesville, VA (Invited Speaker) 2019

Galveston National Laboratory, University of Texas, Galveston, TX (Invited Speaker) 2019

Microbiology and Molecular Genetics Program, Emory University, Atlanta, GA (Invited Speaker) 2019

Cancer Biology Program, U of Arizona, Tucson (Invited Speaker) 2019

Mayo Clinic Individualized Medicine Conference, Scottsdale, AZ (Invited Speaker) 2019

Department of Microbiology, Harvard Medical School, Boston, MA (Invited Speaker) 2019

**In early 2020, I ceased all professional travel for the remainder of the COVID-19 pandemic.**

**Zoom-based Seminars (2020-present):**

Drug Discovery Symposium, Phoenix, AZ (Invited Speaker) 2020

XFEL Seminar Series, Phoenix, AZ (Invited Speaker) 2020

ReImagine Health Symposium, University of Arizona, Phoenix, AZ (Invited Speaker) 2021

AAAS 2021 Annual Meeting (Virtual), Phoenix, AZ (Invited Speaker) 2021

Sips for Science (Virtual), Phoenix, AZ (Invited Speaker) 2021

6th Warsaw Conference on Perspectives of Molecular Oncology (Invited Speaker) 2021

ASU Biodesign-China Joint Symposium (Invited Speaker) 2022

**RECORD OF PREVIOUS GRANT SUPPORT (Canada):**

**Year Agency Nature of Grant Amount Granted**

1981-82 AHFMR Establishment $ 136,818

# 1982 AHFMR Equipment 31,242

1981-83 PCHB Operating 61,607

1981-83 U of A Hospital EBV Serology Contract 13,195

1983-85 U of A CRF 5 Short Term Operating 23,413

1981-1996 AHFMR Post-Doctoral Allowances 61,000

(A. Delange; C. Upton; W. Block;

L. Sedger; M. Barry)

1984-1996 AHFMR Grad. Student Allowances 44,500

(C. Macaulay; A. Opgenorth;

D. Stuart; J. Macen; M. Schreiber;

K. Mossman; P. Nash; A. Lalani)

1986-87 ACB Operating 44,563

1991 AHFMR/CCS Renovation Funds 198,000

# 1993 AHFMR Conference Grant 10,000

1994-1995 AHFMR Technology Transfer Grant (phI) 25,000

1995-1997 BIOGEN Operating 170,000

1997-1998 RRI Establishment 150,000

1983-1999 CIHR (Telomeres) Operating 92,000 p.a.

2000-2003 CIHR (Chemokine Receptors) Operating 96,242 p.a.

1981-2007 NCI (Anti-Immune Proteins) Operating 150,000 p.a.

1996-2007 CIHR (Anti-Immune Proteins) Operating 233,731 p.a.

1997-2009 CIHR (Signaling) Operating 167,115 p.a.

1997-2007 Viron Therapeutics Contract 177,00 p.a.

2000-2007 NCE (CANVAC) Operating 84,000 p.a.

2001 CFI (CRC) Equipment 387,000 (one time)

2003-2004 SAVI Operating 40,000 p.a.

2004-2006 Myriad Corporation Contract 80,000 p.a.

2005-2006 Wellstat Contract 125,000 p.a.

2005-2007 HHMI Operating 100,000 US p.a.

2002-2007 NCIC Operating 150,000 p.a.

2004-2007 NCIC Operating $65,000 p.a.

**RECORD OF COMPLETED RESEARCH SUPPORT (United States):**

**McFadden Lab Completed Operating Grant Support (U.S.)**

1- Agency: University of Florida

Term: 5 years (2006-2011)

Amount: $4,100,000 over five years – Start-up Package

2- Agency: Myriad Corp.

Title: Biodefense and Emerging Disease Validation

Current grant: 2 years (4/1/07 – 3/31/09)

Amount: $122,000 p.a. (U.S.) (direct costs)

3- Agency: Viron Therapeutics, Inc.

Title: Discovery of Virus-derived Biotherapeutics

Current grant: 2 years (7/1/07 – 6/30/09)

Amount: $80,000 p.a. (U.S.) (direct costs)

4- Agency: SERCEB / U of North Carolina, Chapel Hill

Title: Monkeypox virus protein interactions with the human inflammasomes

Current grant: 1 year (3/1/08 – 2/28/09)

Amount: $150,000 p.a. (U.S.) (direct costs)

5- Agency: SERCEB (U54 AI057157) U of North Carolina, Chapel Hill

Title: NAPPA Core for Pathogenic Human Viruses

Current grant: 2 years (3/1/09 – 2/28/11)

Amount: $100,000 p.a. (U.S.) (direct costs)

6- Agency: NCI (R21 CA149869)

Title: Virotherapy for pancreatic cancer with WT and armed MYXV

Current grant: 2 years (1/1/11 – 12/31/12) (PI: McFadden)

Amount: $130,500 p.a. (U.S.) (direct costs)

7- Agency: Bankhead-Coley Cancer Research Program (1BT02)

Title: Exploiting Oncolytic Virotherapy to Selectively Target Human Hematopoietic Cancer Stem Cells

Current grant: 3 years (7/1/10 – 6/30/13) (PI: McFadden)

Amount: $434,783 p.a. (U.S.) (direct costs)

8- Agency: NCI Phase I STTR (R41CA179706-01A1)

Title: Ex vivo purging strategy for treatment of multiple myeloma

Current grant: 1 year (6/1/14 – 5/31/15) (Sponsor: DNAtrix Corp, PI: McFadden)

Amount: $160, 632 p.a. (U.S.) (total costs); $64,429 pa (UF direct costs)

9- Agency: NCI (R01 CA13854-01)

Title: Myxoma Virus (MV) Oncolysis for Treating Human Cancer

Current grant: 4 years, 10 months (3/1/10 – 12/31/14) (PI: McFadden)

Amount: $197,587 p.a. (U.S.) (direct costs)

10- Agency: DNAtrix Corp (Sponsored Research Agreement at UF)

Title: Exploiting Oncolytic Myxoma Virus

Current grant: 2 years (5/1/15 – 5/1/17) (PI: McFadden)

Amount: $166,667 total direct costs in Yr1 (U.S.)

11- Agency: James Ester King Biomedical Research Program (5JK04)

Title: First-of-its-kind study of oncolytic virotherapy for small cell lung carcinoma

Current grant: 3 years (5/25/15 – 5/15/18) Renewall (PI: F. Kaye) (McFadden Subproject)

Amount: $367,234 for 3 years: $122,411 p.a. (U.S.) (direct costs)

12- Agency: NIAID (R01AI100987-01A1)

Title: Manipulation of inflammasomes and NF-κB signaling in human myeloid cells by Myxoma Virus

Current grant: 5 years (1/1/13 – 12/31/17) (PI: McFadden) (No Cost Extension-12/31/18)

Amount: $250,000 p.a. (U.S.) (direct costs)

13- Agency: NIAID (R01 AI080607)

Title: Studies in Poxvirus Host Range Genes and Tropism

Current grant: 5 years (2/28/09 – 2/28/14) Renewal: (12/1/14-11/30/19) (PI: McFadden)

(no cost extension approved for 11/30/19-11/30/20)

Amount: $250,000 p.a. (U.S.) (direct costs)

14- Agency: Mayo Clinic Multiple Myeloma SPORE (P50-CA186781-A1)

Title: Oncolytic Virotherapy with Myxoma Virus (Development Research Award)

Current grant: 2 years (09/1/17 – 08/31/19) (Subcontract PI: McFadden)

Amount: $50,000 p.a. (U.S.)

15- Agency: Amgen (Sponsored Research Agreement)

Title: Testing of COVID-19 monoclonal antibodies against SARS CoV-2

Current grant: 0.5 year (06/1/20 – 11/30/20) (PI: McFadden)

Amount: $221,775 (U.S.)

16- Agency: SkySong Innovations (Catalyst award)

Title: Development of an intranasal COVID-19 vaccine that exploits SARS-CoV-2 Virus-like Particles

Current grant: 1 year (05/1/20 – 04/30/21) (PI: McFadden)

Amount: $72,300 (U.S.) (For BSL3-level equipment)

17- Agency: Arizona State University/Biodesign Institute

Title: Startup grant and Core Facility

Current grant: Up to 5 years (11/1/16 – 11/1/21) (PI: McFadden)

Amount: $2 million startup + $1 million Core (total U.S.)

18- Agency: Fast Grants (https://fastgrants.org/)

Title: Development of an intranasal COVID-19 vaccine that exploits SARS-CoV-2 Virus-like Particles

Current grant: 1 year (05/1/20 – 09/30/21) (PI: McFadden)

Amount: $200,000 (total U.S.)

**McFadden Lab Current Operating Grant Support (U.S.)**

1. Agency: OncoMyx Therapeutics (Sponsored Research Agreement)

Title: Oncolytic Virotherapy with Armed Myxoma Virus

Current grant: 3 years (06/1/19 – 05/31/22) (PI: McFadden)

Amount: $300,000 p.a. (total U.S.)

1. Agency: NIAID (R01 AI148302-01)

Title: Viral inhibition of cell death in host immune response (PI: F Chan)

Current grant: 5 years (6/22/20 – 5/31/25) (Sub Co-PIs: G McFadden and M Rahman)

Amount: $250,000 p.a. (U.S.) (total direct costs per year)

1. Agency: NIAID (R21 AI 163910-01)

Title: Unravelling the mechanisms of virus host species jump

Current grant: 2 years (5/26/21 – 4/30/23) (Co-PIs: G McFadden, A Varsani and

M Rahman)

Amount: $150,000 p.a. (U.S.) (total direct costs per year

4. Agency: NIAID (R01 AI080607)

Title: Studies in poxvirus host range genes and tropism

Current grant: 5 years (6/23/21 – 5/31/26) (Co-PIs: G McFadden and M Rahman)

Amount: $250,000 p.a. (U.S.) (total direct costs per year)

**PATENTS:**

1994 (filed April 8, 1994) SERP-1 anti-restenosis protein

(Awarded November 11, 1997 (jointly with Dr. A. Lucas)

United States Patent #: 5,686,409)

(European Patent EP-0-754-054

awarded November 23, 2001)

1995 (filed March 27, 1995) Methods of treating inflammation and compositions thereof

(Awarded June 29, 1999 (jointly with Dr. A. Lucas)

United States Patent #: 5,917,014)

1995 (filed April 19, 1995) Chemokine binding protein and methods of use thereof

(Awarded November 10, 1998 (jointly with Dr. A. Lucas)

United States Patent #: 5,834,419)

(European Patent 0-840-615

Awarded June 25, 2003)

1996 (PCT filed April 19, 1996) Chemokine binding protein and methods of use therefore

(Issued February 20, 2007 (jointly with Dr. A. Lucas)

Canadian Patent #2,218,499)

1997 (PCT filed May 21, 1997) Compositions and methods for preventing and treating

transplant rejection

(jointly with Dr. A. Lucas and R. Zhong)

(Awarded: August 17, 1999 Methods of treating inflammation and compositions thereof

United States Patent #: 5,939,525) (jointly with Dr. A. Lucas)

(European Patent 0-817-646

Awarded August 7, 2002)

1999 (filed Sep. 14, 1999) Chemokine binding protein and methods of use thereof

(Awarded December 17, 2002 (jointly with Dr. A. Lucas)

United States Patent #:6,495,515 B1)

1999 (filed Sept. 15, 1999) Myxoma chemokine binding protein

(Awarded July 8, 2003) (jointly with Dr. A. Lucas)

2000 (PCT filed Sept. 20, 2000) Therapeutic uses of M3 polypeptide

(jointly with Drs. A. Lucas, S. Speck and S. Virgin)

2000 (PCT filed Oct. 27, 2000) Compositions and methods for preventing and treating

(European Patent EP-1-223-971 transplant rejection

Awarded June 8, 2005) (jointly with Dr. A. Lucas and Dr. R. Zhong)

2001 (PCT filed April 2, 2001) Methods and agents for regulating apoptosis

(jointly with Dr. M. Moran)

2001 (PCT filed Sept. 29, 2001) Methods of treating inflammatory and immune reactions

and compositions therefore   
(jointly with Drs. A. Lucas and R. Zhong)

2001 (PCT filed Dec. 4, 2001) Novel immunomodulatory protein and useful embodiments

(CIP filed June 4, 2003) thereof (jointly with Drs. A. Lucas and X. Li)

2002 (PCT filed April 18, 2002) Novel yatapoxvirus gp38 nucleic acid molecules and

polypeptides for immune modulation

(jointly with Dr. K. Essani)

2002 (U.S. Provisional filed May 22, 2002)

A chemokine binding protein and methods of use.

(jointly with Drs. B. Seet and S. Fleming)

2002 (U.S. Provisional filed July 30, 2002)

Vaccine vectors that utilize anti-apoptotic mechanisms

(jointly with Dr. G. Dekaban)

2002 (U.S. Provisional filed Nov. 18, 2002)

M063R Deletion mutant of myxoma virus as a non-

replicating vaccine vector for rabbits.

2003 (U.S. Provisional filed March 2003)

Treatment of human neoplasms using rabbit myxoma virus

(jointly with Dr. J. Bell)

2003 (U.S. Provisional P0061tent filed May 8, 2003)

Use of fragments of M11L for making recombinant Bak

and Bax binding proteins (jointly with E. Jacotot)

2004 (filed March 8, 2004) Use of Myxoma Virus for the Therapeutic Treatment of Cancer and

(Awarded Sept. 1, 2009 Chronic Viral Infection

United States Patent #: 7,582,614 B2) (jointly with Dr. J. C. Bell)

2005 (filed May 9, 2005) Nucleic acid molecules and polypeptides for Immune

(Awarded May 17, 2005 Modulation

United States Patent #:6,894,155) (jointly with Dr. Karim Essani)

2006 (filed June 4, 2003) Protein and Useful Embodiments Thereof

(Awarded Sept. 5, 2006 (jointly with Dr. A. Lucas and Dr. Xing Li)

United States Patent #: 7,101,559 B2)

2007 (Provisional filed June 21, 2006) Optimization of Codon Usage of Poxvirus Genes Allows for

Improved Transient Expression in Mammalian Cells

(filed jointly with Dr. J. Barrett)

2011 (Provisional filed June 9, 2011) Using Myxoma Virus to prevent Graft vs. Host Disease

(US Serial No. 61/495,342) (filed jointly at UF with Dr. C. Cogle and E. Bartee)

(US-2014-0328804-A1: 11/6/14) Licenced to DNAtrix, Feb 2012.

2013 (Provisional filed Mar 11, 2014) Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic (filed jointly at UF with Al Lewin, Masmudur Rahman, Cristhian Ildefonso and Alexandra Lucas)

2017 (IP Disclosures to ASU): AAV Expressed Serpins for Inflammatory Disorders

(D17-268): Provisional IP filed June 21, 2017

2018 (IP Disclosures to ASU): Wound Healing Treatment with Serp-1, a Virus-derived Anti-Inflammatory Protein

(D18-126) Provisional IP filed Feb 28, 2018

A New Method to Improve Yield of Oncolytic Myxoma Virus Yields for GMP Manufacture

(M18-264L-PR1) Provisonal IP filed Aug 9, 2018

A New Oncolytic Virus Platform to Treat Metastatic Cancers

(M18-265L-PR1) Provisional IP Filed July 13, 2018

A New Oncolytic Virus Platform to Treat Hematological Cancers

(M18-266L-PR1) Provisional IP Filed Sept 5, 2018

A New Oncolytic Virus Expressing (Redacted) to Treat Hematological Cancers

(M18-267L-PR1) Provisional IP filed May 24, 2018

2019 (IP Disclosures to ASU): A New Oncolytic Virus Platform to Treat Metastatic Cancers with Triple Transgene Armed Myxoma Virus

(D20-007) Provisional IP filed July 19, 2019

US Patent #11,117,934 awarded Sept 14, 2021

A New Method to Improve Yield of Oncolytic Myxoma Virus for GMP Manufacture (Addendum 2019)

(M20-043) Provisional IP filed Aug 14, 2019

2020 (IP Disclosures to ASU): COVID-19 vaccine based on the myxoma virus platform

(M20-234L-PR1-a) Provisional filed April 2, 2020

**BIOTECH INDUSTRY:**

Co-founder of VIRON Therapeutics, Inc. (founded April 1998)

Consultant, Gene Chem Management 1998-2000

Board Member, ORDCF Protein Expression Facility, Toronto, ON 2000-2001

Consultant, Bio Capital 2000-2002

Consultant, Gilead Sciences 2001

Chair, Scientific Advisory Board, and CSO, VIRON Therapeutics 1998-2014

Consultant, Affinium Corp., Toronto, ON 2002-2004

Consultant, United Devices, Austin, Texas 2002-2004

Consultant, Myriad Genetics, Salt Lake City 2003-2009

Consultant, Theraptosis Pasteur Institut, Paris 2003-2004

Consultant, Bavarian Nordic, Germany 2005-2006

Consultant, Wellstat Biologics Corp., Maryland 2005-2010

SAB member, Jennerex Corp., San Francisco 2009-2013

Consultant, SIGA, Oregon 2010-2012

Consultant, DNAtrix, Houston 2011-2012

Advisor, DNAtrix, Houston 2012-2016

Consultant, SillaJen, San Francisco 2015-16

Advisor, SillaJen, San Francisco 2018

SAC member, Immunovaccine, Halifax, NS 2016-2020

SAB member, StemImmune, San Diego, CA 2017-2018

Consultant, Xeophin, Australia 2017

Co-founder, Board Member, and member of SAB, OncoMyx Therapeutics 2018-present

**BIOTECH COMPANY (OncoMyx) STARTUP:**

In 2018, in collaboration with Steve Potts (CEO) and Mike Wood (COO), I co-founded a new ASU spin-off biotechnology company called **OncoMyx Therapeutics,** that was originally based at the TGen facility in Phoenix (See [https://www.oncomyx.com/](https://urldefense.proofpoint.com/v2/url?u=https-3A__www.oncomyx.com_&d=DwMGaQ&c=l45AxH-kUV29SRQusp9vYR0n1GycN4_2jInuKy6zbqQ&r=ISiKcjh6QSFdElZdYG-48VJH81jkmEHjIeu2hZqNdjE&m=qglIl108EYfXY98KIvx52s9Khk0X_PzbK7tVxINGpts&s=DYe7kPVn7aNARAF2nzQzObgLE3EocWOBOoCWiOLLOaU&e=)). It relocated to the new Wexford Building in Phoenix in May 2021. We completed our Series A financing (US$25 million) in June 2019 and completed Series B financing in November 2021. In 2019-20, nine of my lab members (3 postdocs, 1 scientist plus 5 undergraduate students who rotated through my ASU lab) have been hired by OncoMyx. This new biotech company is devoted to the development of multi-transgene armed oncolytic myxoma virus into human clinical trials for cancer.

**Promotional videos and newscasts about OncoMyx (2020-present):**

<https://vimeo.com/388356100/44549c77b6>

<https://markets.businessinsider.com/news/stocks/skysong-innovations-completes-licensing-agreement-with-asu-spinout-oncomyx-therapeutics-1028889076>

<https://science.kjzz.org/content/1505716/phoenix-based-biotech-company-working-using-virus-potential-cancer-treatment>

[https://podcasts.apple.com/ca/podcast/1-grant-mcfadden-a-pox-on-your cancer/id1512379792?i=1000473964281](https://podcasts.apple.com/ca/podcast/1-grant-mcfadden-a-pox-on-your%20cancer/id1512379792?i=1000473964281)

<https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer>

<https://www.linkedin.com/feed/update/urn:li:activity:6733052699786452992>

<https://twitter.com/OncoMyx/status/1327286695369142272>

<https://www.oncomyx.com/fiercebiotech-arming-the-rabbit-pox-virus-to-fight-cancer/>

<https://www.fiercebiotech.com/research/oncomyx-s-engineered-rabbit-pox-virus-shows-more-power-against-cancer>

<https://www.biospace.com/article/aacr-oncomyx-presents-first-data-showing-myxoma-virotherapy-anti-tumor-efficacy/>

<https://www.oncomyx.com/oncomyx-presents-at-aacr-first-data-showing-multi-armed-myxoma-virotherapy-can-modulate-anti-tumor-immune-response/>

<https://seekingalpha.com/instablog/440063-jonathan-faison/5598916-oncolytic-immunotherapy-q-oncomyx-therapeutics-ceo-steve-potts>

<https://www.oncomyx.com/pharmavoice-100-grant-mcfadden/>

<https://twitter.com/OncoMyx/status/1422211762078707712>

<https://www.linkedin.com/feed/update/urn:li:activity:6827977463411314689/>

https://www.fiercebiotech.com/biotech/oncomyx-nabs-50m-to-jump-into-clinic-its-rabbit-pox-virus-cancer-drug

https://myemail.constantcontact.com/The-latest-news-from-the-PBC.html?soid=1136671499443&aid=Ry8ldVr4lqo

**Publications**

1. Denhardt, D.T., Iwaya, M., McFadden, G. and Schochetman, G. The mechanism of replication of ΦX174 single stranded DNA. VI. Requirements for ribonucleoside triphosphates and DNA Polymerase III. *Can. J. Biochem.* **51:**1588-1597 (1973).
2. McFadden, G. and Denhardt, D.T. The mechanism of replication of ΦX174single stranded DNA. IX. Discontinuous synthesis in an *E. coli* strain with a temperature-sensitive ligase. *J. Mol. Biol.* **99:**125-142 (1974).
3. McFadden, G. and Denhardt, D.T. Mechanism of replication of ΦX174single-stranded DNA. IX. Requirement for the *E. coli DnaG* protein. *J. Virol.* **14:**1070-1075 (1974).
4. Denhardt, D.T., Eisenberg, S., Harbers, B., Lanes, H.E.D. and McFadden, G. Replication of ΦX174 in *Escherichia coli*: Structure of the replicating intermediate and the effect of mutations in the host *lig* and *rep* genes. DNA Synthesis and Its Regulation, eds. M. Goulian, P. Hanawalt and C.F. Fox. Academic Press (1975).
5. McFadden, G. and Denhardt, D.T. Contrasting effects of 2', 3'-dideoxyadenine on 2 steps in the replication of ΦX174 DNA in *Escherichia coli. Virology* **76:**870-875 (1977).
6. Dales, S., Milanovitch, V., Pogo, B.G.T., Wientraub, S.B., Huima, T., Wilton, S. and McFadden, G. Biogenesis of vaccinia: Isolation of conditional lethal mutants and EM characterization of their phenotypically expressed defects. *Virology* **84:**403-428 (1978).
7. McFadden, G., Pace, W.E., Purres, J. and Dales, S. Biogenesis of Poxvirus: Transitory expression of *Molluscum contagiosum* early functions. *Virology* **94:**297-313 (1979).
8. Silver, M., McFadden, G., Wilson, S. and Dales, S. Biogenesis of Poxvirus: Role of the DNA-dependent RNA polymerase II of the host during expression of late functions. *Proc. Natl. Acad. Sci. U.S.A.* **76:**4122-4125 (1979).
9. McFadden, G. and Dales, S. Biogenesis of Poxvirus: Mirror image deletions in vaccinia virus DNA. *Cell* **18:**101-108 (1979).
10. McFadden, G., Essani, K. and Dales, S. A new endonuclease restriction site which is at the locus of a ts mutation in vaccinia virus is associated with true and pseudo-reversion. *Virology* **101:**277-290 (1980).
11. Schumperli, D., Wyler, R., McFadden, G. and Dales, S. Location of a new endonuclease restriction site associated with a temperature sensitive mutation of vaccinia virus. *Virology* **101:**281-285 (1980).
12. McFadden, G. and Dales, S. Biogenesis of Poxvirus: Preliminary characterization of conditional lethal mutants of vaccinia virus defective in DNA synthesis. *Virology* **103:**68-79 (1980).
13. McFadden, G. and Dales, S. Organization and replication of poxvirus DNA. *“*Organization and replication of viral DNA”. (Ed. A.S. Kaplan). CRC Press pp. 173-190 (1982).
14. McFadden, G. and Morgan, A.R. DNA cruciform structures: Implications for telomere replication in eukaryotes and instability of long palindromic DNA sequences in prokaryotes. *J. Theor. Biol.* **97:**343-349 (1982).
15. Wills, A., Delange, A.M., Gregson, C., Macaulay, C. and McFadden, G. Physical characterization and molecular cloning of the Shope Fibroma virus DNA genome. *Virology* **130:**403-414 (1983).
16. Delange, A.M., Futcher, B., Morgan, A.R. and McFadden, G. Cloning of the vaccinia virus telomeres in a yeast plasmid vector. *Gene* **27:**13-21 (1984).
17. Delange, A.M., Macaulay, C., Block, W., Mueller, T. and McFadden, G. Tumorigenic poxviruses: Construction of the composite physical map of the Shope Fibroma Virus Genome. *J. Virol.* **50:**408-416 (1984).
18. Block, W., Upton, C. and McFadden, G. Tumorigenic Poxviruses: Genomic organization of malignant rabbit virus, a recombinant between Shope fibroma virus and myxoma virus. *Virology* **140:**113-124 (1985).
19. Upton, C. and McFadden, G. DNA sequence homology between the terminal inverted repeats of Shope fibroma virus and an endogenous cellular plasmid species. *Mol. Cell. Biol.* **6:**265-276 (1986).
20. Delange, A.M. and McFadden, G. Sequence-nonspecific replication of transfected plasmid DNA in poxvirus-infected cells. *Proc. Natl. Acad. Sci. U.S.A.* **83:**614-618 (1986).
21. Upton, C. and McFadden, G. Tumorigenic poxviruses: Analysis of viral DNA sequences implicated in the tumorigenic of Shope fibroma virus and malignant rabbit virus. *Virology* **152:**308-321 (1986).
22. Delange, A.M., Reddy, M., Scraba, D., Upton, C. and McFadden, G. Replication and resolution of cloned poxvirus telomeres *in vivo* generates linear minichromosomes with intact viral hairpin termini. *J. Virology* **59:**249-259 (1986).
23. Upton, C., Carrell, R.W. and McFadden, G. A novel member of the serpin superfamily is encoded on a circular plasmid-like DNA species isolated from rabbit cells. *FEBS Lett.* **207:**115-120 (1986).
24. Upton, C. and McFadden, G. Identification and nucleotide sequence of the thymidine kinase gene of Shope fibroma virus. *J. Virology* **60:**920-927 (1986).
25. Chang, W., Upton, C., Hu, S.-L., Purchio, A.F. and McFadden, G. The genome of Shope Fibroma Virus, a tumorigenic poxvirus, contains a growth factor gene with sequence similarity to those encoding epidermal growth factor and transforming growth factor alpha. *Mol. Cell. Biol.* **7:**535-540 (1987).
26. Macaulay, C., Upton, C. and McFadden, G. Tumorigenic poxviruses: Transcriptional mapping of the terminal inverted repeats of Shope Fibroma Virus. *Virology* **158:**381-393 (1987).
27. Upton, C., Macen, J. and McFadden, G. Mapping and sequencing of a gene from myxoma virus that is related to those encoding epidermal growth factor and transforming growth factor alpha. *J. Virol.* **61:**1271-1275 (1987).
28. Dickie, P., Morgan, A.R. and McFadden, G. Cruciform extrusion in plasmids bearing the replicative intermediate configuration of a poxvirus telomere. *J. Mol. Biol.* **196:**541-558 (1987).
29. Delange, P., McFadden, G. Efficient resolution of replicated poxvirus telomeres to native hairpin structures requires two inverted symmetrical copies of a core target DNA sequence. *J. Virol.* **61:**1957-1963 (1987).
30. Upton, C., Delange, A.M. and McFadden, G. Tumorigenic poxviruses: Genomic organization and DNA sequence of the terminal inverted repeats of Shope fibroma virus. *Virology* **160:**20-30 (1987).
31. Dickie, P., McFadden, G. and Morgan, A.R. The site-specific cleavage of synthetic Holliday junction analogs and related branched DNA structures by bacteriophage T7 endonuclease 1. *J. Biol. Chem.* **262:**14826-14836 (1987).
32. McFadden, G., Stuart, D., Upton, C., Dickie, P. and Morgan, A.R. Replication and resolution of poxvirus telomeres. *In* “Cancer Cells VI: Eukaryotic DNA Replication”. (Eds. T.J. Kelly and B. Stillman). Cold Spring Harbor Press pp. 77-85 (1988).
33. Evans, D., Stuart, D. and McFadden, G. High levels of genetic recombination between cotransfected plasmid DNAs in poxvirus-infected mammalian cells. *J. Virol.* **62:**367-375 (1988).
34. Dickie, P., Morgan, A.R. and McFadden, G. Conformational isomerization of the Holliday junction associated with a cruciform during branch migration in supercoiled plasmid DNA. *J. Mol. Biol.* **201:**19-30 (1988).
35. Henning, W., Upton, C., Majumdar, R., McFadden, G. and Bridger, W.A. Cloning and sequencing of the cytoplasmic precursor to the -subunit of rat liver succinyl-CoA synthetase. *Proc. Natl. Acad. Sci. U.S.A.* **85:**1432-1436 (1988).
36. Sheng, M., Dougan, S.T., McFadden, G. and Greenberg, M. Calcium and growth factor pathways of *c-fos* transcriptional activation require distinct upstream regulatory sequences. *Mol Cell. Biol.* **8:**2787-2796 (1988).
37. Upton, C., Macen, J.L., Maranchuk, R.A., Delange, A.M. and McFadden, G. Tumorigenic poxviruses: Fine analysis of the recombination junctions in malignant rabbit fibroma virus, a recombinant between Shope fibroma virus and myxoma virus. *Virology* **166:**229-239 (1988).
38. Lobe, C., Upton, C., Duggan, G., Ehrman, N., Letellier, M., Bell, J., McFadden, G. and Bleackley, R.C. Organization of two gene encoding cytotoxic T lymphocyte-specific serine proteases, CCPI and II. *Biochemistry* **27:**6941-6946 (1988).
39. Lobe, C., Shaw, J., Fregeau, C., Duggan, B., Meier, M., Brewer, A., Upton, C., McFadden, G., Patient, R.K., Paetkau, V. and Bleackley, R.C. Transcriptional regulation of two cytotoxic T lymphocyte-specific serine proteinase genes. *Nucleic Acids Res.* **17:** 5765-5779 (1989).
40. McFadden, G. Poxviruses of rabbits. *In* “Virus diseases in laboratory and captive animals”. (Ed. G. Darai). Martinus Nijhoff Publishing, Boston pp. 37-61 (1987).
41. Macaulay, C. and McFadden, G. Tumorigenic poxviruses: Characterization of an early promoter from Shope fibroma virus. *Virology* **172:**237-246 (1989).
42. Delange, A.M. and McFadden, G. The role of telomeres in poxviral DNA replication. *Curr. Top. Microbiol. Imm.* Vol. 163. (R. Moyer, Ed.) Springer Verlag, Berlin. pp. 71-92 (1990).
43. Sheng, M., McFadden, G. and Greenberg, M.E. Membrane depolarization and calcium induce *c-fos* transcription via phosphorylation of transcription factor CREB. *Neuron* **4:**571-582 (1990).
44. Upton, C., Opgenorth, A., Tracktman, P. and McFadden, G. Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase gene. *Virology* **176:**439-447 (1990).
45. Chang, W., Macaulay, C., Hu, S.L., Tam, J.P. and McFadden, G. Tumorigenic poxviruses: Characterization of the expression of an EGF related gene in Shope fibroma virus. *Virology* **179:**926-930 (1990).
46. Upton, C., Macen, J.L., Wishart, D.S. and McFadden, G. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. *Virology* **179:**618-631 (1990).
47. Stuart, D., Graham, K., Schrieber, M., Macaulay, C. and McFadden, G. The target DNA sequence for resolution of poxvirus replicative intermediates is an active late promoter. *J. Virol.* **65:**61-70 (1991).
48. Smith, C.A., Davis, T., Wignall, Upton, C., McFadden G., Din, W.S. and Goodwin, R.G. T2 open reading frame from Shope fibroma virus encodes a soluble form of the tumor necrosis factor receptor. *Bioch. Bioph. Res. Comm.* **176:**335-342 (1991).
49. Upton, C., Macen, J., Schreiber, M. and McFadden, G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. *Virology* **184:**370-382 (1991).
50. Upton, C., Stuart, D. and McFadden, G. Identification and DNA sequence of the large subunit of the capping enzyme from Shope fibroma virus. *Virology* **183:**773-777 (1991).
51. Opgenorth, A., Strayer, D., Upton, C. and McFadden, G. Deletion of the growth factor gene related to EGF and TGF reduces virulence of malignant rabbit fibroma virus. *Virology* **186:**175-191 (1992).
52. Boshkov, L.K., Macen, J.L. and McFadden, G. Virus-induced loss of class I major histocompatibility antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. *J. Immunol.* **148:**881-887 (1992).
53. Massung, R., McFadden, G. and Moyer, R.W., Nucleotide sequence analysis of a unique near-terminal region of the tumorigenic poxvirus, Shope fibroma virus. *J. Gen. Virol.* **73:**2903-2911 (1992).
54. Stuart, D., Ellison, K., Graham, K. and McFadden, G. *In vitro* resolution of poxvirus replicative intermediates into linear minichromosomes with hairpin termini by a virally induced Holliday junction endonuclease. *J. Virol.* **66:**1551-1563 (1992).
55. Opgenorth, A., Graham, K., Nation, N., Strayer, D. and McFadden, G. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. *J. Virol.* **66:**4720-4731 (1992).
56. Graham, K., Opgenorth, A., Upton, C. and McFadden, G. Myxoma virus M11L ORF encodes a protein for which cell surface localization is critical for manifestation of viral virulence. *Virology* **191:**112-124 (1992).
57. Upton, C., Mossman, K., and McFadden, G. Encoding of a homolog of the IFN- receptor by myxoma virus. *Science* **258:**1369-1372 (1992).
58. Lomas, D.A., Evans, D.L., Upton, C., McFadden, G. and Carrell, R.W., Inhibition of plasmin, urokinase, tissue plasminogen activator and C1S by a myxoma virus serine proteinase inhibitor. *J. Biol. Chem.* **268:**516-521 (1993).
59. Opgenorth, A., Nation, N., Graham, K. and McFadden, G. Transforming growth factor alpha, Shope fibroma growth factor and vaccinia growth factor can replace myxoma growth factor as a virulence gene in the induction of myxomatosis in rabbits. *Virology* **192:**701-709 (1993).
60. Upton, C., Stuart, D. and McFadden, G. Identification of a poxvirus gene encoding a uracil DNA glycosylase. *Proc. Natl. Acad. Sci., USA* **90:**4518-4522 (1993).
61. Stuart, D., Upton, C., Higman, M.A., Niles, E.G. and McFadden, G. A poxvirus-encoded uracil DNA glycosylase is essential for virus viability. *J. Virol.* **67:**2503-2512 (1993).
62. Macen, J., Upton, C., Nation, N. and McFadden, G. SERP-1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. *Virology* **195:**348-363 (1993).
63. McFadden, G. Myxoma, rabbit fibroma, hare fibroma, squirrel fibroma and swinepox viruses. Encyclopedia of Virology (Ed. R.G. Webster and A. Granoff). Sanders Scientific Pub. pp. 1153-1160 (1994).
64. Kane, K. and McFadden, G. How DNA viruses perturb functional MHC expression to evade the immune response. *Adv. in Cancer Res.* **63:**117-209 (1994).
65. McFadden, G. DNA viruses that affect cytokine networks (Chapter 27). *In “*Human Cytokines: Their Role in Health and Disease”. (Eds. B.B. Aggarwal and R.K. Puri). Blackwell Press, pp. 403-422 (1994).
66. Upton, C. and McFadden, G. Detection of viral homologues of cellular -interferon receptors. *In* “Molecular Virology Techniques. Part A”. (Methods in Molecular Genetics. Vol 4). (Ed. K.W. Adolph). Academic Press, Inc. pp. 383-390 (1994).
67. Upton, C., Schiff, L., Rice, S.A., Dowdeswell, T., Yang, X. and McFadden, G. A poxvirus protein with a RING finger motif binds zinc and localizes in virus factories. *J. Virol.* **68:**4186-4195 (1994).
68. McFadden, G. and K. Graham. Modulation of cytokine networks by poxviruses: The myxoma virus model. *Semin. Virol.* **5:**421-429 (1994).
69. Schreiber, M. and McFadden. G., The myxoma virus TNF receptor homologue (T2) inhibits TNF in a species-specific fashion. *Virology* **204:**692-705 (1994).
70. McFadden, G., Graham, K. and Opgenorth, A. Poxvirus growth factors. *In* "Viroceptors, virokines, and related mechanisms of immune modulation by DNA viruses." (Ed. G. McFadden). R.G. Landes Co. pp. 1-15 (1995).
71. Mossman, K., Barry, M. and McFadden, G. Poxvirus-encoded homologues of the gamma-interferon receptor.  *(*"Viroceptors, virokines, and related mechanisms of immune modulation by DNA viruses." Ed. G. McFadden). R.G. Landes Co. pp. 41-54 (1995).
72. McFadden, G., Graham, K., Ellison, K., Barry, M., Macen, J., Schreiber, M., Mossman, K., Nash, P., Lalani, A. and Everett, H. Interruption of cytokine networks by poxviruses: Lessons from myxoma virus. *J. Leuk. Biol.* **57:**731-738 (1995).
73. Mossman, K., Ostergaard, H., Upton, C., and McFadden. G. Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability. *Virology* **206:**572-582 (1995).
74. Mossman, K., Upton, C. and McFadden, G. The myxoma virus-soluble interferon- receptor homolog, M-T7, inhibits interferon- in a species specific manner. *J. Biol. Chem.* **270:**3031-3038 (1995).
75. Mossman, K., Buller, R.L., Upton, C. and McFadden, G. Species specificity of ectromelia virus and vaccinia virus interferon -binding proteins. *Virology* **208:**762-769 (1995).
76. Barry, M., Lee, S.F., Boshkov, L. and McFadden, G. Myxoma virus induces extensive CD4 downregulation and dissociation of p56lck in infected rabbit CD4+ T lymphocytes. *J. Virol.* **69:**5243-5251 (1995).
77. McFadden, G. Getting to know you: Viruses meet CD40 ligand. *Nature Medicine (News and Views)* **1:**408-409 (1995).
78. Lucas, A., Liu, L., Macen, J., Nash, P., Dai, E., Stewart, M., Graham, K., Etches, W., Boshkov, L., Nation, P., Humen, D., Hobman, M.Z. and McFadden, G. A virus-encoded serine protease inhibitor, SERP-1, inhibits atherosclerotic plaque development following balloon angioplasty. *Circulation* **94:**2890-2900 (1996).
79. Macen, J.L., Graham, K., Lee, S.F., Schreiber, M., Boshkov, L. and McFadden, G. Expression of the myxoma virus TNF receptor homologue (T2) and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. *Virology* **218:**232-237 (1996).
80. Maksymowych, W.P., Nation, N., Nash, P., Macen, J., Lucas, A, McFadden, G. and Russell, A.S. Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor. *J. Rheum.* **23:**878-882 (1996).
81. Mossman, K., Nation, P., Macen, J., Garbutt, M., Lucas, A. and McFadden, G. Myxoma virus M-T7, a secreted homolog of the interferon- receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. *Virology* **215:**17-30 (1996).
82. Macen, J.L., Garner, R.S., Musy, P.Y., Brooks, M.A., Turner, P.C., Moyer, R.W., McFadden, G. and Bleackley, R.C. Differential inhibition of the Fas and granule-mediated cytolysis pathways by the orthopoxvirus crmA/SPI-2 and SPI-1 protein. *Proc. Natl. Acad. Sci., USA* **93:**9108-9113 (1996).
83. Mossman, K., Lee, S.F., Barry, M., Boshkov, L. and McFadden, G. Disruption of M-T5, a novel myxoma virus gene member of the poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. *J. Virol.* **70:**4394-4410 (1996).
84. Nathanson, N. and McFadden, G. Viral virulence. *In* "Viral Pathogenesis" (Ed. N. Nathanson). Lippincott-Raven Press pp. 85-103 (1996).
85. Schreiber, M., Rajarathnam, K. and McFadden, G. Myxoma virus T2 protein, a TNF-receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNF but the dimer is a more potent TNF inhibitor. *J. Biol. Chem.* **271:**13333-13341 (1996).
86. Ellison, K.S., Peng, W. and McFadden, G. Mutations in active-site residues of the uracil-DNA glycosylase encoded by vaccinia virus are incompatible with virus viability. *J. Virol.* **70:**7965-7973 (1996).
87. Schreiber, M. and McFadden, G. Mutational analysis of the ligand-binding domain of M-T2 protein, the TNF receptor homologue of myxoma virus. *J. Immunol.* **157:**4486-4495 (1996)
88. Sedger, L. and McFadden, G. M-T2: A poxvirus TNF receptor homologue with dual activities. *Immunology and Cell Biol.* **74:**538-545 (1996).
89. McFadden, G., Graham, K. and Barry, M. New strategies of immune modulation by DNA viruses. *Transplantation Proc.* **28:**2085-2088 (1996).
90. Barry, M. and McFadden, G. Virokines and Viroceptors. *In* "Cytokines in Health and Disease, 2nd Ed." (Eds. J.S. Friedland and D. G. Remick). Dekker Press pp. 251-262 (1997).
91. Nash, P., Lucas, A. and McFadden, G. SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. *In* “Chemistry and Biology of Serpins” (Eds. F. Church, D. Cunningham, D. Ginsburg, M. Hoffman, S. Stone and D. Tollefsen). *Advances in Experimental Medicine and Biology Series.* pp. 195-205 (1997).
92. McFadden, G., Schreiber, M. and Sedger, L. Myxoma T2 protein as a model for poxvirus encoded TNF receptors homologs. *J. Neuroimmunology* **72:**119-126 (1997).
93. Schreiber, M., Sedger, L. and McFadden, G. Distinct domains of M-T2, the myxoma virus TNF receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. *J. Virol.* **71:**2171-2181 (1997).
94. Mossman, K., Barry, M. and McFadden, G. Regulation of interferon- gene expression and extracellular ligand function by immunomodulatory viral proteins. *In* "Gamma Interferon: A Pleiotropic Cytokine with Antiviral Activity" (Ed. G. Karupiah), R.G. Landes, Austin pp. 175-188 (1997).
95. Lalani, A., Graham, K., Mossman, K., Rajarathnam, K., Lewis, I.C., Kelvin, D. and McFadden, G. The purified myxoma virus gamma interferon receptor homolog, M-T7, interacts with the heparin-binding domains of chemokines. *J. Virol.* **71:**4356-4363 (1997).
96. McFadden, G. and Kelvin, D. New strategies for chemokine inhibition and modulation: You take the high road and I’ll take the low road. *Biochem. Pharm*. **54:**1271-1280 (1997).
97. Graham, K., Lalani. A., Macen, J., Ness, T.L., Barry, M., Liu, L., Lucas, A., Clark-Lewis, I., Moyer, R. and McFadden, G. The T1/35kDa family of poxvirus secreted proteins bind chemokines and modulate with leukocyte influx into virus-infected tissues. *Virology* **229:**12-24 (1997).
98. Barry, M., Hnatiuk, S., Mossman, K., Lee, S.W., Boshkov, L. and McFadden, G. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained in the endoplasmic reticulum and is important for the productive infection of lymphocytes. *Virology* **239:**360-377 (1997).
99. Lalani, A. and McFadden, G. Secreted poxvirus chemokine binding proteins. *J. Leuk. Biol.* **62:**570-576 (1997).
100. Barry, M. and McFadden, G. Virus encoded cytokines and cytokines receptors. *Parasitology* **115:**S89-S100 (1998).
101. McFadden, G. Even viruses can learn to cope with stress. *Science* **279:**40-41 (1998).
102. McFadden, G. Viruses and the immune system: Lessons from HIV. *UWO Medical Journal* **67:**39-40 (1998).
103. McFadden, G. and Barry, M. How poxviruses oppose apoptosis. *Semin. Virol.* **8:**429-442 (1998).
104. McFadden, G., Lalani, A., Everett, H., Nash, P. and Xu, X. Virus-encoded receptors for cytokines and chemokines. *Semin. Cell Dev. Biol.* **9:**359-368 (1998).
105. Barry, M. and McFadden, G. Apoptosis regulators from DNA viruses. *Curr. Opin. Immunol.* **10:**422-430 (1998).
106. Nash, P., Whitty, A., Handwerker, J., Macen, J. and McFadden, G. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. *J. Biol. Chem.* **273:**20982-20991 (1998).
107. Lalani, A.S., Ness, T.L., Singh, R., Harrison, J.K., Seet, B.T., Kelvin, D.J., McFadden, G. and Moyer, R.W., Functional comparisons among members of the poxvirus T1/35kDa family of soluble CC-chemokine inhibitor glycoproteins. *Virology* **250:**173-184 (1998).
108. Everett, H. and McFadden, G. Apoptosis as an innate immune response to virus infection.  
     *Tr. Microbiol.* **7:**160-165 (1999)*.*
109. Lalani, A., Nash, P., Seet, B. and McFadden, G. Interaction of DNA virus proteins with host cytokines. *In “*DNA Viruses: A Practical Approach”. (Ed. A. Cann), Practical Approach Series, Oxford University Press. pp. 177-208 (1999).
110. Nash, P., Barrett, J., Cao, J.-X., Hota-Mitchell, S., Lalani, A.S., Everett, H., Xu, X.-M., Robichaud, J., Hnatiuk, S., Ainslie, C., Seet, B. and McFadden, G. Immunomodulation by viruses: The myxoma virus story. *Immunol. Rev.* **168:**103-120 (1999).
111. McFadden, G. Poxviruses (Poxviridae): Leporipoxviruses and Suipoxviruses. *In* “Encyclopedia of Virology,”Second Edition, (Eds. R.G. Webster and A. Granoff). Academic Press pp. 1381-1388 (1999).
112. Lalani, A.S., Masters, J., Graham, K., Liu, L., Lucas, A. and McFadden, G. Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis.  *Virology* **256:**233-245 (1999).
113. Lucas, A. and McFadden, G. Harvesting viral proteins. *Can. Med. Assoc. J.* **16:**1134 (1999).
114. Zuniga, M.C., Hong, W., Barry, M., and McFadden, G. Endosomal/lysosomal retention and degradation of major histocompatibility complex Class I molecules is induced by myxoma virus. *Virology* **261:**180-192(1999).
115. Hnatiuk, S., Barry, M., Zeng, W., Liu, L., Lucas, A., Percy, D. and McFadden, G. Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis. *Virology* **263:**290-306 (1999).
116. Lalani, A.S. and McFadden, G. Evasion and exploitation of chemokines by viruses. *Cyt. Growth Factor Rev.* **10:**219-233(1999).
117. Lalani, A.S., Masters, J., Zeng, W., Barrett, J., Pannu, R., Everett, H., Arendt, C.W. and McFadden, G. Use of chemokine receptors by poxviruses. *Science* **286(5446):**1968-1971 (1999).
118. Christov, A., Dai, E., Liu, L., Miller, L.W., Nash, P., Lalani, A., McFadden, G., Nation, P.N., Tulip, J., and Lucas, A. Detection of transplant vasculopathy in a rat aortic allograft model by fluorescence spectroscopic optical analysis. *Lasers Surg Med.* **24(5):**346-359 (1999).
119. Willer, D.O., McFadden, G. and Evans, D.H.. The complete genome sequence of Shope (rabbit) fibroma virus *Virology* **264:**319-343(1999).
120. Cameron\*, C. Hota-Mitchell\*, S., Chen, L., Barrett, J., Cao, J.-X., Macaulay, C., Willer, D., Evans, D. and McFadden, G. The complete DNA sequence of myxoma virus. *Virology* **264:**298-318 (1999). (\* denotes co-authorship).
121. Nash, P., Barry, M., Seet, B.T., Veugelers, K., Hota, S., Heger, J., Hodgkinson, C., Graham, K., Jackson, R.J. and McFadden, G. Post-translational modification of the myxoma virus anti-inflammatory serpin, SERP-1 by a virally encoded sialyltransferase. *Biochem. J.* **347:**375-382 (2000).
122. Lalani, A.S., Barrett, J. and McFadden G. Modulating chemokines: More lessons from viruses. *Immunol. Today* **21(2):** 100-106 (2000).
123. Barry, M. and McFadden, G. Regulation of apoptosis by poxviruses. *In* “Effects of Microbes on the Immune System” (Eds. M.W. Cunningham and R.S. Fujinami). Lippincott Williams and Wilkins pp. 509-520 (2000).
124. Miller, L.W., Dai, E., Nash, P., Liu, L., Icton, C., Klironomous, D., Fan, L., Nation, P.N., Zhong, R., McFadden, G. and Lucas, A. Inhibition of transplant vasculopathy in a rat aortic model after infusion of an anti-inflammatory viral serpin. *Circulation* **101:**1598-1605(2000).
125. Everett, H., Barry, M., Lee, S.F., Sun, X., Graham, K., Stone, J., Bleackley, C. and McFadden, G. M11L: A novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes. *J. Exp. Med.* **191(9):** 1487-1498 (2000).
126. Liu, L., Lalani, A., Dai, E., Seet, B., Macaulay, C., Singh, R., Fan, L., McFadden, G. and Lucas, A. The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. *J. Clin. Invest.* **105(11):** 1613-1621 (2000).
127. van Berkel, V., Barrett, J., Tiffany, H.L., Fremont, D.H., Murphy, P.M., McFadden, G., Speck, S.H. and Virgin IVth, H.W. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. *J. Virol.* **74(15):** 6741-6747 (2000).
128. Xu, X., Nash, P. and McFadden, G. Myxoma virus expresses a TNF receptor homolog with two distinct functions. *Virus Genes* **21:**97-109 (2000).
129. McFadden, G. and Murphy, P.M. Host-related immunomodulators encoded by poxviruses and herpesviruses. *Curr. Opin. Microbiol.* **3(4):** 371-378 (2000).
130. Christov, A., Dai, E., Drangova, M., Liu, L., Abela, G.S., Nash, P., McFadden, G. and Lucas, A. Optical detection of triggered atherosclerotic plaque by fluorescence emission analysis. *Photochem. Photobiol.* **72(2):** 242-252 (2000).
131. Nash, P., McFadden, G. and Whitty, A. Application of linear free energy relationships to the serpin-proteinase inhibition mechanism.  *FEBS Letters* **475(1):**1-6 (2000).
132. McFadden, G. Virus “Star Wars.”  *Science and Medicine* **7(3):** 38-47 (2000).
133. Lucas, A., Dai, E., Liu, L., Guan, H., Nash, P., McFadden, G. and Miller, L. Transplant vasculopathy: Viral anti-inflammatory serpin regulation of atherogenesis. *J. Heart Lung Transplant.* **19(11):** 1029-1038 (2000).
134. McFadden G. and Moyer R. Poxvirus TNF Receptor Homologs. *In “*Cytokine Database”. (Eds. J.J. Oppenheim and M. Feldmann). Academic Press <http://www.academicpress.com/cytokinereference> (2000).
135. McFadden, G. and Moyer, R. Poxvirus Secreted Chemokine-binding Proteins. *ibid* (2000).
136. McFadden, G. and Moyer, R. Poxvirus IL-1β Receptor Homologs. *ibid* (2000).
137. McFadden, G. and Moyer, R. Poxvirus IFNγ Receptor Homologs. *ibid* (2000)
138. McFadden, G. and Moyer, R. Poxvirus IFNα/β Receptor Homologs. *ibid* (2000).
139. McFadden, G. and Moyer, R. Vaccinia Virus Semaphorin. *ibid* (2000).
140. McFadden, G. and Moyer, R. Serp-1, a Secreted Poxviral Serpin *ibid* (2000).
141. McFadden, G. and Moyer, R. Poxvirus Vascular Endothelial Growth Factor (VEGF) Homologs of Orf Virus. *ibid* (2000).
142. McFadden, G. and Moyer, R. Poxvirus Growth Factors Related to Epidermal Growth Factor. *ibid* (2000).
143. McFadden, G. and Moyer, R. Poxvirus Secreted Complement Control Proteins. *ibid* (2000).
144. McFadden, G. and Moyer, R. Parapoxvirus (Orf Virus) Il-10 Homolog. *ibid* (2000).
145. McFadden, G. and Moyer, R. Poxvirus Membranebound G Protein-coupled Receptor Homologs. *ibid* (2000).
146. McFadden, G. and Moyer, R. CC Chemokine of Molluscum Contagiosum Virus. *ibid* (2000).
147. Barrett, JW, Cao, J.-X, Hota-Mitchell, S, and McFadden, G. Immunomodulatory proteins of myxoma virus. *Semin. Immunol.* **13:**73-84 (2001).
148. Everett, H. and McFadden, G. Viral proteins and the mitochondrial apoptotic checkpoint. *Cyt. Growth Factor Rev.* **12:**181-188 (2001).
149. Cao, J.-X. and McFadden, G. Manipulation of the immune system virus: Myxoma virus model. *Mod. Aspects Immunobiol.* **1(5):**179-181 (2001).
150. O’Brien, WJ, Heimann, T, Tsao, L, Seet, BT, McFadden, G and Taylor, JL Regulation of nitric oxide synthase 2 in rabbit corneal cells. *Invest. Ophthalmol. Vis. Sci.* **42(3)**: 713-719 (2001).
151. Seet, BT, Barrett, J, Robichaud, J, Shilton, B., Singh, R, and McFadden, G. Glycosaminoglycan-binding properties of the myxoma virus CC-chemokine inhibitor, M-T1 *J. Biol. Chem*. **276(32):**30504-30513 (2001).
152. Seet, BT, Singh, R, Paavola, C, Lau, E, Handel TM and McFadden, G. Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor *PNAS* **98(16):** 9008-9011 (2001).
153. Everett, H. and McFadden, G. Viruses and apoptosis: meddling with mitochondria *Virology* **288:**1-7 (2001).
154. Cao, J.-X and McFadden, G. Characterization of the myxoma virus M118L protein: A novel essential poxvirus IMV-associated protein *Virus Genes* **23:**303-313 (2001).
155. Masters, J, Uddin, S, Platonias, LC, Zeng, W, McFadden, G. and Fish, E. Poxvirus infection rapidly activates tyrosine kinase signal transduction. *J. Biol. Chem.* **276:**48371-48375 (2001).
156. Cao, JX, Teoh, MCT, Moon, M, McFadden, G and Evans, D. Leporipoxvirus CnZn superoxide dismutase hemologs inhibit cellular superoxide dismutase but are not essential for virus replication or virulence.  *Virology* **296:**125-135 (2002).
157. Kerr, P. and McFadden, G. Leporipoxviruses. *In “*The Springer Index of Viruses”. http://oesys.springer.de/viruses/database.htm (2002).
158. Seet, BT and McFadden, G. Viral chemokine binding proteins. *J. Leuk. Biol.* **72:**24-34 (2002)
159. Kerr, P and McFadden, G. Immune responses to myxoma virus. *Viral Immunology* **15:**229-246 (2002).
160. Everett, H and McFadden, G. Poxviruses and apoptosis: A time to die. *Curr. Op. Microbiol.* **5(4):** 395-402 (2002).
161. Smith, GL and McFadden, G. Smallpox: Anything to declare? *Nature Reviews Immunology* **2:**521-527 (2002).
162. Everett, H, Barry, M, Lee, SF, Frantz, C, Berthiaume, LG, McFadden, G.(\*) and Bleackley, R.C.(\*). The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore (\*denotes co-corresponding authors) *J. Exp. Med.* **196:**1127-1139 (2002).
163. Moyer, RM and McFadden, G. Virus-encoded caspase inhibitors. *In* “Caspases---Their Role in Cell Death and Cell Survival” (Eds. M. Los and H. Walczak) *Landes Bio Science* Ch 6, pp. 105-122 (2002).
164. Chang,.CS and McFadden, G. Characterization of a monoclonal antibody specific for a novel primate cell surface with distinct biochemical properties on human erythroleukemia and myeloid cell lines. *Hybridoma and Hybridomics* **21:**271-280 (2002).
165. Chang, CS and McFadden, G. Characterization of a pan-species reactive monoclonal antibody specific for a cell surface epitope which could serve as a marker for human monocytic and megakaryocytic differentiation. *Hybridoma and Hybridomics* **21:**445-456 (2002).
166. Johnson, DC and McFadden, G. Viral Immune Evasion. *In* “Immunology of Infectious Diseases” (Eds. Stefan H. E. Kaufman, Alan Sher and Rafi Ahmed). *ASM Press* Ch. 24 (2002).
167. Mansouri, M, Bartee, E, Gouveia, K, Nerenberg, BTH, Barrett, J, Thomas, L, Thomas, G, McFadden, G and Freu, K. The PHD/LAP-domain protein M153R of myxoma virus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4 *J. Virology* **77:**1427-1440 (2003).
168. McFadden, G. Viroceptors: Virus-encoded receptors for cytokines and chemokines. *In* “Cytokines and Chemokines in Infectious Diseases Handbook,” (Eds. M. Kotb and T. Calandra). *Humana Press* pp. 285-299 (2003).
169. Seet, BT, Johnston, J, Brunetti, C, Barrett, J, Everett, H, Cameron, C, Sypula, J, Nazarian, S., Lucas, A and McFadden, G. Poxviruses and immune evasion. *Ann. Rev. Immunol.* **21:** 377-423 (2003).
170. Li, X, King, E, Macaulay, C, Lucas, A and McFadden, G. Three Activity-Based Assays for Serp-1 *BioProcess International* **1:** 48-55 (2003).
171. Brunetti, C, Paulose-Murphy, M, Singh, R, Qin, J, Barrett, JW, Tardivel, A, Schneider, P, Essani, K, and McFadden, G. A secreted high affinity inhibitor of human TNF from tanapox virus *PNAS* **100:**4831-4836 (2003).
172. Johnston, JB, Barrett, JW, Chang, W, Chung, C, Zeng, W, Masters, J, Mann, M, Wang, F, Cao, J, and McFadden, G. Role of the serine-threonine kinase, PAK-1, in myxoma virus replication. *J. Virology* **77:10** 5877-5888 (2003)
173. Johnston, J and McFadden G. Poxviruses Immunomodulation Strategies: Current Perspectives *J. Virology* **77:**6093-6100 (2003).
174. Dai, E, Guan, H, Liu, L, Little, S, McFadden, G, Vaziri, S, Cao, H, Ivanova, IA, Bocksch, L and Lucas, A Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. *J. Biol. Chem.* **278:** 18563-18572 (2003).
175. Bedard, ELR, Kim, P, Jiang, J, Parry, N, Liu, Y, Wang, H, Garcia, B, Li, X, McFadden, G, Lucas, A and Zhong, R. Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts *Transplantation* **76:**249-252 (2003).
176. Brunetti, CR, Amano, H, Ueda, Y, Qin, J, Miyamura, T, Suzuko, T, Li, S, Barrett, JW and McFadden, G. The complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus *Journal of Virology* **77(24):**13335-13347 (2003).
177. Seet, BT, McCaughan, CA, Handel, TM, Mercer, A, McFadden, G and Fleming, SB Analysis of an orf virus chemokine-binding protein: shifting ligand specificity among a family of poxvirus viroceptors. *Proc. Nat. Acad. Sci. USA* **100(25):**15137-15142 (2003).
178. Sypula, J, Wang, F, Ma, Y, Bell, J and McFadden, G. Myxoma virus tropism in human tumor cells. *Gene Therapy and Molecular Biology* **8:**103-114 (2004).
179. Seet, B and McFadden, G. Interaction analysis of viral cytokine-binding proteins using surface plasmon resonance. In “Methods in Molecular Biology” Vol. 269, Ed. S. Isaacs. *Humana Press* 219-242 (2004).
180. Liu, L, Dai, E, Miller, L., Seet, B, Lalani, A, Macauley, C, Li, X, Virgin, HW, Bunce, C, Turner, P, Moyer, R, McFadden, G, and Lucas, A. Viral chemokine binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. *Transplantation* **77(11):**1652-1660 (2004).
181. Wang, G, Barrett, JW, Nazarian, S H, Everett, H, Gao, X, Bleackley, C, Colwill, K, Moran, MF and McFadden, G. Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak *J. Virology* **78:**7097-7111 (2004).
182. Johnston, JB and McFadden, G. Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. *Cellular Microbiology* **6(8):**695-705 (2004).
183. Lucas, A and G. McFadden. Secreted immunomodulatory proteins as novel biotherapeutics. *J. Immunology* **173:**4765-4774 (2004).
184. McFadden, G. Smallpox: An ancient disease enters the modern era of virogenomics. *Proc. Nat. Acad. Sci*, USA **101:**14994-14995 (2004).
185. Wang, F, Ma, Y, Barrett, JW, Gao, X, Loh, J, Barton, E, Virgin IV, HW and G. McFadden, Disruption of ERK-dependant type I interferon induction breaks myxoma virus species barrier. *Nature Immunology* **5:**1266-1274 (2004).
186. Nazarian, SH, McFadden, G and Huycke, M.M. Smallpox Ch 11 *In* “Biodefense: Principles and Pathogens” (Eds. M. Bronze and R.A. Greenfield). *Horizon Scientific Press* pp. 279-312 (2005).
187. Perez, DR, Nazarian, SH, McFadden, G and Gilmore, M.S. Miscellaneous threats: Highly pathogenic avian influenza and novel bio-engineered organisms. Ch 21 *In* “Biodefense: Principles and Pathogens” (Eds. M. Bronze and R.A. Greenfield). *Horizon Scientific Press* pp. 711-734 (2005).
188. Johnston, JB, Nazarian, S, Natale, R and McFadden, G. Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses *Virology* **332:**235-248 (2005).
189. McFadden, G. Poxvirus tropism *Nature Reviews Microbiology* **3:**201-213 (2005).
190. Cameron, CM, Barrett, JW, Liu L, Lucas, AR and McFadden, G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation *in vivo*. *Journal of Virology* **79(20):**6052-6067 (2005).
191. Cameron, C, Barrett, JW, Mann, M, Lucas, Alexandra R, and McFadden G. Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the down-regulation of macrophage activation *in vivo*. *Virology* **337:**55-67 (2005).
192. Stanford, MM. and McFadden, G. The ‘supervirus’?: Lessons from IL-4 expressing poxviruses. *Trends in Immunology* **26(8):**339-345 (2005).
193. McFadden, G. Gleevec casts a pox on poxvirus. *Nature Medicine,* **11(7):**711-712 (2005).
194. Johnston, JB, Wang, G. Barrett, JW, Nazarian, SH, Colvill, K, Moran, M and G. McFadden. Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. *Journal of Virology* **79(16):** 10750-10763 (2005).
195. Lun, Xueqing, Yang, Wenqing, Alain, Tommy, Shi, Zhong-Quiao, Muzik, Huong, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, Peter A. Forsyth. Myxoma virus is a novel oncolytic virus with significant activity against experimental gliomas *Cancer Research* **65(21):**9982-9990 (2005).
196. Johnston, JB J Barrett, SH Nazarian, M Goodwin, D Ricciuto, G Wang and G McFadden. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection *Immunity* **23:**587-598 (2005).
197. Gilbert, Philippe-Alexandre, Lacrimioara Comanita, John Barrett, Andrew Peters, Marta Szabat, Grant McFadden, Gregory A. Dekaban. 2005. Current status for high titre poxvirus stocks preparation in CEF under serum-free medium conditions: Implication for vaccine development. *Cytotechnology* **18:**79-88 (2005).
198. Gao, M, N Bruffato, T Chen, LL Murley, R Thalakada, M Domagala, B Beattie, D Mamelak, V Athanasopoulos, D Johnson, G McFadden, C Burks and L Frappier. Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system. *Journal of Proteome Research* **4:**2225-2235 (2005).
199. Johnston, JB and McFadden, G. Immunomodulation by poxviruses: insights into virus-host interactions by selectively deleting poxvirus genes. *In* “Modulation of Host gene expression of innate immunity by viruses.” (Ed. P. Palese). *Kluwer Plenum Press,* Ch. 8,pp. 163-186 (2005).
200. Nazarian, Steven H and McFadden G. Immune evasion by poxviruses. *Future Virology* **1(1):**123-132 (2006).
201. Lucas, A, McIvor, D. and McFadden, G. Virus-encoded chemokine modulators as novel anti-inflammatory reagents. *In* “Progress in Inflammatory Research” (Eds. B. Moser, GL. Letts and K. Neote). *Birkhauser Publishing, Basel*, Switzerland, Vol. 1: pp. 165-182 (2006).
202. Su J\*, Wang G\*, Barrett JW, Irvine TS, Gao X and McFadden G. Myxoma virus M11L blocks apoptosis through inhibition of the conformational activaton of Bax at the mitochondria *Journal of Virology* **80(3):** 1140-1151 (2006).
203. Rahman, MM and McFadden, G Modulation of tumor necrosis factor (TNF) by microbial pathogens *PLoS Pathogens* **2:**66-77 (2006).
204. Finlay B and McFadden G. Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens *Cell* **124:**767-782 (2006).
205. Bedard, ELR, J Jiang, J Arp, H Wang, H Guan, L Liu, LN Parry, P Kim, B Garcia, X Li, C Macauley, G McFadden, A Lucas and R Zhong. Prevention of chronic renal allograft rejection by SERP-1 protein. *Transplantation* (2006) **81:**908-914.
206. Wang G\*, Barrett JW\*, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ and McFadden G (\*denotes co-lead authorship) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. *PNAS* **103(12)** 4640-4645(2006).
207. Dai E, Viswanathan K, Sun YM, Li X, Liu L, Togonu-Bickersteth B, Richardson, J, Macaulay C, Nash P, Turner P, Nazarian SH, Moyer R, McFadden G and Lucas AR. Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses *J Biol. Chem.* **281:** 8041-8050 (2006).
208. Barrett JW, Sun Y, Nazarian SH, Belsito T and McFadden G. Optimization of codon usage of poxvirus genes allows for improved transient expression of mammalian cells *Virus Genes* **33**:15-26 (2006).
209. Rahman MM, Barrett JW, Brouckaert P and McFadden G. Variation in ligand binding specificities of a novel class of poxvirus-encoded TNF-binding protein, (2006) *J Biol. Chem.* **281**:22517-22526 (2006).
210. Sedger, LM, Osvath, SR, Xu, X, Li, G, Chan, F.K-M, Barrett, J. and McFadden, G. Poxviral Tumour Necrosis Factor Receptor (RNFR)-like T2 proteins contain a conserved pre-ligand assembly domain (PLAD) that inhibits cellular TNF-R1 induced cell death *J. Virology* **80(18):**9300-9309 (2006).
211. Gilbert, PA and McFadden, G. Poxvirus cancer therapy. *Rec. Pat. Anti-Infective Drug Dis.* **1**:309-321 (2006).
212. Barrett, JW and McFadden, G. *“*The Leporipoxviruses” *In* Advances in Infectious Diseases (Ed. Andrew Mercer)Birkhäuser Publishing, Basel Switzerland, pp. 183-201 (2007).
213. Nazarian, SH. and McFadden, G. *“*Immunomodulation by Poxviruses” *In* Advances in Infectious Diseases (Ed. Andrew Mercer) Birkhäuser Publishing. Basel Switzerland, pp 273-296 (2007).
214. Barrett, JW, Sypula, J, Wang, F, Alston, L, Shao, Z, Gao, X, Irvine, TS, and McFadden, G. M135R is a novel cell surface virulence factor of myxoma virus. *J. Virology* **81**:106-114 (2007).
215. Stanford, MM, Barrett, JW, Nazarian, SH, Werden, S and McFadden, G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells, *Journal of Virology* **81:**1251-1260 (2007).
216. Stanford M, Werden S, and McFadden G. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. *Veterinary Research*. **38:**299-318 (2007).
217. Werden, S, Barrett, JW, Wang, G, Stanford, M, and McFadden, G. M-T5, the ankyrin repeat, host range protein of myxoma virus activates Akt and can be functionally replaced by PIKE-A. *Journal of Virology***81:**2340-2348 (2007).
218. Stanford, MM, McFadden, G., Karupiah, G, and Chaudhri, G. Immunopathology of poxvirus infections: forecasting the impending storm. *Imm. Cell. Biol.*  **85(2):**93-102 (2007).
219. Barrett, JW, Chang, CS, Wang, G, Werden, SJ, Shao Z, Barrett, C, Gao, X, Belsito, TA, Villeneuve, D, and McFadden, G. Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. *Virology* **361:**123-132 (2007).
220. Douglas, AE, Corbett, KD, Berger, JM, McFadden, G, and Handel, TM. Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. *Protein Sci.* **16:**695-703 (2007).
221. Rahman, MM, and McFadden G. BAFfled by Poxviruses? *Cell Host & Microbe* **1:**159-160 (2007).
222. Nazarian, SH, Barrett, JW, Frace, AM, Olsen-Rasmussen, M, Khristova, M, Shaban, M, Neering, S, Li, Y, Damon, IK, Esposito, JJ, Essani K, and McFadden, G. Comparative genetic analysis of genomic DNA sequences of two human isolates of Tanapox virus. *Virus Research* **129:**11-25(2007).
223. Lun, XQ, Zhou, H, Alain, T, Sun, B, Wang, L, Barrett, JW, Stanford, MM, McFadden, G, Bell, J, Senger, DL, and Forsyth PA. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. *Cancer Research* **67(18):**8818-8827 (2007).
224. Nazarian, SH, Barrett, JW, Stanford, MM, Johnston, SB, Essani, K, and McFadden, G. Tropism of *Tanapox virus* infection of primary human cells. *Virology* **368:**32-40 (2007).
225. Stanford, MM, Barrett, JW, Gilbert, P-A, Bankert, R, and McFadden, G. Myxoma virus expressing human IL-12 does not induce myxomatosis in European rabbits. *J Virology* **81(22):**12704-12708 (2007).
226. Johnston JB, Rahman MM, and McFadden G. Strategies that modulate inflammasomes – insights from host-pathogen interactions. *Sem in Immunopathology* **29(3):**261-274 (2007).
227. Jiang, J, Arp, J, Kubelik, D, Zassoko, R, Liu, W, Wise, Y, Macaulay, C, Garcia, B, McFadden, G, Lucas, AR, and Wang, H. Induction of indefinite cardiac allograft survival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibityor-1 (Serp-1) treatment. *Transplantation* **84:**1158-1167 (2007).
228. Barrett, JW, Alston, LR, Wang, F, Stanford, MM, Gilbert, P-A, Gao, X, Jimenez, J, Villeneuve, D, Forsyth, P and McFadden, G. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. *J NeuroVirology* **13(6):**549-560 (2007).
229. Stanford, MM, and McFadden, G. Myxoma virus and oncolytic virotherapy: A new biological weapon in the war against cancer. *Exp. Op. Bio. Ther.* **7:**1415-25 (2007).
230. Nazarian, SH, Rahman, MM, Werden, SJ, Villeneuve, D, Meng, X, Brunetti, C, Valeriano, C, Wong, C, Singh, R, Barrett, JW, Xiang, Y, and McFadden, G. Yaba monkey tumor virus encodes a functional inhibitor of IL-18. *J. Virology* **82(1):**522-528 (2008).
231. Stanford, MM, Shaban, M, Barrett JW, Gilbert, PA, Bondy-Denomy J, Mackenzie L, Graham KC, Chambers AF, and McFadden, G. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo *Molecular Therapy* **16:**52-59 (2008).
232. Stanford, MM, Breitbach, CJ, Bell, JC, and McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: Friends or foes? *Curr. Op. Molec. Therapeutics* **10(1)**:32-37 (2008).
233. Wu, Y, Lun, X, Zhou, H, Wang, L, Sun, B, Bell, JC, Barrett, JW, McFadden, G, Biegel, JA, Senger, DL, and Forsyth, PA. Oncolytic efficacy of recombinant vesicular stomatitis virus (VSVΔM51) and myxoma virus in experimental models of rhabdoid tumors. *Clin. Cancer Res.* **14(4):**1218-1227 (2008).
234. Werden, SJ, and McFadden, G. The role of cell signaling in poxvirus tropism: The case of the M‑T5 host range protein of myxoma virus. *BBA-Proteins and Proteomics.* **1784:**228-237 (2008).
235. Su, J, Willert, C, Comanita, L, Peters, A, Gilbert, P-A, Strathdee, C, O’Connell, P, McFadden, G, and Dekaban GA. Anti-apoptotic molecule M11L enhances CD8+ T cell responses to HIV-1 envelope protein in a prime-boost vaccine regimen. *Virology* **375:**48-58 (2008).
236. McFadden, G. Leporipoxviruses and Suipoxviruses.  *In* Encyclopedia of Virology Third Edition (Eds. BWJ Mahy and MHV Van Regenmortel), pp. 225-230. Oxford: Elsevier (2008).
237. Barrett JW and McFadden G. Yatapoxviruses. *In* Encyclopedia of Virology Third Edition (Eds. BWJ Mahy and MHV Van Regenmortel), pp. 461-465. Oxford: Elsevier (2008).
238. Werden, SJ, Rahman, MM, and McFadden, G. Poxvirus host range genes. *Adv. Virus Research* **71:**135-171 (2008).
239. Barrett, JW and McFadden, G. Origin and Evolution of Poxviruses. *In*: Origin and Evolution of Viruses, 2nd Edition. (Ed. E. Domingo, C.R. Parrish, and J. Holland). pp. 431-446 Oxford: Elsevier Publishing (2008).
240. Woo, Y, Stanford, MM, Galanis, C, Chun, YS, Fong, Y, and McFadden, G. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. *Ann. Surg. Oncology* **15(8)**:2329-2335 (2008).
241. Haldar, K., G. McFadden, and J. A. Young. "Change in the editorial leadership of PLoS Pathogens." *PLoS.Pathogens* **4(9):** e1000167. doi:10.1371/journal.ppat.1000167 (2008).
242. Lucas, A, Liu, L, Dai, E, Bot, Il, Viswanathan, K, Munuswamy-Ramunujam, G, Davids, JA, Bartee, MY, Richardson, J, Christov, A, Wang, H, Macaulay, C, Poznansky, M, Zhong, R, Miller, L, Biessen, E, Richardson, M, Moyer, R, Hatton, M, Lomas, DA, and McFadden G. The Serpin Saga; Development of a New Class of Virus Derived Anti-Inflammatory Protein Immunotherapeutics. *In:* Pathogen-derived Immunomodulatory Molecules (Ed. P. Fallon)   
     Landes Bioscience (2008) http://www.eurekah.com/chapter/4036.
243. Adams, MM, van Leeuwen, BH, McFadden, G, and Kerr, PJ. Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells. *Vet Research* **39:**60 DOI: 10.1051/vetres:2008037 (2008) www.vetres.org.
244. Wang, F, Gao, X, Irvine, T, Barrett, JW, Shao, Q, Cao, J, and McFadden, G. R1G-I-mediated induction of tumor necrosis factor is essential for human cellular innate restriction to myxoma virus. *PLoS Pathogens* **4:**e1000099 (2008).
245. Li, X, Schneider, H, Peters, A, Macaulay, C, King, E, Sun, Y, Liu, L, Dai, E, Davids, JA, McFadden, G, Lucas, A. Heparin alters viral serp-1, anti-thrombolytic activity to anti-thrombotic activity. *Open Biochem. J.* **2**:6-15 (2008).
246. Bartee, E, Mohamed, MR, and McFadden G. Tumor necrosis factor and interferon: Cytokines in harmony.  *Curr. Op. Micro.* **11(4)**:378-383 (2008).
247. Moussatché, N, Damaso, CR, and McFadden, G. When good vaccines go wild: Feral orthopoxvirus in the third world and beyond. *J. Inf. Developing Countries* **2(3):**156-173 (2008).
248. Rahman, MM, Lucas, AR, and McFadden, G. Viral TNF inhibitors as potential therapeutics. *In:* Pathogen-derived Immunomodulatory Molecules (Ed. P. Fallon) *Landes Bioscience* (2009). Chapter 5, pp. 64-77.
249. Bartee, E, Mohamed, MR, Lopez, C, Baker, H, and McFadden, G. Addition of TNF plus IFN-β induces a novel synergistic anti-viral state against poxviruses in primary human fibroblasts. *J Virology* **83(2)**:498-511 (2009).
250. Rahman, M, Jeng, D, Singh, R, Coughlin, J, Essani, K, McFadden, G. Interaction of human TNF and β2-microglobulin with Tanapox virus-encoded TNF inhibitor, TPV-2L. *Virology* **386:**462-468(2009).
251. Zhang, L, Villa, N, and McFadden, G. Interplay between poxviruses and the cellular ubiquitin/ubiquitin-like (Ub/Ubl) pathways. *FEB Lett* **583:**607-614 (2009).
252. Wang, F, Barrett, J, Shao, Q, Gao, X, Dekaban, G and McFadden, G. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of Tyk2. *Virology* **387:**136-146 (2009).
253. Bartee, MY, Dai, E, Liu, L, Munuswamy-Ramanujam, G, Macaulay, C, McIvor, D, McFadden, G, Lucas, AR. M-T7: Measuring chemokine-modulating activity. *Methods in Enzymology* **460:** 209-228 (2009).
254. Wang, F, Barret, JW, Ma, Y, Dekaban, GA, McFadden, G. Induction of Alpha/Beta interferon by myxoma virus is selectively abrogated when primary murine embryo fibroblasts become immortalized. *J. Virology* **83(11):** 5928-5932 (2009).
255. Liu, J, Weinnier, S, Reinhard, M, Roy, E, MacNeill, A, McFadden, G. Myxoma virus expressing IL-15 fails to cause lethal myxomatosis in European rabbits. *J. Virology* **83:** 5933-5938 (2009).
256. Enquist, LW, Beemon, KL, Caughey, BW, Dermody, TS, Diamond, MS, DiMaio, DC, Doms, RW, Ganem, DE, Greenberg, HB, Hahn, BH, Imperiale, MJ, Koup, RA, Lyles, DS, McFadden, G, Nelson, JA, Palese, PM, Perlman, S, Raab-Traub, N, Ross, SR, Sandri-Goldin, RM, Semler, BL, Sen, GC, Simon, A. Virology in the 21st century. *J. Virology* **83(11):** 5296-5308 (2009).
257. Mohamed, M, Rahman, M, Lanchbury, J, Shattuch, D, Neff, C, Dufford, M, van Buuren, N, Fagan, K, Barry M, Smith, S, Damon, I, McFadden, G. Proteomic screening of variola reveals a novel NF-кB inhibitor that is highly conserved among pathogenic orthopoxviruses. *Proc. Nat. Acad. Sci. USA* **106(22):** 9045-9050 (2009).
258. Madhani, HD, Haldar, K, McFadden, G. “Pearls”: A new type of open-access educational resource. *PLoS Pathogens* **5(6):** e1000499 (2009).
259. McFadden, G, Mohamed, MR, Rahman, MM, Bartee, E. Cytokine determinants of viral tropism. *Nature Reviews Immunology* **9:**645-655 (2009).
260. Kerr, P, and McFadden, G. Leporipoxviruses In: Tidona, C., Darai, G. (Eds.) The Springer Index of Viruses, 2nd ed. Springer, New York, USA (2009).
261. Barrett, JW, Werden, SJ, Wang, F, Jimenez, J, Villeneuve, D, McFadden, G, and Dekaban, GA. Myxoma virus M130R is required for lethal myxomatosis in rabbits. *Virus Research* **144:**258-265 (2009).
262. Bartee, E, McFadden, G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by Tumor Necrosis Factor plus Interferon-β. *Cytokine* **47:**199-205 (2009).
263. Mohamed, MR, Rahman, MM, Rice, A, Moyer, R, Werden, S, McFadden, G. Cowpox virus expresses a novel ankyrin repeat NF-кB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis. *J. Virology* **83(18):**9223-9236 (2009).
264. Zhang, L, Stanford, M, Liu, J, Barrett, C, Jiang, L, Barclay, NA, McFadden, G. Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200). *J. Virology* **83(18):**9602-9607 (2009).
265. Mohamed, MR, & McFadden, G. NFкB inhibitors: Strategies from poxviruses. *Cell Cycle* **8(19):** 3125-3132 (2009).
266. Zhang, L, Villa, N, Rahman, MM, Smallwood, S, Shattuck, D, Neff, C, Dufford, M, Lanchbury, J, LaBaer, J, McFadden, G. Analysis of Vaccinia Virus – Host Protein – Protein Interactions: Validations of Yeast Two-Hybrid Screenings. *J. Proteome Research* **8:**4311-4318 (2009).
267. Kim, M\*, Madlambayan, G\*, Rahman, M, Smallwood, S, Joseph, S, Meacham, A, Hosaka, K, Scott, EW, Cogle, C, McFadden, G. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. (\*co-lead authors). *Leukemia* **23:**2313-2317 (2009).
268. Werden, S, Lanchbury, J, Shattuck, D, Neff, C, Dufford, M, McFadden, G. Myxoma virus M-T5 ankyrin-repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells. *J. Virology* **83:**12068-83 (2009).
269. Rahman, MM, Mohamed, MR, Kim, M, Smallwood, S, McFadden, G. Co-regulation of NF-кB and inflammasome-mediated inflammatory responses by Myxoma virus pyrin domain-containing protein M013. *PLoS Pathogens* **5(10):** e1000635 (doi:10.1371/journal.ppat.1000635) (2009).
270. Van Vliet, K, Mohamed, MR, Zhang, L, Villa, N, Werden, S, Liu, J, McFadden, G. Poxvirus Proteomics. *Micro. Mol. Biol. Reviews* **73(4):**730-749 (2009).
271. Lun, X, Alain, T, Zemp, F, Zhou, H, Rahman, M, Hamilton, M, McFadden, G, Bell, J, Senger, DL, Forsyth, PA. Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin. *Cancer Research* **70(2):**598-608 (2010).
272. Josiah, D, Zhu, D, Dreher, F, Olson, J, McFadden, G, and Caldas, H. Adipose-derived Stem Cells as Therapeutic Delivery Vehicles of an Oncolytic Virus for Glioblastoma. *Molecular Therapy* **18(2):**377-385 (2010).
273. McFadden, G. Killing a Killer: What next for Smallpox? *PLoS Pathogens* **6(1):**e1000727 (2010).
274. Werden, SJ and McFadden, G. Pharmacological manipulation of the Akt signaling pathway regulates myxoma virus replication in human cancer cells. *J Virol* **84(7):**3287-3302 (2010).
275. Früh, K, Finlay, B, McFadden, G. On the road to systems biology of host-pathogen interactions. *Future Microbiology* **5(2):**131-133 (2010).
276. Villa, NY, Bartee, E, Mohamed, MR, Rahman, MM, Barrett, JW and McFadden, G. Myxoma and vaccinia virus exploit different mechanisms to enter and infect human cancer cells. *Virology* **401:**266-279 (2010).
277. Dai, E, McIvor, D, Liu, L-Y, Sun, Y, Macaulay, C, King, E, Munuswamy-Ramanujam, G, Esko, JD, Charo, I, McFadden, G, and Lucas, A. Chemokine regulation of inflammatory cell invasion and transplant vasculopathy: analysis of glycosaminoglycan and receptor interactions. *PLOS One* **5(5):**e10510.doi:10.1371/journal.pone.0010510.
278. Rahman, MM, Madlambayan, GJ, Cogle, CR, and McFadden, G. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with myxoma virus. *Cytokine and Growth Factor Reviews* **21:**169-175 (2010).
279. Kim, M, Williamson, C, Bebb, G, Forsyth, PP, Lee, PWK, Lees-Miller, S, McFadden, G, and Johnston, RN. The cellular tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is regulated by common host tumor suppressor genes. *Oncogene* **29:**3990-3996 (2010).
280. Barrett, JW and G. McFadden. Tanapox virus. In Molecular Detection of Human Viral Pathogens (Ed. Lui D.), pp. 1037-1044. Taylor and Francis Publishing (2010).
281. Smallwood, SE, Rahman, MM, Smith, DW and McFadden, G. Myxoma virus: Propagation, purification, quantification and storage. *Current Protocols in Microbiology* (doi:10.1002/9780471729259.mc14a01s17) (2010).
282. Tardif, J-C, L’Allier, PL, Gregoire, J, Ibrahim, R, McFadden, G, Kostuk, W, Knudtson, M, Labinaz, M, Waksman, R, Pepine, C, Macaulay, C, Guertin, M-C, Lucas, A. A Randomized Controlled Trial of the Viral Serpin Serp-1 in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. *Circ. Cardiovasc. Interv.* **3**:543-548 (2010).
283. Liu, J, Wennier, S, and McFadden, G. The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. *Microbes and Infection* **12**:1144-1152 (2010).
284. France, MR, Thomas, DL, McFadden, G, MacNeill, A and Roy, E. Intraventricular Injection of Myxoma Virus Results in Transient Expression of Viral Protein in Mouse Brain Ependymal and Subventricular Cells. *J. General Virology* **92**:195-199 (2011).
285. Liu, J, Wennier, S, Zhang, L, and McFadden, G. M062 is a host range factor with essential role in viral replication and binds to SAMD9 during infection in human cells. *J. Virology* **85**(7): 3270-3282 (2011).
286. Rahman, M and McFadden, G. Modulation of NF-kB signaling by microbial pathogens. *Nat. Rev. Micro.* **9:** 291-306 (2011).
287. Wennier, S, Li, S, and McFadden, G. Oncolytic virotherapy for pancreatic cancer. *Expert Rev. Molecular Medicine* **13:** e18 (2011).
288. Thomas, DL, Doty, R, Tosic, V, Liu, J, Kranz, DM, McFadden, G, MacNeill, A and Roy, E. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. *Cancer Immunol. Immunother.* **60:** 1461-1472 (2011).
289. Chen, H, Zheng, D, Davids, J, Bartee, MY, Thoburn, R, Sobel, E, Moyer, R, McFadden, G and Lucas, A. Viral Serpin Therapeutics: From Concept to Clinic. *Methods Enzymology* **499:** 301-329 (2011).
290. Spiesschaert, B, McFadden, G, Hermans, K, Nauwynck, H, Van de Walle, G. The current status and future directions of myxoma virus, a master in immune evasion. *Veterinary Research* **42:** 76-94 (2011).
291. Dai, P, Cao, H, Merghoub, T, Francesca, A, Wang, W, Parikh, T, Fang, C-M, Pitha, PM, Fitzgerald, KA, Rahman, MR, McFadden, G, Houghton, AN, Shuman, S and Deng, L. Myxoma virus induces type I IFN production in murine plasmacytoid dendritic cells via a TLR9/MyD88, IRF5/IRF7, and the type I IFN receptor-dependent pathway. *J Virology* **85:** 10814-25 (2011).
292. Rahman, M. M., and McFadden, G. Myxoma virus lacking the Pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple TLRs, which independently activate the inflammasome and NF-κB innate response pathways. *J Virology* **85:** 12505-12517 (2011).
293. McFadden, G and Simon, AE. Building bridges between plant and animal viruses. *Current Opinion in Virology* **1**: 319-321 (2011).
294. Jeng, D, Rahman, MM, McFadden, G and Essani, K. Tumor Necrosis Factor Inhibitors from Poxviruses with an Emphasis on Tanapoxvirus-2L Protein. *Recent Pat DNA Gene Seq* **5:** 97-103 (2011).
295. Bais, S, Bartee, E, Rahman, M, McFadden, G and C Cogle. Oncolytic Virotherapy for hematological malignancies. *Advances in Virology, Special issue on Oncolytic Viruses* doi: 10.1155/2012/186512 (2012).
296. \*Madlambayan, GJ, \*Bartee, E, \*Kim, M, Rahman, M, Meacham, A, Smallwood, S, Scott, EW, McFadden, G and Cogle, C. Oncolytic virus tropism *in vitro* does not predict oncolytic efficacy *in vivo*: Oncolytic efficacy of myxoma virus for nonpermissive human myeloid leukemia. *Leukemia Research* **36:** 619-624 (2012) (\* denotes co-lead authors).
297. Wennier, S., Liu, J., Li, S., Rahman, M.M., Mona, M. and McFadden, G. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. *Molecular Therapy* **20 (4):** 759-768 (2012).
298. Correa, RJM, Komar, M, Tong, JGK, Sivapragasam, M, Rahman, MR, McFadden, G, DiMattia, GE and Shepherd, TG. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. *Gynecologic Oncology* **125:**441-450(2012).
299. McFadden, G. Pathogens and People: Reflections from Haiti. PLoS Medicine Blogs <http://blogs.plos.org/speakingofmedicine/2012/03/02/pathogens-and-people-reflections-from-haiti/> (2012)
300. Liu, J, Wennier, S, Moussatche, N, Reinhard, M, Condit, R and McFadden, G. Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits. *J Virology* **86:** 5371-5375 (2012).
301. Cao, H, Dai, P, Wang, W, Li, H, Yuan, J, Fang, CM, Pitha, PM, Liu, J, Condit, RC, McFadden, G, Merghoub, T, Houghton, AN, Young, JW, Shuman, S and Deng, L. Innate immune response of human plamacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. *PLoS One* 7(5): e36823. doi:10.1371/journal.pone.0036823 (2012).
302. Wennier, S, Liu, J and McFadden, G. Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy. *Cur Pharm. Biotechnology* **13(9):** 1817-1833 (2012).
303. Bartee, E, Meachem, A, Wise, E, Cogle, C and McFadden, G. Virotherapy using myxoma virus prevents lethal graft-vs-host disease following xeno-transplantation with primary human hemapoietic stem cells. *PLoS One* **7(8):** e43298 (2012).
304. Bartee, E, Chan, WS, Moreb, JS, Cogle, CR, and McFadden, G. Selective purging of human multiple myeloma cells from autologous stem cell transplant grafts using oncolytic myxoma virus. *Biology of Blood and Marrow Transplantation,* **18(10):** 1540-1551 (2012).
305. Li, S, Tong, J, Rahman, MM, Shepherd, TG and McFadden, G. Oncolytic virotherapy for ovarian cancer. *Oncolytic Virotherapy* **1:** 1-21 (http://dx.doi.org/10.2147/OV.S31626) (2012).
306. Liu, J, Rothenberg S and McFadden, G. The Poxvirus C7L Host range Superfamily: An old story newly told. *Current Opinion in Virology* **2:** 764-772 (2012).
307. Doty, RA, Liu, J, McFadden, G, Roy, EJ and MacNeill, AL. Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma. *Oncolytic Virotherapy* **1:** 1-17 (http://dx.doi.org/10.2147/OV.S37971)(2012).
308. Craig N. Jenne, Connie H. Y. Wong, Braedon McDonald, Franz J. Zemp, Masmudur M. Rahman, Peter A. Forsyth, Grant McFadden and Paul Kubes. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. *Cell Host & Microbe* **13:** 169-180 (2013).
309. Jeng, D, Ma, Z, Barrett, JW, McFadden, G, Loeb, JA and Essani, K. The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. *J Virology* **87:** 3018-3026 (2013).
310. Chan, WM, Bartee, EC, Moreb, JS, Dower, K, Connor, JH and McFadden G. Myxoma and vaccinia viruses bind differentially to human leukocytes. *J Virology* **87:** 4445-4460 (2013).
311. Zemp, FJ, Lun, X, McKenzie, BA, Zhou, H, Maxwell, L, Sun B, Kelly, JJP, Stechishin, O, Luchman, A, Weiss, S, Cairncross, JG, Hamilton, MG, Rabinovich, Rahman, MR, Mohamed, MR, Smallwood, S, Senger, DL, Bell, J, McFadden, G and Forsyth, PA. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. *Neuro-Oncology* **15(7):** 904-920 (2013).
312. Zemp, FJ, Mckenzie, BA, Lun, X, Maxwell, L, Reilly, KM, McFadden, G, Yong, VW and Forsyth, PA. Resistance to oncolytic myxoma virus therapy in Nf1-/-/Trp-/- syngeneic mouse glioma models is independent of anti-viral type I interferon. *PLoS One* **8(6)** e65801 (2013).
313. Ana Lemos de Matos, Jia Liu, Grant McFadden and Pedro J. Esteves. Insights into the evolution, structure and function of SAMD9 and SAMD9-like genes in mammals. *BMC Evolutionary Biology* **13:** 121 (doi: 10.1186/1471-2148-13-121) (2013).
314. Bartee, E and McFadden, G. Cytokine Synergy: An underappreciated contributor to innate anti-viral immunity. *Cytokine* **63:** 237-240 (2013).
315. Chan, WM, Rahman, MM and McFadden G. Oncolytic Myxoma Virus: The path to clinic. *Vaccine* **33:** 4252-4258 (2013).
316. Rahman, MM, Liu, J, Chan, W, Rothenberg, S and McFadden, G. Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication. *Plos Pathogens* **9:7** e1003465 (2013).
317. Ogbomo, H, Lun, X, Zhang, J, Zemp, FJ, Stack D, Rahman, MR, McFadden, G, Mody, CH and Forsyth, PA. Immunovirotherapy for brain tumors: Myxoma virus accelerates NK lysis of malignant gliomas *in vitro* and *in vivo*. *PLoS One* **8(6):** e66825 (2013).
318. De Matos, AL, McFadden, G and Esteves, PJ. Positive evolutionary selection on the RIG-I-like receptor genes in mammals. *PLoS One* **8(11):** e81864 (2013).
319. Hao Chen, Donghang Zheng, Jeff Abbott, Liying Liu, Mee Y Bartee, Maureen Long3 Jennifer Davids, Jennifer Williams, Heinrich Feldmann, Colin Macaulay, Grant McFadden, Robert Thoburn, David A. Lomas, Francis G. Spinale, Herbert W. Virgin, and Alexandra Lucas. Poxvirus-derived Serpin Prolongs Survival as a Unique Therapeutic Approach in Unrelated Lethal Mouse Viral Infections. *Antimicrobial Agents and Chemotherapy* **57(9):** 4114-4127 (2013).
320. Liu, L, Dai, E, Kidwai, B, Davids, J, Macaulay, C, McFadden, G and Lucas, A. Comparative analysis of plaque growth after arterial stent implant with anti-inflammatory chemokine and serine protease inhibitors treatment. *J Clinical Experimental Cardiology* **4:274,** DOI: 10.4172/2155-9880.1000274 (2013).
321. Zheng, D, Chen, H, Martee, MY, Williams, J, Davids, J, Lomas, DA, McFadden, G and Lucas, AR. Myxomaviral anti-inflammatory serpin reduces myeloid-derived suppressor cells and human pancreatic cancer cell growth in mice. J. Cancer Sci Ther **5:** 291-299, DOI: 10.4172/1948-5956.1000219 (2013).
322. Haller, SL, Peng, C, McFadden, G and Rothenberg, S. Poxviruses and the evolution of host range and virulence. *Infection, Genetics and Evolution* **21:** 15-40 (2014).
323. De Matos, AL, McFadden, G and Esteves, PJ. Evolution of viral sensing RIG-I-like receptor genes in Leporidae genera *Oryctolagus, Sylvilagus* and *Lepus.* *Immunogenetics* **66:** *43-52* (2014). DOI: 10.1007/s00251-013-0740-7
324. Bell, J and McFadden, G. Viruses for tumor therapy. *Cell Host & Microbe* **15:** 260-265 (2014).
325. Weng, M, Gong, W, Ma, M, Chu, B, Qing, Y, Zhang, M, Lun, X, McFadden, G, Forsyth, P, Yang, Y, and Quan, Z. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin *in vitro* and further improved by hyaluron *in vivo*. *Molecular Cancer* **13:** 82- 97 (2014).
326. Damon, I, Damaso, CR and McFadden, G. Are we there yet? The smallpox research agenda using live variola virus. *PLoS Pathogens* **10(5):** e1004108 (2014).
327. Brahn, E, Lee, S, Lucas, A, McFadden, G and Macaulay, C. Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus. *Clinical Immunology* **153:** 254-263(2014).
328. Chan, W and McFadden, G. Oncolytic poxviruses. *Ann. Rev. Virology* **1:** 191-214 (2014).
329. Lamb, SA, Rahman, MM and McFadden, G. Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulence. *Virology* **464-465:** 134-145 (2014).
330. Tosic, V, Thomas, DL, Kranz, DM, Liu, J, McFadden, G, MacNeil, AL and Roy, EJ. Myxoma virus expressing a fusion protein of Interleukin-15 (IL-15) and IL-15 Receptor alpha has enhanced antitumor activity. *PLoS One* **9(10):** e109801 (2014).
331. Davids, JA, Dai, E, Chen, H, Bartee, MY, Liu, L, Fortunel, A, Moyer, R, McFadden, G and Lucas, AR. Viral anti-inflammatory proteins target diverging immune pathways with converging effects on arterial dilatations, plaque and apoptosis. *European J of Inflammation*, **12(1):** 131-145 (2014).
332. Liu, J and McFadden, G. SAMD9 is an innate antiviral host factor with stress response properties than can be antagonized by poxviruses. *J Virology* **89(3):** 1925-1931 (2015).
333. Zemp, FJ, McKenzie, BA, Lun, X, Reilly, KM, McFadden, G, Yong, VW and Forysth, PA. Cellular factors resistance to effective treatment of glioma with oncolytic myxoma virus. *Cancer Research* **74(24):** 7260-7273 (2015).
334. Ildefonso, CJ, Jaime, H, Rahman, MR, Li, Q, Boye, SE, Hauswirth, WW, Lucas, AR, McFadden, G, and Lewin, AS. AAV vector expressing a virus-derived dual inhibitor of inflammasomes and NF-kB is a novel therapeutic for inflammatory eye disease. *Human Gene Therapy* **26:** 59-68 (2015).
335. Boutard, B, Vankerckove, S, Markine-Goriaynoff, N, Sarlet, M, Desmecht, D, McFadden, G, Vanderplasschen, A and Gillet, L. The alpha-2,3-sialyltransferase encoded by myxoma virus is a virulence factor that interferes with inflammation. *PLoS One* **10(2):** e011806 (2015).
336. McFadden, G and Haldar, K. Introducing “Research Matters”. *PLoS Pathogens* **DOI:** 10:1371/journal.ppat.1005014 (2015).
337. McFadden, G. The curious road from basic pathogen research to clinical translation. *PLoS Pathogens* **DOI:** 10:1371/journal.ppat.1004997 (2015).
338. Kim, M, Rahman, MM, Cogle, CR and McFadden, G. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. *Biochemical and Biophysical Research Communications* **462:** 283-287 (2015).
339. Villa, NY, Wasserfall, C, Meachem, A, Wise, E, Chan, W, Wingard, JR, McFadden, G and Cogle, CR. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. *Blood* **125 (24):** 3778-3788 (2015).
340. Tong, JG, Valdes, YR, Barrett, JW, Bell, JC, Stojdl, D, McFadden, G, McCart, A, DiMattia, GE and Shepherd, TG. Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis. *Molecular Therapy-Oncolytics* **2:** e15013 (2015).
341. Lucas, A, Wakefield, D, Bryant, M, Chen, H, Ambadapadi, S, Morshed, S, DeJesus, D, Clapp, W and McFadden, G. Glycosaminoglycans (GAGs) in Cardiovascular Disease: Searching for the Sweet Spot. *J Clin. Exp. Cardiology* **7(1):** 1000e141 (2016).
342. Villa, N, Bais, S, Meachem, AM, Wise, E, Rahman, MM, Moreb, J, Rosenau, EH, Wingard, JR, McFadden, G and Cogle, CR. *Ex vivo* virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells *Cytotherapy* **18:** 465-480(2016).
343. Pisklakova, A, McKenzie, B, Zemp, F, Lun, X, Etame, A, Kenchappa, RS, Rahman, MR, Reilly, K, Pilon-Thomas, S, McFadden, G, Kurz, E and Forsyth, P. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. *Neuro-Oncology* **18:**1088-1098 (2016).
344. Peng, C, Haller, S, Rahman, MM, McFadden, G and Rothenberg, S. Myxoma virus M156 is a specific inhibitor of rabbit PKR and contains a loss-of-function mutation in Australian virus isolates. *PNAS* doi: 10.1073/pnas.1515613113 (2016).
345. Villa, NY, Rahman, MM, McFadden, G and Cogle, CR. Therapeutics for Graft-vs-Host-Disease: From conventional therapies to novel virotherapeutic strategies. *Viruses* **8:85;** doi:10.3390/v8030085 (2016).
346. Andrade, LG, Albarnaz, JD, Mugge, FLB, David, BA, Abrahao, JS, Fonseca, FG, Kroon, EG, Menezes, GB, McFadden, G and Bonjardim, CA. Vaccinia virus dissemination requires p21-activated kinase 1. *Archives Virology* DOI 10.1007/s00705-016-2996-3 (2016).
347. McFadden, G. Speaking of Medicine Community Blog: Reflections from Haiti-2016. PLoS Medicine, Pathogens, Neglected Tropical Diseases Blogs (2016): <http://blogs.plos.org/speakingofmedicine/2016/04/01/reflections-from-haiti-2016/>
348. Lilly, CL, Villa, NY, de Matos, AL, Ali, HM, Dhillon, JKS, Hofland, T, Rahman, MM, Chan, W, Bogen, B, Cogle C and McFadden, G. *Ex vivo* oncolytic virotherapy with myxoma virus arms multiple allogeneic bone marrow transplant leukocytes to enhance graft-vs-tumor. *Molecular Therapy-Oncolytics* doi.org/10.1016/j.omto.2016.12.002 (2017).
349. Rahman, MM and McFadden, G. Species specific inhibition of type I interferon responses by the dsRNA-binding protein M029 regulates myxoma virus cell species tropism independently of PKR. *Viruses* **9**(2): 27 doi:[10.3390/v9020027](http://dx.doi.org/10.3390/v9020027) (2017).
350. Rahman, MM, Bagdassarian, E, Ali, MAM, and McFadden, G. Identification of host DEAD-box helicases that regulate cellular tropism of oncolytic myxoma virus in human cancer cells. *Scientific Reports,* **7:** 15710| DOI:10.1038/s41598-017-15941-1 (2018).
351. Esteves, PJ, Abrantes, J, Baldauf, HM, BenMohamed, L, Chen, Y, Christensen, N, González-Gallego, J, Giacani, L, Hu, J, Kaplan, G, Keppler, OT, Knight, KL, Kong, XP, Lanning, DK, Pendu, J, Lemos de Matos, A, Liu, J, Liu, S, Lopes, AM, Lu, S, Lukehart, S, Manabe, YC, Neves, F, McFadden, G, Pan, R, Peng, X, de Sousa-Pereira, P, Pinheiro, A, Rahman, MM, Ruvoën-Clouet, N, [Subbian](javascript:void(0);), S, Tuñón, MJ, van der Loo, W, Vaine, M, Via, L, Wang S, and Mage, R.The wide utility of rabbits as models of human diseases. *Experimental and Molecular Medicine* DOI 10.1038/s12276-018-0094-1 (2018).
352. Forbes, NS, Coffin, R, Deng, L, Evgin, L, Fiering, S, Giacalone, M, Gravekamp, C, Gulley, JL, Gunn, H, He, M, Hoffman, RM, Kaur, B, Liu, K, Lyerly, K, Marciscano, AE,Moradian, E, Rasooly, A, Ruppel, S, Saltzman, DA, Tattersall, PJ, Thorne, S, Vile, RG, Zhang, HH, Zhou, S, and McFadden, G. White Paper on Microbial Anti-Cancer Therapy and Prevention. *Journal for Immunotherapy of Cancer* **6:**78 <https://doi.org/10.1186/s40425-018-0381-3> (2018).
353. Phelps, MP, Yang, H, Patel, S, Rahman, MM, McFadden, G and Chen, E. Oncolytic virus-mediated RAS targeting in rhabdomyosarcoma. *Molecular Therapy-Oncolytics* **11:** https://doi.org/10.1016/j.omto.2018.09.001. (2018).
354. Villa, NY and McFadden, G. Virotherapy as adjunct therapy for Graft-vs-Host Disease. *Current Pathobiology Reports* **6:** 247–263. https://doi.org/10.1007/s40139-018-0186-6 (2018).
355. Wolfe, AM, Rahman, M, McFadden, G and Bartee, E. Refinement and successful implementation of a scoring system for myxomatosis in a susceptible rabbit (*Oryctolagus cuniculis*) model. *Comp. Med* **68(4):** 280-285 (2018).
356. Lucas A, Yaron J, Zhang L, Macaulay C, McFadden G. Chapter 17. Serpins; Development for Therapeutic Applications. (*Editor A Lucas)* *Serpins, Methods in Molecular Biology, Springer Nature Press,* DOI: 10.1007/978-1-4939-8645-3 (2018).
357. Mahon,BP, Ambadapadi S, Yaron, JR, Lomelino CL, Pinard, M, Keinan, S, Kurnikov, I, Macaulay C, Zhang, L, Reeves, W, McFadden G, Tibbetts, S, McKenna R, and Lucas AR. Crystal structure of cleaved Serp-1, a Myxomavirus-derived immune modulating serpin: Structural design of serpin reactive center loop peptides with improved therapeutic function. *Biochemistry* **57(7):** 1096-1107 (2018).
358. Van Vloten, JP, Santry, LA, McAusland, TM, Karimi, K, McFadden, G, Petrik, JJ, Wootton, SK and Bridle, BW. Quantifying antigen-specific T-cell responses when using antigen-agnostic immunotherapies. *Molecular Therapy-Methods & Clinical Development* **13:** 154-166 doi: 10.1016/j.omtm.2019.01.012 (2019).
359. Van Vloten, JP, Klafuric, EM, Karimi, K, McFadden, G, Petrik, JJ, Wootton, SK and Bridle, BW. Quantifying antibody responses induced by antigen-agnostic immunotherapies. *Molecular Therapy-Methods & Clinical Development* **14:** 189-196 doi: 10.1016/j.omtm.2019.06.010 (2019).
360. Tang, B, Schane, C, Yan, D, Guo, ZS, Bartlett, DL, Liu, J, McFadden, G, Grosenbach, D, Shisler, JL and Roy, EJ. A cautionary note on the selectivity of oncolytic viruses. *Oncolytic Virotherapy* **8:** 3-8 (2019).
361. Alves, JM, Carneiro, M, Cheng, JY, Lemos de Matos, A, Rahman, MM, Loog, L, Campos, PF, Wales, N, Eriksson, A, Manica, A, Strive, T, Graham, SC, Afonso, S, Bell, DJ, Day, JP, Fuller, SJ, Marchandeau, S, Palmer, WJ, Queney, G, Surridge, AK, Vieira, FG, McFadden, G, Nielsen, R, Gilbert, MTP, Esteves, PJ, Ferrand, N, and Jiggins, FM. Parallel adaptation of rabbit populations to myxoma virus. *Science* **363:** 1319-1326 (doi 10.1126/science.aau7285) (2019).

See also examples of commentaries regarding this paper:

<https://biodesign.asu.edu/news/hop-it-researchers-evaluate-rabbits%E2%80%99-evolved-resistance-myxoma-virus>

<http://science.sciencemag.org/content/363/6433/1277>

(Many Press releases and articles have discussed this particular paper on virus-host co-evolution).

1. Garg, R, Jackson, C, Rahman, MM, Khan, AR, Lewin, AS and McFadden, G. Myxoma virus M013 protein antagonizes NF-kB and inflammasome pathways via distinct structural motifs. *J Biol. Chemistry* **294(21):** 8480-8489(2019).
2. Shabashvili, D, Kellish, P, Rahman, MM, Nawab, A, Guijarro, MV, Zhang, M, Cao, C, Moussatche, N, Reinhard, M, Jantz, M, Mehta, HJ, McFadden, G, Kaye, FJ, and Zajac-Kaye, M. Oncolytic myxoma virotherapy for small cell lung cancer induces immune cell infiltration and prolongs survival. *J Clinical Investigation* https://doi.org/10.1172/JCI121323 (2019).
3. Torres-Dominguez, LE and McFadden, G. Poxvirus oncolytic virotherapy. *Expert Opinion Biol Therapies* **6:** 561-573. doi: 10.1080/14712598.2019.1600669 (2019).
4. Zhang, L, Yaron, JR, Tafoya, AM, Wallace, SE, Kilbourne, J, Haydel, S, Rege, K, McFadden, G, and AR Lucas. A virus-derived immune modulating serpin accelerates wound closure with improved collagen remodeling. *J Clinical Medicine* **8(10)** E1626, doi: 10.3390/jcm8101626 (2019).
5. Yaron, JR, Kwiecien, JM, Zhang, L, Ambadapadi, S, Wakefield, DN, Clapp, WL, Dabrowski, W, Burgin, M, Munk, BH, McFadden, G, Chen, H, and AR Lucas. Modifying the organ matrix pre-engraftment: A new transplant paradigm? *Trends Mol Medicine* **7:** 626-639 (2019).
6. Agueda-Pinto, A, Lemos de Matos, A, Abrantes, M, Kraberger, S, Risalde, MA, Gortazar, C, McFadden, G, Varsani, A and Esteves, PJ. Genetic characterization of a recombinant myxoma virus leap into the Iberian hare (*Lepus granatensis*). *Viruses* **11,** 530; doi:10.3390/v11060530

BioRxiv: <https://www.biorxiv.org/content/10.1101/624338v1#disqus_thread> (2019).

1. Villa, NY, Franco, LS and McFadden, G. *Ex vivo* virotherapy with myxoma virus to treat cancer. "Oncolytic Viruses: Methods and Protocols", in the series *"Methods in Molecular Biology"* **2958:** 95-110. Springer Nature Press. doi 10.1007/978-1-4939-9794-7\_6 (2020).
2. Rahman, MM and G McFadden. Oncolytic virotherapy with myxoma virus. *J Clin Med.* **9:** 171 doi:10.3390/jcm9010171 (2020).
3. De Matos, AL\*, Franco, LS\* and G McFadden (\*co-lead authors). Oncolytic viruses and the immune system: The dynamic duo. *Mol Therapy-Methods & Clinical* *Development* **17:** 349-358 (2020). https://doi.org/10.1016/j.omtm.2020.01.001
4. Rodriguesa, TCS, Subramaniama, K, Varsani, A, McFadden, G, Schaefere, AM, Bossarte, GD, Romeroa, CH and TB Waltzek. Genome characterization of cetaceanpox virus from a managed Indo-Pacific bottlenose dolphin (Tursiops aduncus). *Virus Research* (2020). https://doi.org/10.1016/j.virusres.2020.197861
5. McFadden, G. Passing the torch. *PLoS Pathogens* **16 (1):** e1008306. (2020). <https://doi.org/10.1371/journal.ppat.1008306>
6. Rahman, MM and G McFadden. Myxoma virus-encoded host range protein M029: A multifunctional antagonist targeting multiple host antiviral and innate immune pathways. *Vaccines* **8:** 244; doi:10.3390/vaccines8020244 (2020).
7. Hadrys, A, Sochanik, A, McFadden, G and J Jazowiecka-Rakus. Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses. *Eur J Pharmacology* **874:** 172991 (2020). <https://doi.org/10.1016/j.ejphar.2020.172991>
8. Villa, NY, Rahman, MM, Mamola, J, D’Isabella, J, Goras, E, Kilbourne, J, Lowe, K, Daggett-Vondras, J, Torres, L, Christie, J, Appel, N, Cox, AL, Kim, JB, and G McFadden. Autologous transplantation using donor leukocytes loaded ex vivo with oncolytic myxoma virus can eliminate residual multiple myeloma. *Molecular Therapy-Oncolytics* **18:** Sept 2020 https://doi.org/10.1016/j.omto.2020.06.011 (2020).
9. Yaron, JR, Zhang, L, Burgin, M, Schutz, L, Awo, E, Wise, L, Krause K, , Ildefonso, C, Kwiecien, J, Rahman, MM, McFadden, G, and AR Lucas. Deriving immunomodulating drugs from viruses - A new class of biologics. *J Clin Med* **9:** 972; doi:10.3390/jcm9040972 (2020).
10. Everts, A, Bergeman, M, McFadden, G and Kemp, V. Simultaneous tumor and stroma targeting by oncolytic viruses. Biomedicines **8,** 474; doi:10.3390/biomedicines8110474 (2020).
11. Jazowiecka-Rakus, J, Sochanik, A, Rusin, A, Fidyk, W, Ciomber, A, Rahman, MM, Villa, N, Franco L, and McFadden, G. Human mesenchymal stem cells can function as efficient cell carriers for oncolytic myxoma virus. *Molecular Therapy-Oncolytics* **18:** https://doi.org/10.1016/j.omto.2020.07.003 (2020).
12. Tang, B, Guo, ZS, Bartlett, D, Yan, D, Schane, C, Liu, J, McFadden, G, Thomas, D, Shisler, J, and Roy, E. Synergistic combination of oncolytic virotherapy and immunotherapy for glioma. *Clinical Cancer Research* **26(9):** 2216-2230. doi: 10.1158/1078-0432.CCR-18-3626 (2020).
13. Liu, Z, Nailwal, H, Jonah, R, Rahman, MM, Sam, R. McFadden, G and Chan, F. A class of viral inducer of RIPK3 degradation regulates poxvirus pathogenesis. *Immunity* <https://doi.org/10.1016/j.immuni.2020.11.020> (2020).
14. Torres, L, Lemos, A, Rahman, MM and McFadden, G. Methods for construction of recombinant oncolytic myxoma virus. Springer Protocols Book: “Viruses as Therapeutics” (Ed AR Lucas), *Methods in Molecular Biology* 2225, Chapter 4, p63-75 (2020).
15. Cornejo, Y, Li, M, Dellinger, TH, Mooney, R, Rahman, MM, McFadden, G, Aboody, KS and Hammad, M. NSCs are permissive to oncolytic *Myxoma virus* and provide a delivery method for targeted ovarian cancer therapy. *Oncotarget* **11:** No. 51, pp: 4693-4698 (2020).
16. Agueda-Pinto, A, Kraberger, S, Lund, MC, Gortazar, C, McFadden, G, Varsani, A and Esteves, P. Coinfections of novel polyomavirus, anelloviruses and a recombinant strain of Myxoma Virus-MYXV-Tol identified in Iberian hares. *Viruses* **12:** 340; doi:10.3390/v12030340 (2020).
17. Woo, Y, Susanne G Warner, SG, Rula Geha, R, Stanford, MM, Decarolis, P, Rahman, MM, Singer, S, McFadden, G and Fong, Y. The oncolytic activity of myxoma virus against soft tissue sarcoma is mediated by the overexpression of ribonucleotide reductase. *Clinical Medicine Insights: Oncology* Vol **15:** 1–7. DOI: 10.1177/1179554921993069 (2021).
18. Jazowiecka-Rakus, J, , Hadrys, A, Rahman, MM, McFadden, G. Fidyk, W, Chmielik, E, Pazdzior, M, Grajek, M, Kozik, V and A, Sochanik. Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma. *Cancers* *13,* 1394. <https://doi.org/10.3390/cancers13061394> (2021).
19. Rahman, MM, Gutierrez-Jensen, AD, Glenn, HL, Abrantes, M, Moussatche, N and McFadden, G. RNA helicase A/DHX9 forms unique cytoplasmic anti-viral granules that restrict oncolytic myxoma virus replication in human cancer cells. *J Virology* **95(14):** e00151-21(2021).
20. Agueda-Pinto, A, Alves, LQ, Neves, F, McFadden, G, Jacobs, BL, Castro, FC, Rahman, MM and Esteves, PJ. Convergent loss of the necroptosis pathway in disparate mammalian lineages shapes viruses countermeasures. *Frontiers in Immunology* Vol **12:** Article 747737, Sept 2021 DOI: 10.3389/fimmu.2021.747737 (2021).
21. Christie, JD, Appel, N, Canter, H, Achi, JG, Elliott, NM, Lemos de Matos, A, Franco, L, Kilbourne, J, Lowe, K, Rahman, MM, Villa, NY, Carmen, J, Luna, E, Joseph Blattman, J, and McFadden, G. Systemic leukocyte delivered Myxoma virus armed with TNF plus immune checkpoint inhibitors eliminate lung metastatic syngeneic mouse osteosarcoma. *Molecular Therapy-Oncolytics* <https://doi.org/10.1016/j.omto.2021.07.014> (2021).
22. Rahman, MM and McFadden, G. Oncolytic viruses: Newest frontier for cancer immunotherapy. *Cancers* **13,** 5452. <https://doi.org/10.3390/cancers13215452> (2021).
23. van Vloten, JP, Minott, JA, McAusland, TM, Ingrao, JC , Santry, LA, McFadden, G, James J. Petrik, JJ, Bridle, BW and Wootton, SK. Production and purification of high-titre Orf virus for preclinical studies in vaccinology and cancer therapy. *Mol Therapy-Methods & Clinical Development* **23**: <https://doi.org/10.1016/j.omtm.2021.08.004> (2021).
24. Christie, JD, Appel, N, Zhang, L, Lowe, K, Kilbourne, J, Daggett-Vondras, J, Elliott, N, Lucas, AR, Blattman, JN, Rahman, MM and McFadden, G. Systemic delivery of mLIGHT-armed Myxoma Virus is therapeutic for later-stage syngeneic murine lung metastatic osteosarcoma. *Cancers* **14,** 337. <https://doi.org/10.3390/cancers14020337> (2022).
25. Kong, W, Fu, L, Fan, J, Maity, S, McFadden, G, and Shi, Y. PD-L1 interacts with Frizzled 6 to activate β-catenin and form a positive feedback loop to promote cancer stem cell expansion. *Oncogene* <https://doi.org/10.1038/s41388-021-02144-2> (2022).
26. Villa, NY, Rahman, MM, Mamola, J, Sharik, ME, Lemos de Matos, A, Kilbourne, J, Lowe, K, Daggett-Vondras, J, D´Isabella, J, Goras, E, Chesi,M,Bergsagel, PL and McFadden, G. Transplantation of autologous bone marrow pre-loaded *ex vivo* with oncolytic myxoma virus is efficacious against drug-resistant Vk\*MYC mouse myeloma. *Oncotarget,* (2022, in press).
27. Agueda-Pinto, A, Kraberger, S, Everts, A, Gutierrez-Jensen, A, Glenn, H, Dalton, K, Podadera, F, Parra, F, Martinez-Haro, M, Alberto, J, Varsani, A, McFadden, G, Rahman, MM and Esteves, PJ. Identification of a novel Myxoma C7-like host range factor that enables a species leap from rabbits to hares. (submitted, 2021).
28. van VlotenJP, Matuszewska, K, Minow, MAA, Minott, JA, Santry, LA, Stegelmeier, A, McAusland, TM, Klafuric, EM, Karimi, K, Colasanti, J, McFadden, G, Petrik, JJ, Bridle, BW and Wootton, SK. Oncolytic Orf virus activates innate and adaptive anti-tumor mechanisms to treat preclinical late-stage ovarian cancer. (in prep, 2021).
29. François, RA, Rahman, MM, Kellish, PC, Nawab, A, Barrigon, MG, Trevino, JG, Reinhard, MK, Kaye, FJ, Li, S, McFadden, G and Zajac-Kaye, M. Gemcitabine plus myxoma virus combination inhibits progression to invasive Grade 3 pancreatic ductal adenocarcinoma (in prep, 2021).